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Huntington’s disease (HD) is a late-onset, autosomal, dominant and progressive 
neurodegenerative disorder for which there is no disease-modifying therapy. An abnormal 
trinucleotide CAG repeats expansion (>36 CAG repeats) in exon 1 of the gene coding for the 
Huntingtin (HTT) protein is the causative mutation for the disease. Animal models of HD, such 
as the R6/2 mouse model, already exist. Yet, in order to understand the disease at a molecular 
level, cellular models of HD are also needed. At the beginning of this project, existing models 
had been developed from tumour cell lines using genome-integrating lentiviral delivery system 
carrying a mutated HTT exon 1. This model was not optimal, as the cells will always have non-
innate extra copies of HTT, which expression is driven by exogenous promoter. In order to 
circumvent this, we were aiming to develop two human stem cell models of HD and use them as 
tools in drug discovery and further understanding of molecular mechanisms of the disease.  
The first model is human embryonic stem cells (hESCs) isolated from clinically unsuitable 
embryos, donated by consenting couples. The embryos carrying a mutation in HTT gene, as 
determined by Preimplantation Genetic Diagnosis (PGD), were used to derive HD-specific 
mutation-carrying hESC lines (HD-hESC). Seven HD- hESCs lines were derived at the Assisted 
Conception Unit (ACU) at Guy’s Hospital, King’s College London (KCL).  
The second model is induced pluripotent stem cells (iPSCs) that I would derive from 
keratinocytes obtained from plucked hairs of consenting HD patients. Their greater availability 
means that we would be able to derive lines representing a larger spectrum of HD phenotype 
due to variations in CAG repeats expansion. Reprogramming will be done using a combination 
of modified mRNAs and/or a lentiviral vector encoding the transcription factors needed for 
reprogramming.  
The overall goal of the project was to optimize culture conditions for the HD-hESC and HD-iPS 
cell lines, fully characterise them, and differentiate them in vitro. Epidemiology studies suggest 
that cardiac failure is the second cause of death in HD patients. For this reasons, HD-ESCs 
were differentiated into cardiac cells (cardiomyocytes) in order to define and characterize the 
cardiac HD phenotype.  
Here, I am describing thorough characterization of normal and HD-hESC lines and their 
differentiation into cardiomyocytes. I am also presenting my data on reprogramming of human 
fibroblasts into iPSC using synthetic modified mRNA. Due to time limit and several technical 
issues outlined in the text, I was unable to successfully reprogram cells from keratinocytes 
obtained from plucked hairs of consenting HD patients.  
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qPCR Quantitative Polymerase Chain Reaction 
RNA Ribonucleic Acid 
ROCK Rho-Associated Kinase  
rpm Revolutions Per Minute 
RPMI Roswell Park Memorial Institute 
RT Room Temperature 
SEM Standard Error Of The Mean  
SMA Smooth Muscle Actin 
TBS Tris Buffered Saline 
TEM Transmission Electron Microscopy 
TGF-#  Transforming Growth Factor !  
Tris Tris(Hydroxymethyl)Aminomethane 
VPA Valproic Acid 
WT Wild Type 
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Chapter 1 GENERAL INTRODUCTION 
 
1.1 Huntington’s Disease 
1.1.1 Clinical features of HD 
Huntington’s disease (HD) was named after George Huntington, who very accurately described 
the disease in his brief report “On Chorea” in 1872 (Huntington, 1872, Figure 1-1). His precise 
observations are still relevant today and admirably describe the major traits associated with HD. 
They can serve as an introduction to the disease. 
 
Figure 1-1: Picture of G. Huntington aged 22, and of the title page of his article “On 
Chorea” in the Medical and Surgical Reporter, 1872. 
 
i) Chorea is one of the hallmarks of HD. 
“Chorea is essentially a disease of the nervous system. The name "chorea" is given 
to the disease on account of the dancing propensities of those who are affected by 
it, and it is a very appropriate designation. […] The disease commonly begins by 
slight twitchings in the muscles of the face, which gradually increase in violence and 
variety. The eyelids are kept winking, the brows are corrugated, and then elevated, 
the nose is screwed first to the one side and then to the other, and the mouth is 
drawn in various directions, giving the patient the most ludicrous appearance 
imaginable. The upper extremities may be the first affected, or both simultaneously. 
All the voluntary muscles are liable to be affected, those of the face rarely being 
exempted.” 
Chorea, derived from the Greek word !"#$%&, to dance, describes the involuntary movements 
suffered by HD patients. They are associated with the neurodegeneration of the central nervous 
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system (CNS) and will only worsen throughout the duration of the illness. The beginning of 
chorea usually marks the onset of the disease (Margolis and Ross, 2003).  
 
ii) HD is an autosomal, dominantly inherited disease. 
“Of its hereditary nature. When either or both the parents have shown 
manifestations of the disease, and more especially when these manifestations have 
been of a serious nature, one or more of the offspring almost invariably suffer from 
the disease, if they live to adult age. But if by any chance these children go through 
life without it, the thread is broken and the grandchildren and great-grandchildren of 
the original shakers may rest assured that they are free from the disease.” 
G. Huntington was able to describe the autosomal, dominant inheritance pattern of HD thanks 
to long epidemiological studies carried out by himself, his father and his grandfather. Together, 
these three generations of physicians cumulated 78 years of clinical observations. This was 
prior to our current knowledge on genetics and the acceptation of Mendel’s theory of the 
principle of hereditary transmission (Mendel, 1865) 
 
iii) HD patients also suffer from cognitive decline and a tendency to suicide. 
“A tendency to insanity and suicide. […] The tendency to insanity, and sometimes 
that form of insanity which leads to suicide, is marked. I know of several instances 
of suicide of people suffering from this form of chorea, or who belonged to families 
in which the disease existed. As the disease progresses the mind becomes more or 
less impaired, in many amounting to insanity, while in others mind and body both 
gradually fail until death relieves them of their sufferings. At present I know of two 
married men, whose wives are living, and who are constantly making love to some 
young lady, not seeming to be aware that there is any impropriety in it. They are 
suffering from chorea to such an extent that they can hardly walk, and would be 
thought, by a stranger, to be intoxicated. They are men of about 50 years of age, 
but never let an opportunity to flirt with a girl go past unimproved. The effect is 
ridiculous in the extreme.” 
 
Cognitive decline, irritability and depression are common features of HD that can affect up to 
80% of HD patients. They can manifest before the onset of motor-deficits and are usually most 
prominent in the year preceding clinical diagnosis and during the early stages of the 
development of motor symptoms (Epping and Paulsen, 2011; Margolis and Ross, 2003). 
Depression is not a symptom measured relative to disease progression (Epping and Paulsen, 
2011), nevertheless suicide is a significant cause of mortality amongst HD patients (Chiu and 
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Alexander, 1982; Lanska et al., 1988; Sorensen and Fenger, 1992) and patients have to be 
monitored for it to minimise risks. 
 
iv) HD is a late onset, progressive neurodegenerative disorder. 
“I do not know of a single case that has shown any marked signs of chorea before 
the age of thirty or forty years, while those who pass the fortieth year without 
symptoms of the disease, are seldom attacked. It begins as an ordinary chorea 
might begin, by the irregular and spasmodic action of certain muscles, as of the 
face, arms, etc. These movements gradually increase, when muscles hitherto 
unaffected take on the spasmodic action, until every muscle in the body becomes 
affected (excepting the involuntary ones), and the poor patient presents a 
spectacle which is anything but pleasing to witness. I have never known a recovery 
or even an amelioration of symptoms in this form of chorea; when once it begins it 
clings to the bitter end. No treatment seems to be of any avail, and indeed 
nowadays its end is so well-known to the sufferer and his friends, that medical 
advice is seldom sought. It seems at least to be one of the incurables.” 
G. Huntington accurately describes the late-onset and progressive nature of HD. However, a 
juvenile form of the disease (JHD) also exists, with a different clinical manifestation. Age of 
onset of HD is predominantly determined by the size of the mutation of the HD gene, which will 
be discussed in section 1.1.2. JHD patients also suffer from dementia and other cognitive 
deficits. However, their major motor feature manifestation tends to be rigidity rather than chorea 
(Siesling et al., 1997). 
Unfortunately, G. Huntington’s description of the fatal nature of HD with the absence of 
treatment is still factual, despite the discovery of the cause of the disease 20 years ago. 
Intriguingly, epidemiology studies indicate that cardiac failure is the second cause of death 
amongst HD patients (Sorensen and Fenger, 1992; Lanska et al., 1988; Chiu and Alexander, 
1982). The cause for this is yet to be investigated. 
 
1.1.2 Huntingtin 
The HD gene, Huntingtin (HTT), was discovered by The Huntington Disease Collaborative 
Research Group in 1993 (The Huntington Disease Collaborative Research Group, 1993). It is 
located on chromosome 4 and is characterised by an increased polymorphic polyglutamine 
trinucleotide motif (CAG) in its first exon. This causes the translation of an abnormally long 
polyglutamine track within the Huntingtin (HTT) protein. In healthy individuals, the CAG repeat 
number ranges from 11 to 34 while HD-specific repeats are above 36. There is a strong 
negative correlation between the number of CAG repeats and the age of onset / severity of the 
symptoms (The Huntington Disease Collaborative Research Group, 1993; Trottier et al., 1994; 
Squitieri et al., 2001; Figure 1-2). 
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Figure 1-2: Negative correlation between HD age of onset and CAG repeat size. 
“Linear correlation obtained by simple regression analysis plotting the age at onset (y-axis) with 
the CAG repeat expansion (x-axis; n = 464, r2 = 0.54, p = 0.0001)” taken from Squitieri et al., 
(2001) 
 
Individuals who have CAG repeat numbers in the higher abnormal range i.e. above 55 repeats 
tend to develop Juvenile Huntington’s Disease (JHD), a more severe form of the disease, with 
slightly different clinical manifestations that develop in their youth instead of in their third to fifth 
decade. The mutation is unstable, showing both decreases and increases in size (Duyao et al., 
1993; The Huntington Disease Collaborative Research Group, 1993). The largest increases are 
found during spermatogenesis, leading to JHD mainly being the result of anticipation with a bias 
towards paternal inheritance (Telenius et al., 1993; Duyao et al., 1993). HD patients baring 
homozygous mutations do not automatically have a lower age of onset, nevertheless they will 
have a more severe phenotype and faster disease progression (Squitieri et al., 2001). Instability 
of the CAG repeat sizes have also been reported in somatic tissues, with the largest expansion 
being observed in the brain (Telenius et al., 1994; Kennedy et al., 2003). 
The discovery of HTT allowed for the development of predictive testing for individuals at risk, 
including embryos, and the development of in vivo and in vitro models of the disease. 
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1.1.3 Function of Huntingtin 
HTT is a large protein (348 kD) that is ubiquitously expressed, with the highest levels found in 
the brain and testis (The Huntington Disease Collaborative Research Group, 1993; Li, S.H. et 
al., 1993; Strong et al., 1993; Sharp et al., 1995). Its endogenous function is still not completely 
understood as it has very little homology to other known proteins (The Huntington Disease 
Collaborative Research Group, 1993). Nevertheless it has been discovered that HTT is 
essential for development, its double knockout (KO) causes embryonic lethality in mice. 
Apoptotic cell death is observed from embryonic day 6 (E6.0), primarily in the distal region of 
the epiblast. By E11.5, no embryonic tissue could be observed; only extraembryonic tissues 
(mostly yolk sac membrane) could be recovered (Zeitlin et al., 1995). HTT is also important for 
neurodevelopment and fertility. Its KO (by Cre/loxP-mediated inactivation in the forebrain and 
cerebellum using the Camk2a promoter in E.15 or postnatal mice day 5) or knockdown (in Htt-
shRNA-transfected E12.5) in mice resulted in the progressive neurodegeneration and sterility of 
these latter (Dragatsis et al., 2000; Tong et al., 2011). HTT is also involved in cellular trafficking 
as a scaffold protein, interacts with different organelles such as the Golgi apparatus, 
mitochondria and the endoplasmic reticulum, is also involved in the endosome–lysosome 
pathway and plays a role in transcriptional regulation (Landles and Bates, 2004; Harjes and 
Wanker, 2003). When HTT misfolds, it aggregates and forms inclusions pre-dominantly in the 
neural cells of the central nervous system (CNS) and to a lesser extent in peripheral tissue 
cells. WT-HTT is predominantly found in the cytoplasm while aggregates tend to be found in the 
nucleus. The nuclear localisation of mutant HTT can lead to its abnormal binding to different 
transcription factors, subsequently leading to the formation of aggregates and the disruption of 
transcriptional expression (Harjes and Wanker, 2003). This could be described as a WT-HTT 
loss of function, coupled with a mutant HTT gain of function, which could explain the defects, 
mainly neurological, observed in HD (Davies et al., 1997; Scherzinger et al., 1997; Sathasivam 
et al., 1999). 
 
 
1.2 Models of Huntington’s Disease 
In order to study human diseases, researchers have strived to create disease models. These 
range from animals to primary or genetically modified cell types. It is expected for a valid HD 
model to exhibit key features of HD in a progressive and measurable way. For instance, it is 
preferable for murine models to have a mid-to late-life disease onset characterised by motor 
impairment. 
 
1.2.1 In vivo models of HD 
HD does not naturally develop in animals. Therefore, in vivo models were created by the use of 
toxins that mimic the mutation or by the transgenic expression of the mutation. 
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1.2.1.1 Toxin-induced models of Huntington’s Disease 
Prior to the discovery of HTT, HD models were developed by the delivery of toxins to rodent and 
non-human primates to reproduce an HD-like phenotype. Toxins such as quinolinic acid and 3-
Nitropropionic Acid (3-NP), a mitochondrial inhibitor, can cause neuronal cell death. This in turn 
induces symptoms such as cognitive deficit and motor impairment which are also found in HD. 
Drawbacks associated with these models are the lack of progressive cell death and the 
absence of HTT aggregates, two hallmarks of the disease (Ramaswamy et al., 2007). 
 
1.2.1.2 Murine models of HD 
Murine models of HD can be divided into three categories: i) transgenic mice expressing 
fragments of both the promoter and exon 1 of the human HTT gene, ii) transgenic mice 
expressing the full-length human HTT gene and iii) knock-in mice expressing murine HTT with a 
pathogenic CAG repeat expansion. 
i) One of the first murine models of HD was developed in 1996 (Mangiarini et al., 1996). 
They carry a transgene allele of the promoter sequence and the HTT exon 1 N-terminal 
sequences with a CAG expansion of approximately 130 repeats. Of these, the R6/2 strain is the 
best characterised and displays an aggressive phenotype as from 4 weeks of age resulting in 
death between 10 and 13 weeks. Disease progression can be observed by reduced brain 
weight and body weight, chorea-like tremors, motor and cognitive deficits (Mangiarini et al., 
1996), as well as cardiac dysfunction (Mihm et al., 2007). The ability of mutant HTT to form 
intranuclear inclusions or aggregates, particularly in neurons was also discovered thanks to the 
R6/2 model (Davies et al., 1997). It can also be noted that the transgene is expressed in every 
tissue, as expected from the ubiquitous expression of HTT (Mangiarini et al., 1996; Sathasivam 
et al., 1999; Moffitt et al., 2009; Sassone et al., 2009) 
 
ii) Inserting full-length HTT using yeast artificial chromosomes or bacterial artificial 
chromosomes respectively generated the YAC and BAC murine HD models respectively 
(Hodgson et al., 1999; Gray et al., 2008). Unlike the R6/2 models, the YAC murine strains were 
at first generated to study CAG repeat sizes comparable to those present in either adult or 
juvenile HD patients (YAC46 and YAC72 have 46 or 72 CAG repeats respectively) (Hodgson et 
al., 1999). Disease progression in these models is much less aggressive than in the R6/2. 
Particularly in the YAC46, HD behavioral phenotypic characteristics cannot be observed for up 
to 20 months. In order to have a model with a faster disease onset, YAC murine strains with 128 
CAG repeats, the YAC128, were later engineered (Slow et al., 2003). This confirms that there is 
a strong negative correlation between CAG repeats number, age of disease onset and severity 
of HD symptoms (Hodgson et al., 1999). 
 
iii) HD knock-in murine models have been generated by engineering the murine HTT 
homologue (Hdh) to carry a pathogenic CAG repeat number (Levine et al., 1999; Shelbourne et 
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al., 1999; Wheeler et al., 2000). This approach presents the advantage of having HTT 
expressed in an endogenous genomic and proteomic context. Similarly to other full-length HTT 
murine models, the disease phenotype is milder and progression occurs in a longer lifespan 
than the transgenic fragment models (Menalled et al., 2003). This further emphasizes that the 
HTT fragments generated by the expression of exon 1 only are very toxic, and sufficient to 
cause the disease phenotype (Mangiarini et al., 1996; Davies et al., 1997) 
 
There is no doubt that murine models of HD have immensely contributed to the current 
knowledge on HD, especially from a molecular and genetic aspect, as well as pre-clinical 
standpoint. For instance, they led to the discovery of the aggregate phenotype in HD. However 
there are issues associated with these in vivo models. Firstly, they are short lived. In can be 
argued that despite their short lifespan, murine models of HD still recapitulate HD phenotypes 
that can take decades to manifest in humans. Yet, this restricts the study of the disease to very 
short time period, particularly in models such as the R6/2 mice that have a very aggressive 
phenotype manifestation. The size of the HD murine models and consequently the size of their 
brain could also be a limitation associated with these models. Indeed, treatment delivery means 
or doses that are applicable and effective to some extent in murine models cannot necessarily 
be scaled up in humans. It can also be noted that most of the existing HD in vivo models 
manifest a wide-range of symptoms with different timings. For these reasons the need for the 
standardisation of experimental protocols and their statistical analysis has been enounced 
(Hockly et al., 2003). Furthermore, it has been suggested that, prior to being considered for 
clinical trial, a compound of interest should show efficacy in at least two different murine models 
in two different laboratories (Bates and Hockly, 2003). 
 
1.2.1.3 Large animal models of HD 
Large animal models of HD include non-human primates, which were given HD by the 
transgenic expression of HTT exon 1. When expressing exon 1 with 84 CAG repeats the 
monkeys showed motor deficits, chorea and presented HTT neuronal aggregates (Yang, S.H. et 
al., 2008). Compared to murine or non-vertebrate models, non-human primates could offer the 
possibility of a wider range of cognitive tests similar to the ones performed in humans. However, 
the transgenic primates suffered from early deaths (within one day to one month post-natal), 
possibly due to the high expression levels of mutant HTT. HD-specific phenotypes such as 
chorea and apoptotic neurons were also found in HD transgenic pigs expressing a N-terminal 
(208 amino acids) portion of HTT with 105 CAG repeats (Yang et al., 2010). However, like the 
HD monkeys, the pigs suffered from early deaths. This is unlike transgenic HD murine models, 
which can survive longer with even larger CAG repeat sizes. This highlights that the 
endogenous context in which mutant HTT is expressed can influence the resulting phenotype. 
HD transgenic sheep have also been developed (Jacobsen et al., 2010) and survival of up to 
three years has been reported in this model. Unlike the HD monkey, they express the full-length 
human HTT (with 73 CAG repeats), and not only a fragment of exon 1, which seems to be 
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better tolerated. Like monkeys and pigs, sheep have the advantage of having larger brains that 
further resemble those of humans, and advanced cognitive functions (Morton and Avanzo, 
2011). 
 
1.2.1.4 Invertebrate and eukaryotic models of HD 
S.cerevisiae (Mason and Giorgini, 2011), C. elegans (Parker et al., 2001) and D. melanogaster 
(Jackson et al., 1998) are invertebrate species used to model HD, mainly by forced expression 
of HTT exon 1. Their small size and the absence of a blood-brain barrier make them useful for 
high-throughput screening of therapeutic compounds. They also have the advantage of being 
relatively inexpensive, which allows the generation of numerous biological replicates. These 
models have contributed to better understand HTT aggregation and provided further insight into 
the role of HTT, for example by linking HTT interaction with the mitochondria misfunction and 
screen for therapeutics that can later be further validated in other HD models. 
 
1.2.2 In vitro models of Huntington’s Disease 
To complement HD in vivo models, HD in vitro models have also been developed from mouse, 
rat and human cells. Cellular models of HD, such as the transgenic ones presented in Table 
1-1, recapitulate some of the hallmarks features of HD, notably increased cell death and the 
formation of aggregates. They can then be used as a screening platform for therapeutic agents 
that will prevent or delay aggregate formation and / or cell death. 
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Cell line Species origin Cell type Phenotype 
CAG (Q) 
repeat size Reference 
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Table 1-1 continued 
Cell line Species origin Cell type Phenotype 
CAG (Q) 
repeat size Reference 
PC12 Rat Adrenal gland tumour 
Aggregate 
formation 



















Exon 1 (47Q, 
72Q and 103Q 
Canals et 
al. (2004) 




N17 (103Q) Fox et al. 
(2004) 








Exon 1 (25Q, 
















































TrES1 Monkey Pluripotent stem cells 
Presence of 
aggregates 
Exon 1 (84Q) Laowtamm
athron et 
al. (2010) 
Table 1-1: Summary of transgenic cellular models of HD.  
FL: Full-length; N: N-terminal, Q: glutamine. Adapted and completed from Sipione and Cattaneo 
(2001) 
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As can be seen from Table 1-1, many transgenic HD cell lines have been developed. The vast 
majority of them features HD-specific phenotypes, notably with the formation of aggregates and 
increased apoptotic cell death. The same phenotypes have been found in primary cell models 
such as non-immortalised striatal neurons (Saudou et al., 1998; Jovicic et al., 2013; Sontag et 
al., 2012), myoblasts (Ciammola et al., 2006) or organotypic brain slice cultures (Smith and 
Bates, 2004). They have been used as a screening platform for therapeutic agents that can 
prevent or delay aggregate formation and or cell death. These cellular models present the 
important advantage of having isogenic controls. However, apart from the HdhCAG and the 
TrES1 models, which were derived from embryonic stem cells (ESCs), all the other models are 
committed to one cell lineage, mainly neuronal. This restricts the in vitro study of HD. 
Furthermore; these models will always have non-innate extra copies of HTT, whose expression 
is driven by the exogenous promoter. On possibility to circumvent this is to develop human 
embryonic stem cell (hESC) models of HD. HD-hESCs have the great advantage of baring the 
endogenous mutation, can be differentiated into multiple cell lineages and can be kept in culture 
ad infinitum, circumventing the limitations associated with primary cell culture. 
 
 
1.3 Pluripotent stem cells as disease models 
1.3.1 Human Embryonic Stem Cells 
1.3.1.1 Human Embryonic Stem Cell derivation 
hESCs were first derived by Thomson (Thomson et al., 1998) from the inner cell mass (ICM) of 
preimplantation blastocysts (day 5-7 post in vitro fertilization, IVF). hESCs are pluripotent. They 
can self-renew ad infinitum, provided that they are maintained in the right culture conditions. 
They also have the ability to differentiate into the three embryonic germ layers i.e. endoderm, 
mesoderm and ectoderm. 
 
1.3.1.2 PGD and disease-baring hESCs 
Preimplantation Genetic Diagnosis (PGD) is a prenatal genetic diagnostic procedure performed 
on a single blastomere biopsied from in vitro fertilisation (IVF) embryos at risk of inheritable 
single-gene disorders, provided that the mutated gene has been identified, prior to the embryo’s 
implantation in the at risk patient. PGD has been rendered possible by the polymerase chain 
reaction (PCR), a technique that allows the amplification of specific DNA sequences (Mullis et 
al., 1986), and has been successfully used as a diagnostic tool on human IVF embryos since 
the early 1990s (Handyside et al., 1990). As a result of the discovery of the HTT gene by the 
Huntington Disease Collaborative Research Group in 1993 (The Huntington Disease 
Collaborative Research Group, 1993), it is possible to offer PGD services to patients at risk of 
transmitting HD (Schulman et al., 1996). Non-mutation carrying embryos can then be implanted 
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while mutated ones will be discarded or, if the couple consents, can be given to research such 
as the derivation of HD-hESCs. Due to its autosomal dominant nature, HD-hESC lines are 
amongst the most numerous (20 out of 187; 10.7%) disease-bearing hESC lines to have been 
derived between 2005 and 2012. A summary of the 187 diseased-bearing hESC lines is 
presented in Table 1-2. 
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Albinism Ocular, Type1 2 
Alpha-Thalassaemia 2 
Alport Syndrome 2 
Beta thalassemia  6 
Beta thalassemia carrier 3 
Breast cancer  2 
Breast cancer and endocrine neoplasia  1 
Charcot-Marie Tooth Disease, Type 1A 3 
Charcot-Marie Tooth Disease, Type 1B 1 
Cystic fibrosis 22 
Cystic fibrosis carrier 1 
Epidermolysis Bullosa 1 
Fabry Syndrome 1 
Fanconi Anemia – A carrier 1 
Fragile Site Mental Retardation 1, carrier 1 
Fragile X Syndrome 6 
Fragile X Syndrome, carrier 5 
Gaucher Disease 1 
Hemoglobin Alpha Locus 1 
Hemoglobin Beta Locus mutation 3 
Hemophilia A 1 
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Table 1-2. continued 
DISEASE Number 
of lines 
Huntington's Disease 20 
Huntington's Disease & Marfan Syndrome 1 
Hypochondroplasia 1 
Incontinentia Pigmenti 1 
Infantile Neuroaxonal Dystrophy 1 
Juvenile Retinoschisis 1 
Marfan Syndrome 3 
Merosin-Deficient Congenital Muscular Dystrophy, Type 1A 1 
Multiple Endocrine Neoplasia, Type 1 1 
Multiple Endocrine Neoplasia, Type 2 3 
Muscular Dystrophy, Becker 1 
Muscular Dystrophy, Becker, carrier 1 
Muscular Dystrophy, Duchenne 5 
Muscular Dystrophy, Duchenne, carrier 1 
Muscular Dystrophy, Emery-Dreifuss 1 
Muscular Dystrophy, Emery-Dreifuss, carrier  3 
Muscular Dystrophy, Facioscapulohumeral 9 
Muscular Dystrophy, Facioscapulohumeral and Turner syndrome 1 
Muscular Dystrophy, Facioscapulohumeral, putative 2 
Myotonic Dystrophy 6 
Myotonic Dystrophy, type 1 4 
Myotonic Dystrophy, type 2 1 
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Table 1-2. continued 
DISEASE Number 
of lines 
Nemaline Myopathy 2 2 
NEMO Deficiency 2 
Neurofibromatosis, Type I 9 
Osteogenesis Imperfecta, Type 1 1 
Patau Syndrome 1 
Pelizaeus-Merzbacher Disease 1 
Popliteal Pterygium Syndrome 1 
Saethre-Chotzen Syndrome 1 
Sandhoff Disease 1 
Sickle Cell Anemia 2 
Spinal Muscular Atrophy, Type I 3 
Spinocerebellar Ataxia, Type 2 1 
Spinocerebellar Ataxia, Type 7 1 
Torsion Dystonia 1 
Torsion Dystonia 1 4 
Translocation, 7:12 1 
Translocation, 7:17 1 
Translocation, 11:22 1 
Treacher Collins-Francescetti Syndrome 2 
Tuberous Sclerosis, Type 1 3 
Turner Syndrome, mosaic cell line 1 
Vitelliform Macular Dystrophy 2 
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Table 1-2. continued 
 
1.3.1.3 hESCs culture conditions 
The first hESCs were derived and maintained for long-term culture on a feeder layer of mouse 
embryonic fibroblasts (MEF), combined with a culture medium containing foetal bovine serum 
(FBS) (Thomson et al., 1998). Many laboratories continued to use these culture conditions for 
the derivation of new lines and their long-term maintenance. However, despite the efficiency of 
feeder-based culture, it is not optimal as it is not a fully defined condition and it requires manual 
hESC passaging, which is very labour intensive, time consuming and limits the scalability of the 
hESCs cultures. This can prevent downstream applications such as hESC differentiation. 
Indeed, some differentiation protocols can require large amounts of hESCs as a starting point 
(Laflamme et al., 2007). Furthermore, experiments are limited as there is a risk that obtained 
data could be a hindered or altered due to presence of feeders. For these reasons, feeder-free 
culture systems that support the long-term, undifferentiated and pluripotent growth of hESCs 
have been developed. 
One of the most commonly used feeder-free matrix is Matrigel (Xu et al., 2001). Matrigel is a 
gelatinous substance secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, 
composed of a complex mixture of laminin, collagen IV and heparan sulfate proteoglycan (Xu et 
al., 2001;Kleinman et al., 1982). It supports the long-term (# 130 population doublings) feeder-
free culture of undifferentiated, karyotypically normal hESCs. Moreover, it allows the hESCs to 
maintain their capacity to differentiate into the three germ layers (Xu et al., 2001). Along with the 
development of feeder-free matrices, fully defined media have been developed. One of the most 
reliable media to be used in conjunction with Matrigel is mTeSR1 (Ludwig and J, 2007; Akopian 
et al., 2010). mTeSR1 is a fully defined and serum-free culture medium. It mainly maintains 
DISEASE Number 
of lines 
Von Hippel-Lindau Disease 5 
Wilms’ Tumour 1 
Wiskott-Aldrich Syndrome, Cystic Fibrosis carrier 1 
X-linked Myotubular Myopathy 2 
Zellweger Syndrome 1 
Table 1-2: Specific mutation-carrying hESC lines reported by May 17, 2012.  
(Loser et al., 2010;Strulovici et al., 2007); University of Massachusetts Medical School, 
International Stem Cell Registry http://www.umassmed.edu/iscr/GeneticDisorders.aspx; 
http://www.stemride.com/ accessed on May 17, 2012, including those derived at Assisted 
Conception Unit at Guy’s Hospital as of May 17, 2012, sorted by disease type. To be 
published in Stephenson et al. (2014). 
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hESCs pluripotency by having high concentrations of basic Fibroblast Growth Factor (bFGF) 
and transforming growth factor-$ (TGF-$). 
Feeder-free hESC culture present many advantages such as the absence of feeder-cells 
contamination and the facility of hESC culture upscaling. Furthermore, it gives the possibility to 
have a fully defined, xeno-free culture system, which is an advantage to generate hESCs for 
therapeutic uses (Stephenson et al, 2012). However, it cannot be dismissed that feeder-free 
culture maintenance may promote karyotype abnormalities and can prevent downstream cell 
differentiation. 
In the work presented in this thesis, it could be observed that, in our hands, the pluripotency 
maintenance medium of the hESCs had a direct influence on cardiac differentiation outcome 
and efficiency. This will be further discussed in Chapter 5. 
 
1.3.1.4 Limitations of hESCs 
Disease modelling with hESCs is limited by embryo availability and whether or not the disease 
is due to a unique genetic mutation that can be screened by PGD. Furthermore, the destruction 
of the embryo associated with hESC line derivation poses some ethical concerns and has 
limited hESC research in countries such as the USA or France. This gap was breached in 2006 
by the generation of a new type of pluripotent stem cells (PSCs) (Takahashi and Yamanaka, 
2006). 
 
1.3.2 Human Induced Pluripotent Stem Cells 
Human induced Pluripotent Stem Cells (iPSCs) are pluripotent stem cells derived from the 
reprogramming of adult somatic cells. This can be achieved by the forced expression of 
pluripotency genes now known as the “Yamanaka factors”, OCT3/4, SOX2, KLF4 and c-MYC 
(Takahashi et al., 2007; Takahashi and Yamanaka, 2006). Less ethical issues are associated 
with iPSC work than with hESCs generation, as it does not require the destruction of an 
embryo. Once reprogrammed, iPSCs have the same morphology, pluripotency and 
differentiation potential as hESCs. However, iPSCs generation is not an easy task and 
efficiencies were as low as 0.01% when the technique was first developed (Takahashi et al., 
2007; Takahashi and Yamanaka, 2006). As for hESCs, disease-specific iPSC can be 
generated. However, iPSCs are not limited to single gene disorders and can be derived from 
complex diseases such as Alzheimer’s disease (Yagi et al., 2011; Israel et al., 2012). Like 
hESCs, they can then be differentiated into specific tissues affected by the disease in order to 
gain further insight into the molecular mechanisms of the disease. Disease-baring PSCs can 
allow the identification of in vitro phenotypic assay that can help identify therapeutic targets. 
Since iPSCs were first derived, different reprogramming approaches have been developed in 
order to improve efficiency. Variability between protocols includes i) the source of somatic cells 
to be reprogrammed, ii) the vector used for forced ectopic expression of “pluripotency-genes” 
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and iii) the combination of genes used for reprogramming. A summary of the different methods 
used for reprogramming somatic cells into iPSCs is presented in Table 1-3. 
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Table 1-3: Summary of the methods for reprogramming somatic cells to iPSCs.  
Table taken from Robinton and Daley, (2012). OSKM and similar factor names represent 
combinations of reprogramming factors: O, OCT4; S, SOX2; K, KLF4; M, c-MYC and VPA, 
valproic acid. 
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It can be seen from Table 1-3 that since the development of iPSCs in 2006 (Takahashi and 
Yamanaka, 2006), a wide range of somatic cell types can be reprogrammed, using different 
delivery vectors and reprogramming gene combinations. The somatic cell type to be 
reprogrammed can be chosen based on its availability. For instance fibroblasts are a commonly 
used somatic cell type as they can efficiently be derived from a skin biopsy and are easy and 
robust to culture. Keratinocytes, on the other hand, can be chosen for their greater 
reprogramming efficiency. Compared to fibroblasts, reprogramming keratinocytes can be up to 
100-folds more efficient and twofold faster (Aasen et al., 2008). It is worth noting however that it 
has been established that despite reprogramming, iPSCs retain an “epigenetic memory” from 
their somatic source (Kim, K. et al., 2011), which influences their downstream differentiation 
potential. In this way, cord-blood-derived iPSCs will more readily differentiate into hematopoietic 
colonies than iPSCs derived from keratinocytes (Kim, K. et al., 2011). 
 
 
1.4 Pluripotent stem cells disease-modelling. 
PSC disease modelling requires three major steps: i) PSC generation, ii) PSC differentiation 
into a relevant cell type, iii) disease-specific phenotype identification (summarised in Figure 
1-3). 
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Figure 1-3: Disease modelling, therapeutic screen and clinical development using 
pluripotent stem cells (PSCs).  
PSC can be derived from i) patient-derived somatic cells reprogrammed using the “Yamanaka 
factors” or ii) the inner cell mass (ICM) isolated from an embryo. Upon derivation, PSCs are 
characterised and expanded. They can then be differentiated into mature cells to study disease-
specific phenotypes and develop assays. These assays can be used for high-throughput 
therapeutic screening and clinical development to reverse the disease phenotype and benefit 
the patient. Figure realised using the biomedical PPT toolkit by motifolio. 
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i) Disease PSC generation 
Together, hESCs and iPSCs are great complimentary tools for in vitro disease modelling. 
hESCs present the advantage of higher line derivation success. With a well-established 
protocol, hESC line derivation can reach efficiencies as high as 50%-60% (Stephenson et al., 
2012). However, hESC-disease modelling is limited to single single-gene disorders (Verlinsky et 
al., 2005). Despite their lower rate of derivation (0.01% with retroviruses and the four Yamanaka 
factors, (Takahashi et al., 2007; Takahashi and Yamanaka, 2006), iPSCs confer the advantage 
of enabling the derivation of PSCs baring multifactorial diseases, without the limited life-span 
usually associated with primary cell cultures. iPSC generation will be further discussed in 
chapter 4. 
 
ii) Disease PSC differentiation 
PSCs have the ability to differentiated into the endoderm, mesoderm and ectoderm germ layers. 
Part of their pluripotency characterisation consists of spontaneously differentiating them in vivo 
to generate teratomas, which comprise derivatives of the three germ layers (Thomson et al., 
1998). For this project, we were interested in differentiating the HD-PSCs into cardiomyocytes. 
PSC differentiation into cardiomyocytes needs to replicate 4 major developmental steps: i) the 
commitment of the PSCs to the mesoendoderm germ layer, ii) cardiomesoderm commitment, iii) 
cardiac progenitor formation and iv) cardiomyocyte maturation. Several strategies exist in order 
to achieve this. One popular approach to generate PSC-derived cardiomyocytes relies on the 
characteristic that PSCs can be spontaneously differentiated in vitro by forming aggregates in 
suspension called embryoid bodies (EBs) (Itskovitz-Eldor et al., 2000) in the absence of bFGF. 
The EBs become cystic and form derivatives of the three germ layers. Although EB-based 
differentiation is not specific, it has been demonstrated that when plated on gelatin after 7-10 
days in suspension, EBs can reproducibly (8.1%) give rise to cardiomyocytes (Kehat et al., 
2001). Another strategy to differentiate PSCs into a specific lineage consists of PSC co-culture 
with another cell type. For instance, PSCs can be differentiated into cardiomyocytes by co-
culture with the END-2 visceral endoderm-like cells (Mummery et al., 2003). Similarly, PSCs can 
be differentiated into the hematopoietic lineage by co-culture with the S17 mouse bone marrow 
stromal cell line or the C166 mouse yolk-sac endothelial cell line (Kaufman et al., 2001). A third 
method, to generate PSC-derived cardiomyocytes consists of directed differentiation by 
temporal cytokine treatment. In this method, which was chosen for this study, Activin A 
treatment is used to trigger mesoendoerm formation and exposure to Bone Morphogenic 
Protein 4 (BMP4) then further commit the cells to cardiac differentiation (Laflamme et al., 2007). 
Table 1-4 summarises key PSC cardiac differentiation protocol. Cardiac differentiation of HD-
hESCs will also be further discussed in Chapter 5. 
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Protocol outline Reference 
Embryoid Body (EB) based differentiation 
Spontaneous EB 
differentiation with FBS 
containing medium 
Formation of embryoid bodies 
(EBs), suspension aggregates, 
in the absence of bFGF. The 
EBs become cystic and form 
derivatives of the three germ 
layers. After 7-10 days of culture 
in suspension, EBs are plated 
on gelatin and give rise to 
cardiomyocytes (8.1%).  
Kehat et al., 2001 
Forced aggregation EB 
based differentiation in 
chemically defined medium. 
Use of force aggregation for EB 
formation and exposure to PVA, 
Insulin, 1-thioglycerol, BMP4, 
bFGF, and Y-27632.  Very high 
and rapid efficiency (#95% 
cardiomyocytes in 9 days) 
reproducible across multiple cell 
lines. 
Burridge et al., 2011 
Directed EB based 
differentiation 
Successive exposure to 
combinations of BMP4, bFGF, 
Activin A, VEGF and DKK1. Up 
to 40% differentiation efficiency. 
When used on a cell monolayer, 
this protocol gives rise to up to 
50% cardiomyocyte 
differentiation  
Yang et al., 2008 
Controlled size EBs  Generation of EBs containing 
1,000 cells by forced 
aggregation in micro-wells. The 
cells were then exposed to the 
Yang et al. differentiation 
protocol. Yields up to 75% 
cardiomyocytes 
Bauwens et al., 2011 
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Protocol outline Reference 
END-2 co-culture differentiation 
END-2 co-culture PSC differentiation into 
cardiomyocytes by co-culture 
with the END-2 visceral 
endoderm-like cell line. Up to 
35% of the culture wells 
contained beating 
cardiomyocytes. 
Mummery et al., 2003 
END-2 conditioned medium  PSC differentiation by exposure 
to END-2 cell conditioned 
medium and SB203580, a p38 
MAPK inhibitor. Up to 20% 
efficiency. 
Graichen et al., 2008 
Monolayer based differentiation 
Cell monolayer High density PSC monolayer 
culture with high concentrations 
of Activin A and BMP4. Up to 
30% cardiomyocytes 
Laflamme et al., 2007 
The matrix sandwich differentiation 
Cell monolayer overlayed 
by Matrigel  
High density PSC monolayer 
culture overlayed by a fine layer 
of Matrigel and exposure to high 
concentrations of Activin A 
followed by BMP4 and bFGF. 
Gives rise to high purity of 
cardiomyocytes (98%) 
Zhang et al., 2012 
Table 1-4: Key pluripotent stem cell cardiac differentiation methods 
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iii) Disease-specific phenotype identification 
Disease-baring PSCs are complementary tools to animal models. As discussed previously, HD 
in vivo models have successfully recapitulated HD-specific phenotypes. However, this is also 
tampered by the fact that the mutated protein is not expressed in an endogenous context, and 
not in a range usually seen in patients. The advantage of HD-PSCs and other disease-baring 
PSC lies in their expression of the endogenous mutation in the right context, and in their 
pluripotency and ability to differentiation into an array of somatic cell types. Despite HD being a 
late onset disorder HD-PSCs have been differentiated into neural cells (Camnasio et al., 2012; 
Niclis et al., 2009; An et al., 2012; Zhang, N. et al., 2010;The HD iPSC Consortium, 2012), 
which in some cases replicated HD-specific phenotypes in vitro (Table 1-5). Yet, HD in vitro 
study is not limited to PSC-derived neural cells and we have chosen to differentiated HD-hESCs 
into cardiomyocytes in order to study the HD cardiac phenotype. This holds great promise for 
the development of disease-specific phenotypic assays and the screening of HD therapeutic 
compounds. In this way, Timothy syndrome (TS)-iPSCs were differentiated in to both 
cardiomyocytes (Yazawa et al., 2011) and neural cells (Pasca et al., 2011). TS-iPSCs 
recplicated in vitro TS-specific phenotypes (Table 1-5) in both somatic cell types, giving a better 
insight into the disease mechanism. More importantly, they are helping to validate potential 
therapeutic targets. In this example, Roscovitine (Ros), a cycline-dependent kinase inhibitor, or 
Ros related drugs could help rescue the phenotype in both TS-cardiomyocytes and TS-neuronal 
cells (Yazawa et al., 2011; Pasca et al., 2011). Therapeutic compound identification was also 
facilitated using Gaucher’s disease (GD)-iPSCs (Tiscornia et al., 2013). GD-iPSCs were 
differentiated into dopaminergic neurons and macrophages. Both cell type presented with acid-
$-glucosidase expression deficiency, a common phenotype of the disease. Using the cells as a 
screening platform, they identified two nojirimycin analogues that could rescue the GD-specific 
phenotype. 
One limitation, but potentially an advantage, that could be associated with PSC disease 
modelling is the modelling of non-cell autonomous conditions. HD is primarily a neurological 
disorder. However, cardiac failure is a common cause of death amongst HD patients (Sorensen 
and Fenger, 1992; Lanska et al., 1988; Chiu and Alexander, 1982). As described previously, 
PSC-derived cardiomyocytes are able to replicate cardiac disease-specific phenotypes in vitro. 
Since HTT is ubiquitously expressed, by studying PSC-derived HD-cardiomyocytes in vitro, this 
will give us further insight on whether cardiac defects in HD are caused by a cell autonomous or 
a non-cell autonomous process.  
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Table 1-5. continued. 
Disease Mutation In vitro 
phenotype 















































Pasca et al., 
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Table 1-5: Examples of iPSC-modelled disease with an in vitro phenotype. 
 
 
1.5 Aims of the project 
The aim of the work presented in this thesis was to develop, characterise and differentiate PSC 
models of HD. To achieve this, this work is divided in three parts: 
i) Characterisation of five HD-hESC lines derived at the Assisted Conception Unit (ACU), 
King’s College London, and their adaptation to feeder-free culture conditions 
required for downstream differentiations. 
 
ii) The generation of iPSC lines. The final aim was to generate HD-iPSCs from HD-HF-
keratinocytes. To achieve this, HF-keratinocyte derivation protocols and iPSC 
generation using synthetic modified mRNA were optimised. 
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iii) hESC differentiation into cardiomyocytes in order to study the effect of the HD mutation 
in this somatic cell type and determine whether or not the cardiac failure suffered by 
HD patients is a cell autonomous or non-cell autonomous process. 
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Chapter 2 EXPERIMENTAL PROCEDURES 
 
2.1 Human Embryonic Stem Cells 












Table 2-1: Summary of the Wild Type (WT) and HD-hESCs used in this study 
 
Unless specified differently, all cells were cultured at 37°C, 5% O2 and 6% CO2 in a HERAcell 
240 incubator (Heraeus) or a benchtop MINC incubators (Cook). All tissue culture procedures 
were conducted aseptically in a class II biological safety cabinet. 
 
2.1.1 Preparation of Human Foreskin Fibroblast (HFF)-feeders 
The hESC lines were derived and cultured on Human Foreskin Fibroblast (HFF)-feeders 
(Forticell). Frozen stocks had previously been inactivated by &-irradiation at 5,000 rad (50 Gy) 
with a caesium-source irradiator (Nordion International, GammaCell 1000 Elite). Feeder-cells 
were plated in CELLstart (CS) (Gibco, Invitrogen)-coated 4-well plates (Nunc) in M199 (72% 
Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) supplemented with 18% medium 199 
(Invitrogen) and 10% FBS, (Hyclone). CS coating was performed 2 h before HFF plating by 
diluting CS 1:75 in Dulbecco’s Phosphate Buffered Saline with calcium and magnesium 
(DPBSCa2+/Mg2+, Lonza). A volume of 250 'L of diluted CS was added to each well of a 4-well 
dish and the dish placed at 37°C for 2 h. After the incubation, CS was removed and 2.25 x 104 
cells/cm2 inactivated HFF in 500µL of M199 were plated in each well. The HFF-feeders were 
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then returned to the incubator, the medium was changed every two to three days and the cells 
used within two weeks or discarded. 
 
2.1.2 Human ESCs derivation 
Human ESC lines used in this study were derived at the Assisted Conception Unit, Guy's 
Hospital (London, UK). hESCs were derived under the Human Fertilisation and Embryology 
Authority (HFEA; research license number R0133) and local ethical approval (UK National 
Health Service Research Ethics Committee Reference 06/Q0702/90) from healthy 
cryopreserved In Vitro Fertilisation (IVF) embryos and fresh embryos diagnosed with HD 
following Preimplantation Genetic Diagnosis (PGD). Informed consent was obtained from all 
patients and the experiments were compliant with the WMA Declaration of Helsinki and the NIH 
Belmont Report principles. No financial inducements were offered for donation. A sample of 
each line that is derived is deposited in the UK Stem Cell Bank for distribution to academic and 
research centres internationally. 
 
2.1.3 hESCs maintenance on HFF-feeders 
All hESC lines were initially grown and maintained as colonies on an HFF-feeder layer prepared 
as described in 2.1.1. The KOSR-XF complete medium used in this study consisted of 
KnockOut Dulbecco’s Modified Eagle Medium (KO-DMEM) supplemented with 15% KnockOut 
Serum Replacement Xeno-Free (KOSR-XF), 2 mM GlutaMax-1, 2% KOSR Growth Factor 
Cocktail and 0.1 mM $-Mercaptoethanol ($-ME) (all from Gibco, Invitrogen). The medium was 
filtered through a 0.22 'm Polyethersulfone (PES) membrane filter system (Corning), stored at 
4°C and used within 10 days. Cells were fed every two to three days with medium 
supplemented with 24 ng/mL of bFGF (R&D Systems) and pre-equilibrated at 37°C for a 
minimum of 30 min prior to use.  
hESCs were manually passaged once or twice per week. M199 medium was removed from the 
HFF-feeders, the wells rinsed three times with Phosphate Buffer Saline (PBS, Gibco) and 
replaced with 500 µL of KOSR-XF complete medium supplemented with 24 ng/mL of bFGF. 
The HFF-feeders were then returned to the incubator for 30 min prior to use. Colonies were first 
dissected under a Nikon SMZ1000 Stereomicroscope, and pieces were detached using a 
hooked disposable Pasteur Pipette (Volac Cole-Parmer). The seeding of 6-10 pieces onto a 
pre-conditioned fresh cell culture dish marked a single passage. Undifferentiated hESCs form 
tightly packed colonies with well-defined edges and are clear from differentiated cells. Prior to 
passaging, colony regions that presented sign of differentiation were discarded (illustrated in 
Figure 2-1). 
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Figure 2-1: hESC colony presenting signs of differentiation.  
KCL012_HD3 p8. Black arrow indicates differentiated area that needs removal prior to 
passaging. Image was taken at 40x magnification. 
 
 
2.1.4 hESCs maintained on HFF-feeders cryopreservation and thawing  
2.1.4.1 Vitrification 
hESCs cultured on HFF-feeders were cryopreserved by vitrification. All cryopreservation 
solutions (Table 2-2) were prepared fresh, stored at 4°C and used within one week. 
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ES-HEPES solution Volume (mL) Manufacturer 
DMEM/F-12 15.6 Invitrogen 
KOSR-XF 4.0 Invitrogen 
1M HEPES 0.4 Invitrogen 
1M Sucrose Volume (mL) Manufacturer 
Sucrose 3.42g Sigma 
ES-HEPES solution 8.0 Made as above 
KOSR-XF 2.0 Invitrogen 
10% Vitrification Volume (mL) Manufacturer 
ES-HEPES solution 2.0 Made as above 
Ethylene Glycol 0.25 Sigma 
DMSO 0.25 VWR 
20% Vitrification Volume (mL) Manufacturer 
ES-HEPES solution 0.75 Made as above 
1M Sucrose 0.75 Made as above 
Ethylene Glycol 0.5 Sigma 
DMSO 0.5 VWR 
Table 2-2: hESCs vitrification media formulations.  
DMEM/F-12: DMEM/Nutrient Mix F-12; KOSR-XF: Knock Out Serum Replacement Xeno-Free 
 
Prior to starting vitrification, all the cryopreservation solutions were pre-warmed in the incubator 
for a minimum of 30 min. The hESC culture medium of the cells to vitrify was replaced by pre-
warmed KO-DMEM. Colonies were scored and cut into pieces approximately twice the size as 
those generated for subculture. They were then placed in a well of ES-HEPES solution. 
Microdrops of 10% and 20% vitrification solutions were disposed in an inverted culture dish lid 
as illustrated in Figure 2-2. 
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Figure 2-2: Schematic of an inverted lid with microdrops of 10% and 20% vitrification 
solution for the freezing of human embryonic stem cells cultured on feeders. 
 
Six to ten colony pieces at a time were pipetted from the ES-HEPES solution and incubated for 
1 min in the 10% vitrification solution microdrop before being transferred to a 20% vitrification 
solution microdrop for 25 s. Using capillary action, the colony pieces were aspirated into a 
labelled open pulled vitrification straw (MTR), quickly held horizontally with sterile forceps and 
plunged into liquid nitrogen (LN2). Still in LN2, the straw was then placed into a 5 mL labelled 
cryovial (Nunc). This process was repeated for the remaining colony pieces. Each cryovial held 
a maximum of 12 frozen straws. 
 
2.1.4.2 Thawing 
Prior to thawing the cells, the M199 medium in one HFF-feeder plate per cell line was removed, 
cells were washed three times with PBS, and 500 'L of KOSR-XF complete medium 
supplemented with 24 ng/mL bFGF was added per well. Additionally, one thaw plate per cell 
line was prepared by adding complete KOSR-XF medium (without bFGF) to two empty wells of 
a 4-well plate. The HFF-feeder and the thaw plates were left to pre-equilibrate for at least 30 
min at 37°C prior to use. 
A straw of the desired hESC line was removed from LN2 and its tip immediately placed into the 
first well of the thaw dish. In case the medium and colony pieces would not expel immediately, 
the process was aided by inserting the tip of a 100-µL Gilson tip on the opposite side of the 
straw to lightly expel the content. The colony pieces were rapidly moved to the second well of 
the thaw dish to ensure complete removal of any cryopreservation reagents and thoroughly 
wash the cells, left to incubate for 5 min, and transferred to the pre-equilibrated feeder dish. 
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2.1.5 hESCs adaptation to feeder-free culture 
In order to adapt the cells to feeder-free culture, two substrates, Growth Factor Reduced (GFR)-
Matrigel (BD) and extracellular matrix (ECM) from decellularised feeder layer were tested, as 
well as two media, complete KOSR-XF and mTeSR1 (STEMCELL Technologies). 
 
2.1.5.1 GFR-Matrigel preparation 
GFR-Matrigel was thawed overnight on ice at 4°C, and checked for the presence of any gel 
formation. If there were no visible clumps, GFR-Matrigel stock was diluted to a final 
concentration of 0.34 mg/mL in DMEM/Nutrient Mix F-12 (DMEM/F-12, Invitrogen). Four-well 
plates or 6-well plate were coated with 250 'L/well or 1 mL/well of the solution respectively and 
placed in the incubator at 37°C for 2 h. GFR-Matrigel was then removed and replaced with the 
appropriate medium before use. 
 
2.1.5.2 Decellularised feeder preparation  
In order to prepare the decellularised feeder matrix, HFF-feeders were cultured and plated in 4-
well plates as described in 2.1.1. Two protocols using different detergents, either sodium 
deoxycholate (DOC) or Triton X-100 (both from Sigma), were tested for the quality of cell 
monolayer extraction and ECM structure preservation. Both protocols were tried on one to three 
weeks old HFF-feeders monolayer. 
2.1.5.2.1 DOC protocol  
Cell monolayer extraction was performed as described by Klimanskaya et al. (2005). Briefly, 
cells were rinsed twice with PBS before being incubated at 4°C for 30 min with the cell 
extraction buffer (0.5% DOC in 10 mmol/L tris(hydroxymethyl)aminomethane-Hydrochloric acid 
(Tris-HCl), pH 8.0). The decellularised feeder matrices were then gently rinsed five times with 
PBS. The appropriate pre-equilibrated medium could then be added for immediate use or they 
could be stored at 4°C in PBS for up to one week. 
2.1.5.2.2 Triton x-100 protocol  
Cell lysis using Triton X-100 was adapted from the published protocols by Beacham et al. 
(2007) and Vlodavsky (2001). Briefly, cells were rinsed twice with PBS before being incubated 
at 37°C for 3-5 min with the cell extraction buffer (0.5% v/v Triton X-100 and 20 mM NH4OH in 
PBS). The decellularised feeder matrices were then gently rinsed five times with PBS. The 
appropriate medium could then be added for immediate use or they could be stored at 4°C in 
PBS for up to one week. 
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2.1.5.2.3 Decellularised feeder matrix immunostaining 
To confirm the ECM integrity, samples were immunostained for fibronectin. To do so, PBS was 
removed from the decellularised feeder matrices and they were fixed with 3.7% 
paraformaldehyde (PFA; Sigma) for 20 min at room temperature (RT) and then washed three 
times with DPBSCa2+/Mg2+. DPBSCa2+/Mg2+ was chosen over PBS as it helps to keep the cells fixed 
to the dish. Fixed cells were kept at 4°C in DPBSCa2+/Mg2+ for up five days if they were not 
processed immediately. The anti-human fibronectin antibody (Sigma, F3648), developed in 
rabbit, was diluted in DPBSCa2+/Mg2+ to a final concentration of 5 µg/mL. A final volume of 
250'L/well was added to the cells overnight at 4°C. The solution was then removed and cells 
washed three times for 5 min with DPBSCa2+/Mg2+ before adding 15 µg/mL of Donkey anti-rabbit 
IgG, Rhodamine RedTM- X-conjugated (Jackson ImmunoResearch, 711-295-152) diluted in 
DPBSCa2+/Mg2+ for 40 min at RT, shielded from light. Cells were then washed three times for 5 
min in DPBSCa2+/Mg2+, mounted in Vectashield mounting medium containing 4',6-diamidino-2-
phenylindole (DAPI, Vector Laboratories), and covered with a coverslip. Samples were 
assessed using Eclipse 50i upright epifluorescence microscope (Nikon). Images were captured 
with cooled CCD camera Infinity 3 
2.1.6 hESCs adaptation to enzymatic passaging 
hESCs were first adapted to feeder-free culture conditions in 4-well plates and were manually 
passaged as described in 2.1.3. hESCs cultures were then manually expanded to tissue culture 
treated 6-well plates (Corning). Once adapted to 6-well plate feeder-free culture, the cells were 
enzymatically passaged with 1 mg/mL dispase (STEMCELL Technologies). Briefly, 
differentiated cells were manually removed and discarded. The well was then rinsed with pre-
warmed DMEM. Dispase (1 mL/well of a 6-well plate) was then applied and left to incubate at 
37!C for 7 min or until the edges of the colonies began to curl up. Once the colonies edges were 
slightly curled, the dispase was removed and two DMEM washes were performed. 1 mL of 
mTeSR1 was then added to each well before the cells could be scraped off into little clumps. 
The clumps were then seeded at a 1:6 to 1:12 ratio in freshly GFR-Matrigel-coated dishes 
containing 2 mL of mTeSR1. Enzymatic passaging took place once or twice a week. 
 
2.1.7 hESCs maintained in feeder-free conditions cryopreservation and thawing  
Unlike hESCs cultured on feeders, hESCs cultured feeder-free were not cryopreserved by 
vitrification (refer to 2.1.4) but by slow freezing. Only high quality hESCs colonies (less than 
20% of the cells being differentiated based on the assessment of morphology criteria described 
in 2.1.3) were cryopreserved when the confluency in the well reached approximately 70%. Any 
differentiated cells were manually removed prior to the procedure. The colonies were passaged 
as described in 2.1.6, generating cell clumps bigger than for usual subculture. Following, the 
second DMEM wash, the cell suspension was resuspended in 5 mL of DMEM, transferred to a 
15-mL centrifugation tube and centrifuged for 5 min at 1,000 x g. The supernatant was 
Chapter 2 EXPERIMENTAL PROCEDURES 
- 59 - 
discarded and the cell pellet resuspended in RT-pre-warmed mFreSR (1 mL per well of a 6-well 
plate, STEMCELL Technologies) using a 5-mL pipette, taking care not to generate small 
clumps. The hESCs suspension was aliquoted 1 mL per labelled cryovial and stored overnight 
at -80°C into a Mr. Frosty isopropanol cryovessel (Nalgene). Mr. Frosty allows the cells to have 
a cooling rate of –1°C per minute. The following day, the cryovials were transferred into a dewar 
and stored in the LN2 vapor phase. 
To recover hESCs from LN2, cryovials were quickly thawed in a 37°C heating block until only a 
small frozen chunk remained. The contents were transferred into a 15-mL centrifuge tube 
(Falcon) using a 5 mL pipette in order to prevent the generation of very small clumps. Pre-
warmed mTeSR1 (5 mL) was added to the tube dropwise to avoid a sudden change in 
osmolality. The cells were centrifuged 5 min at 1,000 x g. The supernatant was discarded and 
the pellet resuspended in 2 mL of mTeSR1 containing 10 µM of Rho-associated kinase (ROCK) 
I inhibitor Y-27632 (Source Bioscience), still taking care not to disaggregate the clumps further. 
ROCK I inhibitor prevents apoptosis and enhance survival of dissociated hESCs (Watanabe et 
al., 2007). The cells were then seeded in GFR-Matrigel pre-coated 6-well plates (refer to 2.1.5.1 
for GFR-Matrigel preparation). Generally, hESCs cryopreserved from 1 well of a 6-well plate 
were thawed back into 1 well of a 6-well plate. The cells were placed back in the incubator. 
 
2.1.8 hESCs pluripotency characterisation  
2.1.8.1 In vitro spontaneous differentiation 
hESCs were cultured for a minimum of three weeks in KOSR-XF medium supplemented with 
5% FBS and without bFGF. Medium was changed every two to three days. 
 
2.1.8.2 Immunofluorescence  
The presence of pluripotency or germ layer markers was assessed by immunofluorescence. To 
do so, medium was removed from the cells prior to washing them once with DPBSCa2+/Mg2+. 
They were then fixed with 3.7% PFA for 20 min at RT and then washed three times with 
DPBSCa2+/Mg2+. Fixed cells were kept at 4°C in DPBSCa2+/Mg2+ for up five days if they were not 
processed immediately. Permeabilisation was effectuated with 0.5% Triton X-100/DPBSCa2+/Mg2+ 
for 5 min at RT when staining for pluripotency markers; or with cold 90% acetone (Alfa Aesar) 
for 10 min at 4°C when staining for germ layers markers. In both cases, cells were then washed 
three times with DPBSCa2+/Mg2+. The appropriate primary antibody (Table 2-3) was diluted in 
DPBSCa2+/Mg2+ and added to the cells overnight at 4°C. The solution was then removed and cells 
washed three times for 5 min with DPBSCa2+/Mg2+ before adding the appropriate secondary 
antibody (Table 2-4) diluted in DPBSCa2+/Mg2+ for 40 min at RT, shielded from light. Cells were 
then washed three times for 5 min in DPBSCa2+/Mg2+ mounted in Vectashield mounting medium 
containing DAPI, and covered with a coverslip. Samples were assessed using Eclipse 50i 
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upright epifluorescence microscope. Images were captured with cooled CCD camera Infinity 3 
utilising Infinity Capture software and processed in Adobe Photoshop CS5. 
 
Primary antibody Final Dilution Manufacturer 

















Anti-human Oct3/4 rabbit 
IgG 
2 µg/mL 
Sata Cruz Biotechnology  
(sc-9081) 
Antibodies for differentiation staining 
 
Anti-(-fetoprotein mouse 




Anti- (-smooth muscle 





Anti-$-tubulin isotype III 





Table 2-3 Primary antibodies used for pluripotency and germ layer immunodetection of 
human embryonic stem cells 
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Secondary antibody Final Dilution Manufacturer 
Donkey anti-mouse IgM, 




Donkey anti-goat IgG, 











Donkey anti-rabbit IgG, 











Table 2-4 Secondary antibodies used for pluripotency and germ layer immunodetection 
of human embryonic stem cells 
 
2.1.8.3 Alkaline phosphatase activity detection  
Endogenous Alkaline Phosphatase (AP) activity was detected in hESCs using ELF 
Phosphatase Detection Kit (ATCC) according to manufacturer’s protocol. Briefly, cells were 
rinsed twice with PBS before being fixed with a 10% Formalin solution (4% formaldehyde w/v; 
Sigma). Cell membranes were permeabilized with 0.2% Tween 20 (Sigma) in DPBSCa2+/Mg2 for 
10 min at RT. After several rinses in DPBSCa2+/Mg2 the provided ELF phosphate substrate was 
diluted 1:20 in the kit detection buffer before being added to each well for 5 min at RT. Next, the 
cells were washed once for 15 min in wash buffer (DPBSCa2+/Mg2 with 25 mM EDTA and 5 mM 
Levamisole, pH 8.0, both Sigma-Aldrich) and twice for 15 min with rhodamine phalloidin (Gibco 
Invitrogen) diluted 1:250 in the wash buffer at RT protected from light. Finally, cells were rinsed 
twice with wash buffer, mounted in a drop of the provided mounting medium, and covered with a 
coverslip. Samples were assessed using Eclipse 50i upright epifluorescence microscope. 
Images were captured with cooled CCD camera Infinity 3 utilising Infinity Capture software and 
processed in Adobe Photoshop CS5.  
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2.1.8.4 Teratoma assay 
2.1.8.4.1 Cell preparation and mice injection 
hESCs cultures were expanded feeder-free in 6-well plates as described in section 2.1.6. 
Approximately 6 x 106 cells from (one confluent 6-well plate) were used per one injection into 
female, beige, non-obese diabetic severe immunodeficiency (NOD-SCID) mice (Charles River). 
The day prior to hESCs harvesting, an aliquot of GFR-Matrigel was thawed overnight at 4°C. To 
harvest the cells, each well of a 6-well plate was washed with 1 mL of PBS before adding 1 mL 
of accutase (STEMCELL Technologies) per well. The plate was incubated at 37°C, 5% O2, for 
approximately 3 min. Human ESCs were observed under the phase contrast microscope 
(Nikon) to confirm the formation of a single cell suspension. If needed, the cells were returned to 
the incubator for an extra 2 min. If not, the single cell suspension was added to a 15-mL 
centrifuge tube containing 7 mL of DMEM/F-12. Using 1 mL of DMEM/F-12 per well, each well 
was further rinsed to collect any remaining cells. The cells were then"centrifuged at 1,000 x g for 
5 min, after which the supernatant was discarded. The cell pellet was resuspended in a final 
volume of 240 'L 1:3 GFR-Matrigel:DMEM/F-12. The cell suspension was kept on ice until the 
time of injection in order to prevent the GFR-Matrigel from polymerizing. Just prior to injection, it 
was loaded in a 1-mL syringe (Terumo) fitted with a 30-gauge needle (BD Microlance). Air was 
expelled from the syringe and cells were injected subcutaneously in the right or left flank of the 
NOD-SCID mouse. A total of two to three NOD-SCID mice per hESCs line were injected. They 
were observed on a weekly basis and palpated for tumour formation detection. Typically the 
tumours would be observed 6-12 weeks post injection. When sufficient tumour growth was 
achieved (at least 1cm3) and before their discomfort had become too acute, the mice were 
sacrificed using a Schedule 2 method. Mice were cared for and sacrificed in accordance with 
the Home Office license guidelines# 
 
2.1.8.4.2 Teratoma harvesting and preparation for immunohistochemistry analysis 
The mice were sacrificed and the tumours removed. After rinsing with PBS, the tumours were 
placed in 4% PFA to fix the tissue. To ensure rapid, even fixation, the specimens were placed 
on a Rotator at RT, fixed for 2 h, bisected longitudinally and then fixed for a further 48 h. If the 
tumours could not be immediately processed, they were stored at 4°C in PBS containing 0.1% 
azide (Sigma) to prevent microbial and fungal contamination. 
The teratomas preparation, histological staining, immunohistochemistry staining and sample 
analysis were done at the Wolfson CARD Histology laboratory at King's College London.  
Briefly, the teratomas were placed into individual, coded, processing cassettes and processed 
to Paraffin wax (VWR), using a Leica 2010 Processing machine. Upon completion of 
processing, the teratomas were embedded into heated moulds containing molten wax. The 
moulds were then cooled at 4°C until the wax had solidified. The wax-embedded teratomas 
were sectioned in 6 'm serial slices using a rotary microtome, and allowed to float on the 
surface of 45°C heated water to softens the wax and allow the tissues to flatten out. Sections 
Chapter 2 EXPERIMENTAL PROCEDURES 
- 63 - 
were then mounted onto Superfrost Plus Microscope slide (Fisher Scientific). These slides have 
a special pre-treatment that allows the tissue sections to electrostatically adhere to the glass. 
Section–mounted slides were then placed into a 60°C oven for 1 h to ensure maximum 
adhesion. Slides were then stored at RT until required. 
 
2.1.8.4.3 Histological staining and analysis 
It is essential to de-wax the samples prior to histology as wax is hydrophobic and would repel 
the aqueous solution used for histological staining. To do so, two 10 min xylene (SLS) washes 
under agitation at RT were performed to de-solubilize the wax. This was followed by rehydration 
in four short absolute alcohol baths and a final wash in water. Sections were then sequentially 
stained using Mayer’s Haematoxylin (for nuclei) (VWR) and Eosin (for cytoplasmic and all 
extracellular structures) (Sigma). 
 
2.1.8.4.4 Immunohistochemical staining and analysis 
As recognisable tissue structures from each germ layer could not always be readily identified by  
Haematoxylin & Eosin (H&E) examination, additional immunohistochemical staining and 
analysis of the teratomas was performed. Immunohistochemistry using germ layer-specific 
markers allowed confirmation of hESC differentiation into endoderm, mesoderm and ectoderm 
tissues.  
As for histological staining (section 2.1.8.4.3), the teratoma sections required de-waxing prior to 
immunohistochemical staining after which sections were taken to water and blocked for 
endogenous peroxidases using 3% hydrogen peroxide aqueous solution for 10 min at RT 
(Sigma). This step deactivates the samples’ endogenous peroxidase activity, which is essential 
as the detection system is based on a peroxidase activity (Horseradish peroxidase). 
Next, Heat Induced Epitope Retrieval (HIER) was performed on the sections: this is necessary 
as Formalin-fixation and then paraffin wax processing (alcohol dehydration and the 62°C heat of 
the wax) can either destroy or mask antigenic sites (epitopes) of proteins. The precise 
mechanism whereby HIER unmasks hidden epitopes is not known but it appears to be either by 
calcium removal or Heat-inducing conformational changes to the protein, or both, allowing the 
epitopes to be revealed. 
Once completed, slides were rinsed well in tap water before applying blocking solution (1 % 
bovine serum albumin in 1x Tris Buffered Saline (TBS) and 0.1 % azide, pH 7.6) for at least 5 
min to quench (by ionic attraction) non-specific attachment of antibodies.  
After blocking, primary antibodies specific for differentiated germ layers were diluted in blocking 
solution and left for 2 h at RT. The dilutions at which the antibodies were used are indicated in 
Table 2-5. After the primary antibody incubation, the slides were gently rinsed in 1X TBS and 
then washed in 500 mL 1X TBS, with stirring, for 10 min. Excess buffer solution was then flicked 
Chapter 2 EXPERIMENTAL PROCEDURES 
- 64 - 
off the slides before incubating them for 60 min at RT with the biotinylated secondary antibody 
(Table 2-6), also diluted in blocking solution. 
 





(110258) 4 'g/mL  
Anti-(-fetoprotein Mouse IgG 
Sigma 















Anti-$-tubulin isotype III 
Mouse IgG 
Abcam 






Table 2-5: Primary antibodies used for germ layer immunodetection on teratomas.  
*Anti-Desmin is an ascites fluid and the final antibody concentration has not been determined. 
**Anti-Tenascin C and anti-GFAP are whole anti-sera and the final antibody concentration has 




antibody Manufacturer Final concentration 
Goat anti-rabbit IgG Vectorlab BA-1000 3 'g/mL 
Goat anti-mouse IgG Vectorlab BA-9200 3 'g/mL 
Table 2-6: Secondary Biotinylated antibodies used for germ layer immunodetection on 
teratomas 
 
After incubation with the biotinylated secondary antibodies, the slides were rinsed once briefly in 
1X TBS followed by a 10 min wash with stirring in 1X TBS. This was immediately followed by a 
30 min incubation at RT with the StreptABC-HRP complex (VectorLabs), which was made in 1X 
Tris Buffer. The slides were then washed in 1X TBS as above.  
The samples were then developed for 10 min in diaminobenzidin solution (DAB) (VectorLabs) 
prepared following the manufacturer’s instruction, under gentle agitation. Following this, the 
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sections were washed under running tap water for 5 min, counterstained in Mayer’s 
Haematoxylin for 2 min in order to be able to visualise the cells’ nuclei, and washed again under 
tap water it latter was running clear. Before being mounted on the coverslip, the sections had to 
be dehydrated. For this, they were washed in four successive 2 min alcohol baths of 100% 
Industrial Methylated Spirit (IMS) followed by two 5 min Xylene washes to render the section 
hydrophobic. The slides were then ready to be mounted with Di-n-butyl phthalate (DPX, VWR). 
Controls procedures with the omission of either the primary or secondary antibody were 
performed to check the specificity of the antigen:antibody interactions. 
Images were taken with an Axiocam MR colour camera (medium resolution, Zeiss) mounted on 
an axioscope upright microscope (Zeiss) and processed with Photoshop CS5. 
 
2.1.9 CAG repeat number determination 
2.1.9.1 Total DNA extraction 
Total DNA was extracted from trypsinised and pelleted cells using the DNeasy kit (Qiagen) 
according to manufacturer’s protocol. Briefly, cell lysis was performed by the resuspension of 
the pellet in 200 µL of PBS supplemented with 12 mAU/mL proteinase K, followed by the 
addition of 200 µL of buffer AL (with ethanol added), vortexing and a 10 min incubation at 56°C. 
The sample was homogenised by the addition of 200 µL of 100% ethanol and vortexing before 
being pipetted into a QIAgen DNeasy mini spin column and centrifuged at 6,000 x g for 1 min. 
The flow through was discarded and the column was washed with the addition of 500 µL of 
buffers AW1 and AW2 followed by a 6,000 x g for 1 min and a 20,000 x g for 3 min 
centrifugations respectively. To elute the DNA, 200 µL of buffer AE or water was pipetted to the 
column, left to incubate for 1 min at RT and centrifuged for 1 min at 6,000 x g into a DNAse-free 
1.5-mL microcentrifuge tube. DNA concentration was determined using a Nanodrop ND1000 
UV-Vis Spectrophotometer (Labtech Int). The DNA concentration was adjusted to 50 ng/µL 
before proceeding to the repeat sizing polymerase chain reaction (PCR). 
 
2.1.9.2 Repeat sizing PCR 
Determination of the CAG repeat sizing of the different hESC lines was carried out by PCR. The 
10 µL PCR reaction set up is described in Table 2-7 and thermocycling conditions used on the 
Bio-rad MyCycler Thermal Cycler are described in Table 2-8. 
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Component Volume 
DNA (50 ng/'L) 2 'L 
dNTPs (2mM) 1 'L 
DMSO 1 'L 
AM Buffer (2mM) with $-mercaptoethanol 1 'L 
Forward Primer (10 pmol/'L) 
GAGTCCCTCAAGTCCTTCCAGCA 
0.8 'L 
Reverse primer (10 pmol/'L) 
GCC CAAACTCACGGTCGGT 
0.8 'L 
AmpiTaq (5 U/'L) 0.1 'L 
RNAse/DNAse free dH20 3.3 'L 
Table 2-7: PCR reaction set up for CAG repeat sizing.  
dNTPs are from Invitrogen and Ampitaq polymerase is from Applied Biosystem. All the other 






















Final elongation 72ºC 
 
10 min 
Table 2-8: Repeat sizing PCR thermocycling conditions 
  X 35 
cycles 
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After the PCR, for each sample, 1 'L of PCR product was mixed with 9 'L of HiDi Formamide 
(Applied Biosystems) and 0.03 'L l MegaBACE ET900-R Size standards (GE Healthcare) and 
denatured at 95ºC for 5 min. The PCR reaction was stopped by immediately putting the 
samples on ice.  
 
2.1.9.3 CAG repeat size determination 
The samples were then run on an ABI 3730xl PCR machine at GSTS Pathology, Guy’s 
Hospital, London. 
Using the GeneMapper software (Applied Biosystem), the standards’ size were checked first. If 
they were correct, the amplicon’s size could then be established. To determine the actual CAG 
repeat size, the following formula was used: 
CAG Repeat size  = (amplicon size in base pairs – 185)/3 
where 185 corresponds to the products amplified in the 5’ and 3’ sequence of the uninterrupted 
CAG repeat tract. 
 
2.1.10 Array Comparative Genomic Hybridisation karyotyping 
Array Comparative Genomic Hybridisation (aCGH) was performed on each hESC line in order 
to monitor the karyotype and the genomic copy number variation of each cell line by the 
Cytogenetics laboratory (GSTS Pathology, Guy’s Hospital, London). DNA extractions were 
performed on cell pellets of each line using a Chemagen DNA extraction robot according to the 
manufacturer’s instructions. The DNA concentrations were measured using a NanoDrop and 
DNA integrity was confirmed by agarose gel electrophoresis. Following the manufacturer’s 
instructions, 1 µg of DNA was labelled using a CGH labelling kit (Enzo Life Sciences) before 
being purified using the QIAquick PCR purification kit (Qiagen) and run on an Agilent 4 x 44 K 
platform using either Wessex NGRL design 017457 or design 028469. Hybridization, washing 
and scanning of the arrays were all performed according to the manufacturer’s protocols. 
Analysis of the results and interpretation of the data was performed by the Cytogenetics team 
using feature extraction and DNA analytics software packages (Agilent). Only lines with a 
normal karyotype were used in this study. 
 
2.1.11 DNA Fingerprinting 
DNA fingerprinting was performed on each newly derived hESC line by the Cytogenetics 
laboratory (GSTS Pathology, Guy’s Hospital, London). DNA was extracted and quantified as 
described in section 2.1.10. DNA was amplified using two PCR multiplexes (Heath et al., 2000). 
The first one targeted 17 polymorphic microsatellite markers on chromosomes 13, 18 and 21. 
The second targeted 14 markers on the X and Y chromosomes. The various PCR products 
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were separated using an ABI PRISM 3100 Genetic Analyzer, and results were analysed using 
the ABI Genotyper software and interpreted by recording the allele sizes for each marker in 
order to give a unique fingerprint of each cell line by the Cytogenetics laboratory team. 
 
1.1.1 Human Leukocyte Antigen (HLA) typing 
HLA typing was performed and analysed by the Cytogenetics Department and the Clinical 




2.2 Reprograming of somatic cells into iPSCs using synthetic 
modified mRNA  
 
The generation of iPSCs using modified synthetic mRNA as a reprogramming vector was first 
successful in 2010 (Warren et al., 2010). This technique was then modified and commercialised 
by Stemgent. We further improved the protocol and the final protocol that gave rise to iPSCs will 
be described in this section. Key modifications and differences between the original protocol, 
Stemgent’s and mine will be discussed in Chapter 4. 
 
2.2.1 BJ cell culture 
The commercially available neonatal foreskin BJ fibroblasts (CRL-2522, ATCC) were used as a 
positive control. The purchased cryovial containing 6.7 x 105 cells was recovered for culture by 
being quickly transferred from LN2 to a 37°C heating block until most of the cell suspension was 
thawed. The cells were then transferred to a 15-mL centrifuge tube containing 4 mL of pre-
warmed complete BJ medium consisting of Eagle’s Minimum Essential Medium (ATCC) 
supplemented with 10% FBS (Sigma). The cells were centrifuged for 5 min at 1,000 x g and 
were resuspended in 10 mL of complete BJ medium after removal of the supernatant. BJs were 
plated in a T75 flask (Corning) and were fed every 2-3 days.  
Cells were passaged when they reached 80 to 90% confluency. To do so, the cells were 
washed once with PBS and incubated 5 min with 3 mL of TrypLE Select (Invitrogen). The cell 
suspension was then collected in 7 mL of complete BJ medium and centrifuged at 1,000 x g for 
5 min. Once the supernatant was discarded, the cells were resuspended in complete BJ 
medium and subcultured at a 1:6 to 1:10 ratio. In order to store the bank of cells generated, a 
cell pellet was generated as previously described. This latter was resuspended in complete BJ 
medium containing 5% DMSO (VWR), placed in cryovials and put at -80°C in a Mr. Frosty 
isopropanol cryovessel before being transferred to LN2 24 h later. 
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2.2.2 Newborn foreskin fibroblast (NuFF) donor 11  
Gamma-irradiated NuFF donor 11 were purchased from Global Stem (GSC-3001G) and 
recovered as described in 2.2.1 in NuFF culture medium (DMEM, 10% FBS, 1% Glutamax and 
1% Penicillin/Streptomycin). Each vial contains 4-5 x 106 cells. 
 
2.2.2.1 Feeders preparation 
Four wells of a 6-well plate were coated with 0.2% gelatin (Millipore) for a minimum of 30 min 
before evenly plating 2.5 x 105 NuFF per well in 2.5 ml of NuFF medium. 
2.2.2.2 Medium conditioning 
The 3-4 x 106 inactivated NuFFs cells unused for feeders preparation were plated in one T75, in 
10 mL of NuFF culture medium, and left to attach overnight in a 37°C, 20% O2 and 5% CO2 
incubator (Nuaire). The following day, the NuFF culture medium was removed from the T75, the 
cells washed once with PBS and medium replaced with 25 mL of Pluriton (Stemgent) 
supplemented with 4 ng/mL of bFGF and left to incubate overnight. For a total of six days after 
each 24 h incubation the NuFF-conditioned Pluriton was collected, frozen at -20°C and replaced 
by 25 mL of fresh Pluriton supplemented with 4 ng/mL bFGF.  
On the sixth day of conditioned-medium collection, all the previously collected aliquots of NuFF-
conditioned Pluriton Medium were thawed at 4°C. They were all pooled with the final collection 
and filtered using a 0.22 µm pore size, low protein-binding filter (Corning). The filtered NuFF-
conditioned Pluriton medium was re-aliquoted (40 mL aliquots) and re-frozen at -20°C until used 
in the reprogramming protocol or for up to three months. 
 
2.2.3 Hair-follicle derived keratinocyte culture 
The hair-follicle (HF)-keratinocyte derivation protocol used in this study was modified from 
previously published work Aasen and Belmonte (2010). 
2.2.3.1 Patients samples collection  
Sample collection for optimisation of the keratinocyte derivation technique was done under 
study REC Ref: 10/H0716/90 lnduced Pluripotent Stem Cells from Keratinocytes: A neuronal 
model of Huntington's disease, a neurodegenerative disorder (K-iPS cells HD). Patient 
consenting and sample collection to be used for iPSCs generation was done by Dr. S. Haider. A 
repertory of the samples collected is presented in Chapter 4, Table 4-3. 
2.2.3.2 Hair plucking 
After explaining the procedure to the patient and taking consent, a small scalp area of the 
temporal or the occipital part of the head was washed with a 70% ethanol wipe. A few hairs 
were then plucked using single forceps. Hairs in the anagene phase with a visible outer root 
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sheath (ORS, Figure 2-3) were placed into RT DMEM supplemented with 1X of 
antibiotic/antimycotic (Sigma). Hairs with no visible ORS were discarded. 
 
Figure 2-3: Hair follicle in the anagene phase. Arrow indicates the Outer Root Sheath 
(ORS) 
 
2.2.3.3 Hair plating 
Hair plating was adapted from Aasen and Belmonte (2010). Briefly, plucked hairs were single-
plated into wells of a 6-well plates pre-coated with GFR-Matrigel (prepared as in 2.1.5.1). A 22-
mm coverslip (SLS) was then placed onto the hair before 1 mL of mTeSR1 medium 
supplemented with 1X antibiotic/antimycotic mixture was added to each well. Unless otherwise 
indicated, hairs and derived keratinocytes were cultured at 37°C, 20% O2 and 5% CO2 (Nuaire 
incubator). Hair cultures were not disturbed for 72 h to ensure good attachment. Coverslips 
were removed after 72 h. In the event that the hair had attached to the coverslip and not to the 
GFR-Matrigel, the coverslip was just flipped over. 
 
2.2.3.4 Keratinocyte derivation and maintenance  
The mTeSR1 medium was replaced every two days until an outgrowth was observed. At this 
stage, keratinocytes were fed every two to three days with Epilife medium supplemented with 
Human Keratinocyte Growth Supplement (HKGS) (both from Invitrogen) until cells were 
confluent enough to be passaged.  
Prior to passaging, wells of a 6-well plate were coated with recombinant human collagen I in 
order to improve keratinocyte attachment and growth. To do so, the Coating Matrix Kit 
(Invitrogen) was used where recombinant human collagen I was diluted with the provided 
Dilution Medium to a final concentration of 15 µg/mL and added to the wells. The 6-well plate 
was rocked back and forth briskly to ensure even distribution of the Coating Matrix in the well 
and left to incubate at RT for 30 min. Excess coating matrix was removed prior to cell plating.  
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To passage the cells, 1 mL of Tryple Select (Invitrogen) was put in each well before the cells 
were returned to the incubator for 7-10 min. To stop the reaction, 1 mg/mL of trypsin inhibitor 
(Sigma) was used. Cells were collected and centrifuged at 1,200 x g for 5 min. The pellet was 
then resuspended in Epilife and cells split at a 1:3 ratio. Hairs that did not present any outgrowth 
after 10 days were discarded. 
 
2.2.3.5 Keratinocyte cryopreservation and thaw 
As for hESCs, HF-keratinocyte cryopreservation was done when the cells reached 70-80% 
confluency to ensure the cells were actively dividing. Cells were passaged as described in 
2.2.3.4. After the 5 min centrifugation at 1,000 x g, the supernatant was discarded and the cell 
pellet resuspended pre-chilled FBS supplemented with 10% DMSO. Approximately 1 x 106 cells 
were aliquoted in 1 mL per labelled cryovial and stored overnight at -80°C into a Mr. Frosty 
isopropanol cryovessel. They were transferred into a LN2 vapor tank the following day. To 
recover the keratinocytes from liquid nitrogen, cryovials were quickly thawed in a 37°C heating 
block until only a small frozen chunk remained. The contents were transferred into a 15-mL 
centrifuge tube using a 5-mL pipette in order to prevent the generation of very small clumps. 
Pre-warmed Epilife (5 mL) was added to the tube drop wise and the cells were centrifuged 5 
min at 1,000 x g. The supernatant was discarded and the pellet resuspended in 2 mL of Epilife 
before plating the cells in a well of a 6-well plate pre-coated with Coating Matrix (refer to 
2.2.3.4). 
 
2.2.4 Target cell plating 
Primary somatic cells, BJs and HF-keratinocytes, to be reprogrammed into iPSCs are also 
referred to as target cells. The day prior to the beginning of the reprogramming protocol, BJs or 
HF-keratinocytes were passaged as described in 2.2.1 and 2.2.3.4 respectively, counted and 
plated in their culture medium at a density of 7 x 103 or 6 x 104 cells respectively on the NuFF 
feeders prepared as in 2.2.2.1. 
 
2.2.5 Modified mRNA synthesis 
The intronless coding sequences (CDS) of OCT4, SOX2, KLF4, c-MYC and LIN28 were 
retrieved from NCBI (see appendix II). As published by Warren et al. (2010), a KOZAK 
translational initiation signal was added in 5’ UTR and the 3’ UTR terminated with an alpha-
globin driven oligo(dT) sequence for templated addition of a polyA tail. 
The CDS were then codon optimised with the GeneOptimizer expert software by Geneart/Life 
Technologies. Codon optimisation allows more efficient transcription, by avoiding RNA 
secondary structures, adjusting GC content and removing splice-sites for an overall increased 
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protein yield (Fath et al., 2011). The codon optimised CDSs were synthesized and subcloned 
into a pTNT plasmid (Promega) to allow mRNA synthesis (see appendix II). 
Amsbio synthesized the modified mRNA. To do so, PCR templates were generated from the 
linearized plasmids using the same upstream primers for all 6 constructs with six different gene-
specific downstream T120-heeled reverse primers for the addition of the poly(A) tail. The 
templates were transcribed with T7 polymerase and further modified according to Warren et al. 
(2010). Modifications include the complete substitution of 5-methylcytidine (5mC) for cytidine 
and the substitution of pseudouridine (psi) for uridine to increase mRNA viability and ectopic 
protein expression. Furthermore, to promote efficient translation and increase mRNA half-life a 
synthetic 5’ guanine cap was added and 5’-triphosphates were eliminated by phosphatase 
treatment. A “mRNA cocktail” containing OCT4, SOX2, KLF4, C-MYC, LIN28 and d2eGFP in 
molar ratios of (3:1:1:1:1:1) at a final concentration of 100ng/mL was prepared, aliquoted in 
single-use 50 'l aliquots and stored at -80˚C. 
 
2.2.6 mRNA transfection 
On day 0 of the protocol, fresh Pluriton medium was equilibrated at 37°C and low O2 tension for 
a minimum of 2 h prior to use. 1X Pluriton supplement and 300ng/mL B18R (ebioscience) was 
added to Pluriton medium. 
The mRNA transfection complex (for 4 wells of a 6-well plate) was prepared using RNAse-free 
material and working on RNAZAP (Life Technologies) treated surfaces. To do so, a single-use 
50 µL aliquot of the mRNA cocktail (prepared prior to the beginning of the reprogramming) was 
thawed on ice. It was then mixed with 200 µL of Opti-MEM (Invitrogen) and mixed by gentle 
pipetting. In a separate tube, 25 µL of RNAiMAX (Sigma), a lipofectamine transfection reagent, 
was diluted in 225 µL of Opti-MEM and mixed by gentle pipetting. The diluted lipofectamine was 
then carefully added to the diluted mRNA cocktail with gentle pipetting to generate the mRNA 
transfection complex. The complex was incubated at RT for 15 min before 120 µL was in a 
dropwise fashion to each of the 4 wells to be transfected. To ensure uniform distribution of the 
mRNA transfection complex, the 6-well plate was gently rocked from side to side and front to 
back before being incubated for 4 h at 37°C and 5% O2. 
During this time, more Pluriton medium was equilibrated. Just prior to exchanging the 
transfection medium, the equilibrated Pluriton was supplemented with 1X Pluriton supplement 
as well as 300 ng/mL B18R. The cells were returned to incubate overnight at 37°C and 5% O2. 
 
2.2.7 Somatic cell reprogramming with synthetic modified mRNA 
A summary of the mRNA reprogramming protocol adapted from Warren et al. (2010) is 
presented in Table 2-9. The impact of the different modification on the success of the protocol 
will be discussed in Chapter 4. 
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Step Day Adapted mRNA reprogramming protocol 
Feeder cell plating -2 
Plating of NuFF cells donor 11 cells, 2.5 x 
105 cells/well of a 6-well plate and the 
remainder into a T75 flask 
Target cell plating -1 
Plating of target cells at a density of 7 x 103 
cells/well (BJ) or 6 x 104 cells/well (HF-
keratinocytes) 
mRNA transfection 0 
B18R Pre-treatment (300 ng/mL), cell 
transfection with mRNA cocktail in Pluriton 
medium supplemented with 300 ng/mL 
B18R and 1X Pluriton supplement 
Optional 2 to 17 Optional 1 'M Pithilthrin-( treatment 
mRNA transfection 1 to 17  
Cell transfection with mRNA cocktail in 
Pluriton medium supplemented with 300 
ng/mL B18R and 1X Pluriton supplement 
Use of conditioned medium 6 to 17 
Day -1 to Day 6 NuFF-conditioned Pluriton 
medium is pooled together, filtered, 
supplemented with 0.5 mM sodium butyrate 
and used from Day 6 onwards. 
Colony identification 18 to 20  Potential colonies are left to expand and fed daily with Pluriton medium 
Colony picking 21 
Manual picking of primary iPSC colonies 
and passaging on to HFF in KOSR-XF 
medium 
iPSC line expansion, freezing, 
maintenance and adaptation to 
feeder-free culture conditions 
22+  
Daily refeeding. Maintenance and 
expansion of the culture on HFF-feeder in 
KOSR-XF complete medium and adaptation 
to Matrigel/Nutristem feeder-free conditions 
Table 2-9:Summary of mRNA reprogramming protocol adapted from Warren et al (2010) 
!
2.2.8 iPSCs freezing 
iPSCs cultured on feeders were vitrified and thawed similarly to hESCs (described in section 
2.1.4) while iPSCs cultured feeder-free were cryopreserved and thawed similarly to hESCs  
(described in section 2.1.7.) 
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2.2.9 iPSCs characterisation 
2.2.9.1 iPSCs pluripotency characterisation 
iPSCs pluripotency characterisation was identical to hESC characterisation (described in 
section 2.1.8). 
 
2.2.9.2 Array CGH karyotyping 
The protocol for iPSCS karyotyping is identical to the protocol for hESC karyotyping (described 
in section 2.1.10). 
 
2.2.9.3 DNA Fingerprinting 
The protocol for iPSC DNA fingerprinting is identical to the protocol for hESC DNA fingerprinting 
(described in section 2.1.11). 
 
 
2.3 Human Pluripotent Stem Cells (hPSCs) differentiation 
2.3.1 Human pluripotent stem cell culture 
In order to ensure good cardiac differentiation, cells were cultured for at least three passages on 
GFR-Matrigel (refer to 2.1.5.1) with Nutristem medium (Stemgent). Enzymatic passaging was 
performed using dispase (refer to 2.1.6).  
 
2.3.2 Directed cardiac differentiation 
Directed cardiac differentiation was based on the work published by (Laflamme et al., 2007). 
Briefly, undifferentiated hESCs (KCL020, KCL027_HD5, KCL028_HD6, KCL031, KCL034, 
KCL036_HD7 and KCL040) were dissociated into a single-cell suspension by a 3-5 min 
incubation with accutase. Cells were then centrifuged, resuspended, counted and seeded in 
Nutristem onto GFR-Matrigel coated 24-well plates at a density of 2 x 105 cells/cm2, with the 
addition of 10 µM Y-27632 to ensure good cell attachment. This marked day -5 of the 
differentiation protocol. Until day 0, cells were fed daily with 2 mL/well of Nutristem. At day 0, 
cardiac differentiation was induced by feeding the cells with 0.5 mL/well Roswell Park Memorial 
Institute medium (RPMI)-B27 medium (Invitrogen) supplemented with 100 ng/mL of human 
recombinant Activin A (Miltenyi). The following day, the medium was replaced by 1.5 mL/well 
RPMI-B27 supplemented with 10 ng/ml human recombinant BMP4, (Miltenyi) and left 
unchanged for four days. The medium was then exchanged for unsupplemented RPMI-B27 
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every two days for up to 30 days. Figure 2-4 summarises the directed cardiac differentiation 
protocol. 
 
Figure 2-4: Timeline of the directed cardiac differentiation protocol 
 
2.3.3 Cardiomyocytes immunofluorescence 
For immunofluoresence analysis cardiomyocytes were plated on GFR-Matrigel (refer to 2.1.5.1 
for GFR-Matrigel preparation) pre-coated glass-bottomed dishes (MatTek Corporation). The 
medium was removed from the cardiomyocytes monolayers, the cells were rinsed once with 
DPBSCa2+/Mg2+ and then inbubated with 1 mL accutase for 10-15 min at 37˚C. The cells were 
then washed with DMEM, centrifuged at 1,000 x g for 5 min and resuspended in 200 µL/dish of 
RPMI-B27 supplemented with 10 µM Y-27632. They were then fixed with 3.7% PFA for 20 min 
at RT and washed three times with DPBSCa2+/Mg2+. Fixed cells were kept at 4°C in DPBSCa2+/Mg2+ 
for up five days if not processed immediately. Permeabilisation was effectuated with 0.1% Triton 
X-100/DPBSCa2+/Mg2+ for 10 min at RT, followed by three DPBSCa2+/Mg2+ washes. The samples 
were then blocked in PBS with 4% FBS for 2 h at RT. Without rinsing, the anti-Cardiac Troponin 
T antibody (Abcam, ab45932), developed in rabbit, was diluted in DPBSCa2+/Mg2+ to a final 
concentration of 5 µg/mL and added to the cells for 1 h at RT. The solution was then removed 
and cells washed 3 times for 5 min with DPBSCa2+/Mg2+ before adding Donkey anti-rabbit IgG, 
FITC-conjugated secondary (Jackson ImmunoResearch, 711-095-152) at 15 µg/mL in 
DPBSCa2+/Mg2+ for 40 min at RT, shilded from light. Cells were then washed three times for 5 min 
in DPBSCa2+/Mg2+, mounted in Vectashield mounting medium containing DAPI, and covered with 
a coverslip. Samples were assessed using Eclipse 50i upright epifluorescence microscope. 
Images were captured with cooled CCD camera Infinity 3 utilising Infinity Capture software and 
processed in Adobe Photoshop CS5. 
 
2.3.4 Quantitative PCR (qPCR) 
2.3.4.1 Total RNA preparation 
Total RNA was extracted using the RNeasy kit (Qiagen). The cell monolayer was rinsed once 
with PBS before the addition of 350 µL or 600 µL of buffer RLT (for < 5 x 106 or 5 x 106 – 1 x 107 
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cells respectively), supplemented with 10 µL/mL of $-ME to protect the sample from 
endogenous RNases (Frenkel et al., 1987). Samples were homogenised by vortexing for 1 min 
or by going through a QIAshredder spin column for 2 min at 8,000 x g. Equal volumes of 70% 
ethanol were added to the homogenised lysates before loading the samples in an RNeasy spin 
column placed in a collection tube. The columns were centrifuged at 8,000 x g for 15 s and the 
flow-through discarded. 350 µL of buffer RW1 was added and centrifuged at 8,000 x g for 15 s 
to wash the column. After discarding the flow-through, the samples were incubated for 15 min at 
RT with DNase I (27 Kunitz units final) in order to eliminate genomic DNA. Another 350 µL RW1 
wash and centrifugation for 15 s at 8,000 x g stopped the digestion, followed by two 500 µL 
RPE washes with 15 s and 2 min centrifugations at 16,000 x g. In order to prevent ethanol 
carryover, another centrifugation was performed for 1 min at 16,000 x g using an empty 
collection tube. To elute the purified total RNA, 30 µL of RNase-free water was added to the 
column and left to incubate for 1 min before a final 1 min centrifugation at 8,000 x g. RNA 
concentration and purity were determined using a Nanodrop ND1000 UV-Vis 
Spectrophotometer. RNA has a maximal absorbance (A) of 260 nm while proteins have a 
maximal A of 280 nm. Only samples with an A260/A280 ration between 1.8 and 2.1 were used 
for complementary DNA (cDNA) formation. Samples that were not used immediately were 
stored at -80°C. 
 
2.3.4.2 Complementary DNA (cDNA) preparation 
cDNA was prepared from 50 ng of total RNA using the Precision nanoScript Reverse 
Transcription kit (Primer design). Briefly, 0.5 µg of total RNA was mixed with 1 µL oligo-dT and 
brought to a final volume of 10 µL with RNase free water. The samples were heated at 65°C for 
5 min to denature any RNA secondary structures and then directly transferred on to ice to allow 
primer annealing. A 10 µL mastermix consisting of nanoscript 10x buffer, 0.5 mM 
deoxyribonucleotide triphosphate (dNTPs), 10 mM Dithiothreitol, water and 0.7 U/µL final"
reverse transcriptase was added to the samples before incubating them at 55°C for 20 min 
followed by a 15 min inactivation step at 75°C using a MyCycler Thermal Cycler (Bio-rad). 
cDNA samples were stored at -20°C until use. 
 
2.3.4.3 Primer design 
The primer sequences of the target genes used to characterise hESC-derived cardiomyocytes 
are presented in Table 2-10. Information concerning the housekeeping genes used to 
characterise hESC-derived cardiomyocytes are presented in Table 2-11. 
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Gene Accession number Sense Primer Anti-sense primer 
OTC3/4 NM_002701 GCCGTGAAGCTGGAGAAG GTGTATATCCCAGGGTGATCC 
NANOG NM_024865 ATGTCTTCTGCTGAGATGCC GTTGTTTGCCTTTGGGACTG 
TNNT2 NM_000364 CAAAGCCCAGGTCGTTCAT GCAACTCATTCAGGTCCCTTCT 
NKX2.5 NM_004387 GCACCCACCCGTATTTATGT GGGTCAACGCACTCTCTTTAA 
HTT NM_002111 TCTGGGCATCGCTATGGAAC ATTTCTGAGGCCGAACCAGG 
Table 2-10: Sense and Antisense primers of target genes used for hESC-derived 
cardiomyocytes characterisation.  







EIF4A2 NM_001967 900 113 
SDHA NM_004168 1032 120 
Table 2-11 Housekeeping genes designed and synthesized by PrimerDesign Ltd used for 
hESC-derived cardiomyocyte characterisation amplicon context.  
The primer sequences are commercially sensitive information but the details provided in this 
table are MIQE compliant (Bustin et al., 2011) 
 
2.3.4.4 qPCR 
qPCR was performed using the Precision 2X qPCR SYBR green-based Mastermix 
(PrimerDesign). As the cDNA is being amplified, SYBR green proportionally intercalates its 
fluorescent dyes in to the double stranded DNA, emitting fluorescence at the 522 nm 
wavelength. This can be measured by the apparatus and used to quantify gene expression. 
According to the manufacturer’s instruction, cDNA prepared as described in section 2.3.4.2 was 
diluted 1:10 in DNAse/RNAse free water prior to use. The components described in Table 2-12 
were added for each 20 µL qPCR reaction. 
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Components Per reaction 
Precision 2X qPCR Mastermix  10 µL 
Forward and Reverse Primers mix (6 mM stock) 1 µL 
Template cDNA (1:10 diluted) 5 µL 
DNAse/RNAse free water  4 µL 
Table 2-12: Components of each 20 µL qPCR reaction using the Precision 2x Mastermix 
from PrimerDesign Ltd. 
 
All samples were run in technical triplicates in 96-well hard shell white PCR plates (Bio-rad). No 
positive template controls were included. DNAse/RNAse free water was used instead of 
template cDNA as a negative control (refer to Table 2-12). The plate was sealed with a 
microseal adhesive sealer film (Bio-rad). The Bio-Rad CFX96 thermal cycler and accompanying 




Table 2-13 Cycling conditions used for qPCR reactions using the Bio-Rad CFX96 thermal  
 
Considering that SYBR green can bind to non-specific product amplicons or primer-dimers, a 
dissociation melt curves step was added to the thermocycling programme to ensure the 
accuracy of the PCR products analysed. Each PCR product has a particular temperature at 
which it becomes single-stranded and loses the SYBR green fluorescence, corresponding to a 
single peak in the melt-curve analysis.  
Once specific PCR amplification was insured, mRNA quantification could be done using the 
2%%Ct relative quantification method. In this method the difference in Ct (threshold cycle) value of 
genes of interest (GOI) and of housekeeping (HK) genes is first calculated to generate the %Ct 
value. Next, the control-condition %Ct (undifferentiated hESCs) is subtracted from the 
experimental-condition %Ct (differentiated hESCs) to yield the %%Ct value. The negative value 
of this subtraction, the )%%Ct, is then used as the exponent of 2 to calculate the “corrected” 
expression level of the samples. The newly calculated expression value of the control-condition 
Step Temperature Time 
Enzyme activation - HotStart 95ºC 10 
min 
Denaturation 95ºC 15 s 
Data collection 60ºC 30 s 
Melt Curve 59ºC to 95ºC with 0.5ºC increment 10 s 
   
X 40  
cycles 
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was set to 1, and the experimental-conditions’ expression levels were normalised by dividing 
the mean 2%%Ct value by the control-condition mean 2-%%Ct value. 
2.3.4.5 Cardiomyocyte-specific biomarker gene expression 
The Human Cardiomyocyte Differentiation qBiomarker PCR Array (IPHS-102, Qiagen) was 
used to determine the gene expression of cardiomyocyte-specific biomarkers. For this, cDNA 
was synthesized using the RT2 First Strand Kit (Qiagen). The kit includes a genomic DNA 
elimination step (GE). This was performed by mixing 0.5 µg of total RNA with 2 µL of buffer GE 
and water to a final volume of 10 µL. The GE mix was incubated at 42ºC for 5 min after which it 
was immediately put on ice for at least 1 min. The reverse transcription mix was prepared as 
described in Table 2-14 and added to the GE mix. 
 
Component Volume 
BC3 (5X buffer 3) 4 µL 
P2 (primer and external control mix) 1 µL 
RE3 (RT enzyme mix 3) 2 µL 
H2O 3 µL 
Final volume 10 µL 
Table 2-14: Qiagen RT2 First Strand Kit reverse transcription mix (one reaction). 
 
The reverse transcription synthesis was performed by incubating the mix at 42ºC for 15 min, 
immediately followed by an incubation at 95ºC for 5 min. The cDNA was diluted 1:5, mixed with 
RT2 Real Time SYBR® Green/ROXTM qPCR Master Mix (Qiagen) and added to the Human 
Cardiomyocyte Differentiation qBiomarker PCR Array. The array was then loaded in a 7900HT 
Fast Real-Time PCR System (Applied Biosystem). Results were analysed using the web-based 
Qiagen qBiomarker iPSC Data Analysis Software. 
 









Chapter 3 hESC PLURIPOTENCY CHARACTERISATION 
- 81 - 
Chapter 3  hESC Pluripotency Characterisation 
 
Pluripotent hESCs have distinct characteristics. When undifferentiated, they grow as uniform, 
tightly packed colonies with defined edges. They present a large nucleus and a high nucleus to 
cytoplasm ratio. hESCs have the ability to self-renew into the same cell type, provided that they 
are maintained in the correct culture conditions. They also express an array of specific 
“pluripotency markers” and importantly, have the ability to differentiate into any of the three 
germ layers: endoderm, mesoderm and ectoderm (Thomson et al., 1998). The cell lines used in 
this study were characterised using a set of seven criteria as we previously published 
(Stephenson et al., 2012; methods described in section 2.1.8). An “identification card” could 
then be generated for each hESC line. Once the hESC lines were characterised, they could be 
adapted to feeder-free culture conditions for downstream applications.  
 
 
3.1 hESC Pluripotency Characterisation 
Most of the hESC lines used in this study were characterised following seven criteria. A 
representative characterisation set of five out of seven criteria is presented in Figure 3-1. 
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Figure 3-1: Representative hESC characterisation.  
The characterisation set of HD-hESC KCL012_HD3 is presented in this figure. a) Morphological 
criteria. Initial outgrowth (left), KCL012_HD3 cell colony on HFF (middle) and feeder-free 
condition (right). b) Pluripotency markers: alkaline phosphatase (AP) activity, OCT4, NANOG, 
TRA-1–60 and TRA-1–81. c) Genotyping: microsatellite markers specific for chromosomes 13, 
18, 21, X and Y were amplified. The allele sizes in base pair for markers on chromosomes 13, 
18, and 21 are listed in the table. Array comparative genomic hybridization (CGH) did not detect 
any copy number changes using Promega female G1521 as a standard. d) In vitro 
differentiation markers for the three germ layers: smooth muscle actin (mesoderm), $-III tubulin 
(ectoderm) and (-fetoprotein (endoderm). e) In vivo differentiation. Teratoma sections were 
counterstained with hematoxylin and eosin and specific stains are either light blue (Alcian blue) 
or brown (all immunohistochemistry). Mesoderm germ layer markers: Alcian blue– and periodic 
acid–Schiff (PAS)-stained cartilage and desmin. Ectoderm germ layer markers: $-III tubulin and 
glial fibrillary acidic protein (GFAP). Endoderm germ layer marker: GATA4 and (-fetoprotein. 
Positive immunostaining for complex IV type II marker confirms the human origin of the tumour 
(adjacent section of the one stained for desmin). Images were taken at 40x magnification. 
 
1) Morphological criteria: Undifferentiated hESCs form tightly packed colonies with well-
defined edges and are clear from differentiated cells, as represented in Panel a. hESCs were 
considered to be adapted to a new culture condition when they could be propagated 
undifferentiated under said culture condition for a minimum of three passages. 
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2) Detection of pluripotency marker: Pluripotency was evaluated by immunofluorescence 
detection of two pluripotency transcription factors, NANOG and OCT3/4, and two pluripotency 
surface markers, TRA-1-60 and TRA-1-81; as well as by AP enzymatic activity as showed in 
Panel b. 
3) Differentiation into three germ layers in vitro:  hESCs colonies were differentiated in vitro 
for a period of three weeks before performing immunofluorescence to detect markers 
representative of the three germ layers such as (-fetoprotein and/or GATA4 for endoderm, 
smooth muscle actin and/or Brachyury T for mesoderm and $-III tubulin and/or PAX6 for 
ectoderm as showed in Panel d. 
4) Differentiation into three germ layers in vivo: hESCs were injected subcutaneously into 
NOD/SCID mice and tumours were harvested 6–12 weeks post injection. Tumour sections were 
stained with hematoxylin and eosin (H&E) as well as stained by immunohistochemistry to 
confirm the presence of the three germ layers and its human specificity as showed in Panel e. 
5) Genotyping: Each cell line was identified at the molecular level after derivation. For this, 
DNA Fingerprinting by the amplification 17 polymorphic microsatellite markers on chromosomes 
13, 18 and 21 was used. A result example is presented in Panel c. 
6) Determination of genomic stability: Genomic stability was confirmed by the absence of 
chromosomal abnormalities such as deletion or duplications as well as abnormal karyotyping. 
This was assessed at the time of derivation and after 10-20 passages by array-comparative 
genomic hybridization. KCL040 presented a microdeletion at q13.2 of chromosome 5 at 
passage 4 and KCL027_HD5 showed a microdeletion in the long arm of chromosome 2 at 
passage 18. However these were considered as not significant as they are normal population 
polymorphisms. However, KCL013_HD4 showed the addition of a whole chromosome 12 at 
passage 12 and was dismissed from the rest of this study.  
7) Human leukocyte antigen (HLA) typing: HLA typing was performed for HLA-A, -B, -C, and 
DRB1. Results were entered into the MatchView1 database (Be the Match Registry, 
http://marrow.org/Patient/Transplant_Process/Search_Process/View_Potential_Matches/View_
Potential_Matches.aspx, Accessed 17 May 2012) to determine the match level frequency in the 
population. 
In addition to these seven characterisation criteria, the HD-hESCs had their CAG repeat 
number determined. The representative repeat sizing of KCL012_HD3 is presented in Figure 
3-2. 
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Figure 3-2: CAG repeat sizing of KCL012_HD3.  
Repeat sizes were of 17 and 46 CAGs. 
 
A summary of the remaining hESC lines’ characterisation is presented in Table 3-1 and 
additional figures are in appendix I. 
Chapter 3 hESC PLURIPOTENCY CHARACTERISATION 








































+ + + + + + + + + 
M
orphology 
+ + + + + + + + + 
Pluripotency 
















+ + + + + + + + + 
G
enotyping 









Table 3-1: Summary of the hESC characterisation.  
+: Positive result, -; negative result, ND: non-determined. 
Chapter 3 hESC PLURIPOTENCY CHARACTERISATION 
- 86 - 
3.2 Adaptation of hESCs to feeder-free culture 
Feeder cells such as mitotically-inactivated HFF are commonly used to support the derivation 
and long-term maintenance of pluripotent stem cells. The hESCs lines used in this study are no 
exception. HFF-feeders maintain the pluripotent state of hESCs by notably secreting bFGF 
(Park et al., 2011) as well as other unknown growth factors and cytokines. Feeders also 
assemble ECM, a required physical support for hESCs to attach and grow. One goal when 
using hESCs as disease-in-a-dish models is to differentiate them into a specific somatic cell 
type, such as cardiomyocytes, that is affected by the disease. There are a variety of protocols 
describing hESCs differentiation. However, in order to obtain a sufficient yield of differentiated 
cells, large-scale hESCs culture is needed to start with. This is not achievable when cultured on 
feeders, as manual passaging is required. Furthermore, as much as feeder-free culture is 
required in order to obtain enough hESCs for differentiation purposes, it is absolutely essential 
when it comes to the study of a disease-specific phenotype. Indeed, the presence of feeder 
cells could cloud the apparent effects of drugs, small molecules and genetic modifications 
specific to a disease. For these reasons, all the hESCs lines used in this study were adapted to 
feeder-free culture conditions. Two different matrices were tested for this purpose: i) A 
commercially available matrix, GFR-Matrigel (refer to section 2.1.5.1 for preparation) and ii) 
custom made ECM from decellularised feeders from two different protocols (refer to section 
2.1.5.2 for preparation). 
Matrigel is a gelatinous substance secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma 
cells. It is composed of a complex mixture of laminin, collagen IV and heparan sulfate 
proteoglycan (Xu et al., 2001; Kleinman et al., 1982). When diluted and allowed to polymerize, it 
can form a matrix that allows the long-term (# 130 population doublings) feeder-free culture of 
undifferentiated, karyotypically normal, hESCs. Moreover, it allows the hESCs to maintain their 
capacity to differentiate into the three germ layers (Xu et al., 2001). Matrigel also has the 
advantage of being commercially available and very rapid to prepare (#1 h). However, matrices 
generated with Matrigel contain animal products and could lack the endogenous 3 dimensional 
(3D) structure provided by HFF-feeders. For this reason, we also trialed custom made ECM 
from decellularised human fibroblasts. Several decellularisation protocols exist (Beacham et al., 
2007; Vlodavsky, 2001; Klimanskaya et al., 2005) and such decellularised feeder matrices have 
already been successfully used for hESC derivation and culture (Klimanskaya et al., 2005). 
 
3.2.1 Comparison of two protocols for generating decellularised feeders 
In order to obtain an ECM assembled by HFF with optimally preserved 3D structures, two 
protocols were compared in an initial set of experiments. One protocol contained an anionic 
detergent, DOC, and the other one Triton X-100, which is a non-ionic detergent.  
Figure 3-3 demonstrates the presence of fibronectin as an ECM component secreted by 
fibroblasts. To confirm that the cell removal process preserved intact ECM, the decellularised 
feeder matrices were immunostained for fibronectin (Figure 3-4). The staining revealed that 
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both protocols are equivalent in terms of decellularisation as no cell nuclei can be observed 
(negative DAPI staining). However, the DOC protocol left intact mostly high molecular weight 
fibronectin aggregates (arrowheads), whereas the Triton X-100 protocol was gentler and both 
high molecular weight fibronectin aggregates as well as numerous fine fibronectin fibrils 
(arrows) could be seen. According to these results, it was decided that future decellularised 
feeders matrix would only be prepared according to the Triton X-100 protocol as it keeps a 
better integrity of the ECM and from now on, the term decellularised feeder matrix will only refer 
to ECM prepared as such. 
 
Figure 3-3: HFF-generated ECM immunostaining prior to decellularisation.  
Fibronectin (red) and DAPI staining (blue). Images were taken at 40x magnification (Previously 







Figure 3-4: Decellularised feeder fibronectin immunostaining.  
Decellularised feeder matrices made using DOC (left) and Triton X-100 (right) were 
immunostained for fibronectin (red). Images were taken at 100x magnification. In the insets, 
arrowheads indicate high molecular weight fibronectin aggregates and arrows indicate fine 
fibronectin fibrils. DAPI negative result indicates complete decellularisation. 
 
Intact HFF 
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3.2.2 Comparison of two defined media for hESCs feeder-free culture 
We trialled two defined hESC culture media, complete KOSR-XF medium and mTeSR1, in 
combination with GFR-Matrigel or decellularised feeder matrices for hESC feeder-free culture, 
making a total of four feeder-free culture condition to test. They are summarised in Table 3-2. 
 
Medium Complete KOSR-XF mTeSR1 
Decellularised feeder matrix Decellularised feeder matrix Matrix 
GFR-Matrigel GFR-Matrigel 
Table 3-2: Summary of the feeder-free culture conditions tested on the hESCs 
 
As mentioned in section 3.1, we considered that a hESC line is adapted to a new culture 
condition when propagated undifferentiated for over three passages under said condition. 
Maintenance hESC pluripotency was assessed by the following morphological criteria: i) well-
defined colony edges; ii) tightly packed colonies and iii) absence of differentiated cells. The 
results are presented in Table 3-3. 
 
Complete KOSR-XF mTeSR1  








Propagation for >3 
passages in a 
culture condition 
- - + + 
Well defined colony 
edges 
+/- +/- + + 
Tightly packed 
colony 
+/- +/- + + 
Absence of 
differentiated cells 
+/- +/- + + 
Table 3-3: Comparison of hESCs culture on different feeder-free conditions.  
+ = positive ; - = negative ; +/- = intermediate. 
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Complete KOSR-XF medium did not support the propagation of hESCs for over three passages 
on decellularised feeder matrix or on GFR-Matrigel. On the contrary, mTeSR1 allowed hESCs 
feeder-free propagation on both matrices for over three passages. hESC colonies remained 
positive for morphological criteria characteristic of undifferentiated hESCs (Figure 3-5). They 
were also positive for pluripotency markers as illustrated by immunostaining in Figure 3-6 and 
Figure 3-7. 
 
Figure 3-5: Undifferentiated KCL012_HD3 P14 cultured for five passages on GFR-Matrigel 
with mTeSR1 medium.  
The image was taken at 40x magnification. 
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Figure 3-6 KCL012_HD3 P13 pluripotency on GFR-Matrigel in mTeSR1 medium.  
All images were taken at 100x magnification. 
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Figure 3-7: KCL012_HD3 P14 pluripotency on decellularised feeder matrix in mTeSR1 
medium.  
All images were taken at 100x magnification. 
 
Once cultured feeder-free, enzymatic passaging of the hESCs with dispase was attempted. 
Only the mTeSR1/GFR-Matrigel feeder-free culture condition allowed enzymatic passaging. 




In this set of experiments, we investigated whether KCL012_HD3, KCL020, KCL031, KCL034, 
KCL027_HD5, KCL028_HD6, KCL036_HD7 and KCL040, the eight hESCs lines derived at the 
ACU, King’s College London used in this study would fulfil the two main hESC characteristics: i) 
indefinite self-renewal and ii) differentiation in all three germ layers. In order to demonstrate this, 
the hESCs lines, were first tested for the presence of pluripotency markers in undifferentiated 
hESCs and then subjected to differentiation in vitro and in vivo. All eight hESC lines used in this 
study fulfilled these criteria. 
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We also followed genomic stability of each cell lines over an extended period of culture. They all 
presented a normal karyotype upon derivation. However, KCL013_HD4 acquired an extra 
chromosome 12 over time and was thus removed from the study to prevent any biased future 
observation. Genomic instability in pluripotent stem cell culture, especially feeder-free, has been 
extensively discussed (Maitra et al., 2005; Amps et al., 2011; Lefort et al., 2008). Chromosome 
12 aneuploidy in particular has been suggested to provide a selective growth advantage 
(Catalina et al., 2008; Mayshar et al., 2010; Lefort et al., 2008; Draper et al., 2004). 
Prior to any differentiation work, the eight hESCs lines used in this study had to be adapted to 
feeder-free culture conditions as well as enzymatic passaging. Indeed, a differentiation protocol 
such as Laflamme’s cardiogenesis one, requires high undifferentiated hESCs cell numbers to 
begin with (2-4 x 105 cells / cm2) (Laflamme et al., 2007). A feeder-free culture condition with 
enzymatic passaging allows reaching such numbers in a considerably shorter-time. For this, two 
matrices, HFF-feeder-derived ECM from decellularised feeders and GFR-Matrigel, as well as 
two media, complete KOSR-XF medium and mTeSR1, were tested. It was first determined by 
morphological assessment that in our hands, mTeSR1 was the best medium for feeder-free 
culture with either matrix. 
In addition to the ones tested in this study, there are many other feeder-free matrices available 
for hESC feeder-free culture. Human serum matrix has been shown to support undifferentiated 
hESC culture for over three months when used in combination with medium conditioned by 
hESC-derived fibroblast-like cells (Stojkovic et al., 2005). ECM from human placenta, rich in 
collagen IV, laminin and fibronectin, has also been used for feeder-free hESC culture (Wang, Q. 
et al., 2012). ). Many ECM components of GFR-Matrigel and decellularised feeders e.g. laminin, 
fibronectin and vitronectin, can be used as individual ECM proteins to support feeder-free hESC 
culture. These are attractive as they are fully defined and can offer less batch-to-batch 
variability. Laminin can be used as a matrix when used in combination with high concentrations 
of bFGF (Li, Y. et al., 2005). Amit et al. (2004) cultured hESCs on 2D layers of fibronectin for 
over 50 passages when used with a medium containing KOSR, bFGF, TGF-$ and leukemia 
inhibitory factor LIF. Cells interact with their matrices via integrins. Vitronectin (Braam et al., 
2008; Kim, H.T. et al., 2013), E-cadherin (Nagaoka et al., 2010) and collagen I (Furue et al., 
2008) are also matrices supporting long-term feeder-free culture. Some groups have now 
moved on from biological components to fully chemically defined synthetic matrices (Irwin et al., 
2011; Melkoumian et al., 2010), which could in the long term be cheaper and better for up-
scaling hESC cultures. Another alternative is to completely bypass a 2D or 3D adherent cell 
culture system and culture the hESCs in suspension. Using mTeSR1 medium supplemented 
with Y-27632, Rho-associated kinase (ROCK) I inhibitor, hESC suspension culture has been 
shown to be efficient for long-term (over 20 passages) hESC feeder-free maintenance (Olmer et 
al., 2010). The cells retained pluripotency and their ability to differentiate into the three germ 
layers. Interestingly, the hESCs cultured in suspension had a higher proliferation rate than cells 
cultured on feeder or on 2D-feeder-free matrices. This is attractive for the upscaling required by 
some differentiation protocols. 
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The eight hESC lines used in this study all had satisfactory undifferentiated morphologies when 
cultured in mTeSR1 with either GFR-Matrigel or decellularised feeder matrix. The pluripotency 
of the hESCs was nevertheless further confirmed by immunostaining for NANOG, OCT3/4, 
TRA-1-60 and TRA-1-81 (Figure 3-6 and Figure 3-7). The results were positive and support a 
previous comparative study that demonstrated that hESCs cultured feeder-free have a similar 
global gene expression pattern as hESCs cultured on feeders (Yoon et al., 2010). In our hand, 
enzymatic passaging with dispase was only possible with the mTeSR1/GFR-Matrigel culture 
condition. This latter feeder-free culture condition was therefore used for the rest of this study. 
This is consistent with the International Stem Cell Initiative Consortium’s results of a multicentre 
study that concluded that mTeSR1 used with Matrigel as a matrix and dispase for enzymatic 
passaging is one of the best combinations to support maintenance of most undifferentiated 
hESC lines (Akopian et al., 2010). 
This set of experiments confirms that the hESCs used in this study, whether wild-type of HD-
specific, are i) pluripotent and ii) can be maintained in feeder-free culture conditions with 
enzymatic passaging, which is essential for up-scaling to obtain the large numbers of cells 
required for lineage specific differentiation. 
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Chapter 4 Induced Pluripotent Stem Cell Generation 
 
The use of synthetic modified mRNA for fibroblast cell reprogramming resulted in a twice as 
fast, 36-fold higher reprogramming efficiency than retroviral reprogramming (Warren et al., 
2010). This method also presents the advantage of being non-integrative, meaning that the 
cells’ genome will not be altered. 
In this chapter are presented the repetition of the original Warren protocol (Warren et al., 2010) 
on fibroblasts and HF-keratinocytes. When using retroviral vectors, HF-keratinocytes have been 
showed to reprogram 100 fold more efficiently and twofold faster than fibroblasts (Aasen et al., 
2008). It was hypothesized that combining HF-keratinocytes as a somatic cell source and 
synthetic modified mRNA as a delivery vector would result in a very efficient and rapid iPSC 
generation protocol. Furthermore, HF-keratinocytes are an easily accessible source of somatic 
cells. Hair plucking is a non-invasive and non-painful procedure, two important aspects when 
collecting patient samples. The original mRNA reprogramming protocol could not generate 
iPSCs in either cell type. It was later modified and allowed the successful reprogramming of the 
BJ fibroblast cells. 
 
 
4.1 Fibroblast reprogramming with synthetic modified mRNA 
4.1.1 Original mRNA reprogramming protocol (Warren et al., 2010) 
We first tested fibroblast reprogramming with synthetic modified mRNA on HFFs, which will be 
referred to as target cells. To do so, we plated 0.5 x 105 target cells on a layer of 1 x 105 HFF-
feeders and transfected daily with mRNA reprogramming cocktail using RNAimax, a 
lipofectamine transfection reagent. The mRNA cocktail contains low-stability GFP (d2eGFP) 
mRNA, rendered nuclear with a 3’ nuclear localisation sequence, for monitoring transfection 
efficiency. As indicated in the original mRNA reprogramming protocol (Warren et al., 2010). 
Nutristem, a reprogramming medium, and 200 ng/mL of B18R, an interferon inhibitor, were 
included in the protocol. These conditions, however, did not support HFF reprogramming in our 
hands. Despite good transfection efficiency shown by uniform d2eGFP expression (data not 
shown), no mesenchymal-epithelial transition (MET) was observed. The experiment was 
terminated at day 15, as the cells survival was too low. It is worth noticing that even the cells 
that endured a 15 days mock transfection regimen (all the reagents but the mRNA) also had 
high cell death by day 15 (Figure 4-1). Lipofectamine had previously been reported to be of high 
efficiency and low toxicity. However, this was when used for two consecutive transfections, not 
17 as required by this protocol (Zhao, M. et al., 2008). 
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Figure 4-1: Human Foreskin Fibroblast at day 1 and 15 of the Warren (2010) mRNA 
reprogramming protocol.  
On the far right are presented fibroblasts after 15 mock transfections (no mRNA). Images were 
taken at 40x magnification. 
 
In this first experiment, we used three-times less HFF-feeders than in the original publication, 
which could be a factor contributing to the high cell death observed. In the second round of 
experiments, the number of feeders was increased to 3 x 105 cells/well of a 6-well dish, as 
outlined in the original protocol. Furthermore, different target cell densities ranging from 0.5-1.5 
x 105 cells/well were evaluated. Reprogramming was still unsuccessful due to great cell death. 
Valproic Acid (VPA), a Histone Deacetylase (HDAC) inhibitor, was reported to greatly increase 
fibroblast reprogramming (Huangfu et al., 2008). Therefore, on our subsequent mRNA 
reprogramming experiment, we supplemented the reprogramming medium with 1 mM of VPA 
as from day five of the reprogramming protocol. In our hands, VPA did not improve 
reprogramming efficiency. No MET could be observed and the protocol had to be discontinued 
due to high cell death within 15 days of reprogramming. Even though VPA has been 
demonstrated to improve fibroblast reprogramming (Huangfu et al., 2008), possibly by 
increasing protein production (Wulhfard et al., 2010), VPA can also inhibit clonal cell 
proliferation and increase apoptosis even when used at doses lower than the one used in this 
protocol (Takai et al., 2004; Fujiki et al., 2013; Fortson et al., 2011). 
These results are in agreement with Warren’s who trialled adding VPA to the mRNA 
reprogramming regimen and did not observe an increased reprogramming efficiency either. 
 
4.1.2 Modified mRNA reprogramming protocol 
During the course of this study, Stemgent started commercialising an mRNA reprogramming kit 
with a protocol that contained substantial modifications to the original published one. 
Modifications included: i) a lower target cells plating density, ii) a new reprogramming medium, 
iii) the use of conditioned-medium as from day 6 of the reprogramming protocol, iv) a different 
source and density of feeder cells and v) the elimination of the passaging step during the 
reprogramming protocol. 
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We took these changes into account in the next round of mRNA reprogramming protocol 
optimisation. Therefore, the target cell density was decreased from 0.5 x 105 cells / well of a 6-
well plate to 7 x 103 per well of a 6-well plate. NuFF feeders from donor 11 were used instead of 
our regular HFF-feeders. Pluriton cell culture medium was used instead of Nutristem and NuFF-
conditioned Pluriton was used from day 6 of the reprogramming protocol. Due to the high cell 
loss experienced previously, B18R concentration was increased from 200 ng/mL to 300 ng/mL. 
This was to further suppress the innate immune response triggered by the exogenous mRNA 
cocktail, which in turn would be beneficial for the cells to resist the consecutive transfections 
required by our protocol (Angel and Yanik, 2010). Furthermore, the cells were incubated with 
the B18R 4 h prior to the first transfection in order to condition the cells. Our last variation to the 
protocol was to add 0.5 mM final of Sodium Butyrate (NaBu) as from day 6 of the mRNA 
reprogramming protocol, with or without 1 µM of pifithrin-( (PTA-() from day 2 of the mRNA 
reprogramming protocol. NaBu is an HDAC inhibitor which when used at 0.5 mM, can not only 
improve cell reprogramming, but do so at a greater efficiency than VPA (Zhang, Z. et al., 2011). 
p53 negatively regulates somatic cell reprogramming, notably by its pro-apoptotic role. 
Transiently inhibiting it with an inhibitor such as PTA-( can increase iPSC generation by up to 
four folds (Hong et al., 2009; Kawamura et al., 2009; Zhao, Y. et al., 2008; Marion et al., 2009). 
A summary of the modifications is presented in Table 4-1. 
Procedure Warren et al.(2010) Modified protocol 
Feeder cell density 
3 x 105 cells/well of 6-well 
dish 
2.5 x 105 cells/well 
Target cell density 5-30 x 104 cells/well 7 x 103 cells/well 
Reprogramming medium 
Nutristem with 
100 ng/mL bFGF 
Pluriton with 1X Pluriton 
supplement 
Use of conditioned 
medium 
No Yes, as from day 6 
B18R concentration 200 ng/mL 300 ng/mL 
Sodium butyrate (NaBu) 
concentration 
0 0.5 mM 
Pifithrin-( (PTA-() 
concentration 
0 1 µM from day 2 (optional) 
Table 4-1: Summary of the differences between the original Warren et al. (2010) mRNA 
reprogramming protocol and our modified one. 
 
The modified protocol allowed the reprogramming of BJ fibroblasts into iPSCs using mRNA 
reprogramming cocktail. The cells were monitored daily for morphological changes and d2eGFP 
expression. The reprogramming experiments are presented in Figure 4-2 and Figure 4-3. 
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Figure 4-2: Representative morphology of BJ fibroblasts plated on NuFF-feeders 
undergoing mRNA reprogramming with daily transfections and NaBu treatment. 
Images were taken at 40x magnification. Day 1: Healthy cells after the first transfection. Day 3: 
Cell loss and cell rounding, a pre-apoptotic sign (arrows) can be observed. Day 5: Cells start 
undergoing MET and adopt an epithelial morphology (arrows) Day 7 and 9: Increase in cell 
death. Surviving cells are transitioning. Day 11: First sign of compaction and colony formation 
(arrow). Day 13: Increased compaction. Cells become smaller and more hESC-like (arrow). Day 
15. Increase in colony size (arrow). Day 17: Last transfection. Note that only reprogrammed 
cells survived all 17 transfections and keep increasing in colony size. Day 19: Cells are fed with 
NuFF-conditioned Pluriton. Colony center (arrow) keeps compacting as cells continue to 
reprogram and adopt a stem cell morphology. Day 20: The colony center is ready for picking 
and being plated on HFF-feeders in complete KOSR medium. 2 days after plating: All the 
colonies plated have attached and can be left to expand. 
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Figure 4-3: Representative morphology of BJ fibroblasts plated on NuFF-feeders 
undergoing mRNA reprogramming with daily transfections and NaBu and PTA-! 
treatment.  
Images were taken at 40x magnification. Day 1: Healthy cells after the first transfection. Day 3: 
Cell loss and cell rounding, a pre-apoptotic sign (arrow) can be observed. Day 5: Cells start 
undergoing MET and adopt an epithelial morphology (arrows) Day 7 and 9: Increase in cell 
death. Surviving cells are transitioning. Day 11: First sign of compaction and colony formation 
(arrow). Day 13: Increased compaction. Cells become smaller and more hESC-like (arrows). 
Day 15. Increase in colony size (arrows). Day 17: Last transfection. Colonies are compact and 
increase in size. Day 19: Cells are fed with NuFF-conditioned Pluriton. Colony center (arrow) 
keeps compacting as cells continue to reprogram and adopt a hESC-like morphology. Day 20: 
Colonies are very big with defined edges (white arrow heads). Colony center (asterix) is ready 
for picking and being plated on HFF-feeders in complete KOSR medium. 2 days after plating: 
All the colonies plated have attached and can be left to expand (arrow). 
 
Chapter 4 INDUCED PLURIPOTENT STEM CELL GENERATION 
- 100 - 
The modified mRNA reprogramming protocol successfully gave rise to iPSC colonies. Good 
d2eGFP, representing good transfection efficiency, could be observed throughout the 
reprogramming experiments (data not shown). Less cell death was observed in the presence of 
PTA-( (Figure 4-2), and the emerging colonies were more compact and easier to pick. 
Reprogramming efficiency was greater in the presence of 1 'M PTA-( (0.86% vs. 0.66%, 
illustrated in Figure 4-4). Nevertheless, this was still lower than the 4% efficiency reported by 
Warren et al. (2010). 
 
 
Figure 4-4 Trypan blue staining of colonies formed in the presence or absence of 1 "M 
PTA-α in one well of 6-well plate and an average reprogramming efficiency from two 
independent experiments. 
Good d2eGFP could be observed throughout the reprogramming experiments (data not shown). 
Less cell death was observed in the presence of PTA-(, and the emerging colonies were more 
compact and easier to pick. Reprogramming efficiency seemed greater in the presence of PTA-
(. However, by day 20 of the reprogramming protocols, the iPSC colonies were big and merged 
together. A final number of iPSC colonies could not be determined. Regardless, iPSC colonies 
from both treatment groups could successfully be plated in our regular hESCs culture conditions 
(i.e. on HFF-feeders in complete KOSR medium). The cells attached and expanded well. Upon 
passaging on HFF-feeders, they maintained typical undifferentiated hESC morphology and 
presented with typical hESC morphology (Figure 4-5). 
 
Figure 4-5: iKCL004 and iKCL011 colonies cultured in complete KOSR medium on HFF-
feeders.  
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iKCL004 P2 (left) and iKCL011 P2 (right). The cells have typical hESC morphology. Images 
were taken at 40x magnification. 
 
 
4.2 Adaptation of iPSCs to feeder-free culture conditions. 
Two iPSC lines with similar population doublings were selected for characterisation, iKCL004 
and iKCL011. The former was reprogrammed with NaBu treatment only and the latter was 
reprogrammed with both NaBu and PTA-( treatments. Both iPSC lines were successfully 
adapted to feeder-free culture conditions (GFR-Matrigel / mTeSR1) as illustrated in Figure 4-6. 
No differences in morphology or proliferation rate could be observed between the cell lines. 
 
Figure 4-6: iKCL004 P11 and iKCL011 P11 iPSCs lines cultured feeder-free on GFR-
Matrigel with mTeSR1 medium.  




4.3 iPSCs characterisation 
4.3.1 Pluripotency characterisation 
The two chosen iPSC lines, iKCL004 and iKCL011, were characterised by following the 
methods described in section 2.1.9 according to five criteria: i) morphological criteria, ii) 
detection of pluripotency markers: alkaline phosphatase activity, OCT4, NANOG, TRA-1-60 and 
TRA-1-8, iii) differentiation into three germ layers in vivo, iv) genotyping, v) determination of 
genomic stability. HLA typing was omitted since the cell lines will be used for research only and 
not clinically. The morphological criteria were met for both lines as the cells presented with an 
hESC-like undifferentiated morphology (Figure 4-5 and Figure 4-6). The pluripotency 
characterisation and teratoma formation results for iKCL004 are presented in Figure 4-7 and 
Figure 4-8 respectively and the pluripotency characterisation and teratoma formation results for 
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iKCL011 are presented in Figure 4-9 and Figure 4-10 respectively. The positive results confirm 
that the iPSCs derived from the BJ cell line using the modified mRNA reprogramming protocol. 
iPSCs generated with or without p53 inhibition are equally pluripotent and express the same in 
vitro pluripotency markers as the hESCs used in this study. Similarly to our hESC lines, both 
iPSC lines also have the ability to differentiate in vivo into the three germ layers. 
 
 
Figure 4-7: iKCL004 cultured on GFR-Matrigel with mTeSR1 pluripotency 
characterisation.  
All images were taken at 40x magnification. 
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Figure 4-8: iKCL004 Teratoma characterisation  
Histological images were taken at 40x magnification. 
 
 
Figure 4-9: iKCL011 cultured on GFR-Matrigel with mTeSR1 pluripotency 
characterisation.  
All images were taken at 40x magnification. 
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Figure 4-10: iKCL011 teratoma characterisation.  
Histological images were taken at 40x magnification. 
 
4.3.2 DNA Fingerprinting 
We confirmed that the two preferred iPSC lines, iKCL004 and iKCL011 were derived from the 
BJ somatic donor cells with DNA fingerprinting. Results are presented in Table 4-2. 
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Table 4-2: DNA fingerprinting results for the BJ somatic fibroblast cell line and the 
iKCL004 and iKCL011 iPSC lines derived from it.  
The occasional 1bp size difference is due to the size differentiation by capillary electrophoresis. 
 
 
4.4 Keratinocyte-derived iPSCs generation using synthetic modified 
mRNA 
4.4.1 Keratinocytes derivation and culture 
As mentioned previously, the target HD somatic cells for iPSC reprogramming were HF-
keratinocytes. Firstly, HF-keratinocytes derivation and culture were optimised from the Aasen 
protocol (Aasen et al., 2008) on samples from healthy donors. After taking patient consent, hairs 
were plucked and only hair follicles with a visible ORS, and indication of being in the 
proliferative anagene phase (Alonso and Fuchs, 2006), were kept. The adapted protocol 
(described in 2.2.3) allowed good HF-keratinocyte derivation and culture. Positive 
immunostaining for Keratin 14 (K14), a basal epithelial keratinocyte marker. confirmed that the 
cells migrating out of the ORS are keratinocytes (Figure 4-11). 
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Figure 4-11: Keratinocyte keratin 14 immunostaining.  
Keratin 14 (red) and Hoechst (blue) staining of hair follicle-derived keratinocytes. Image was 
taken at 40x magnification. Inset image is 400x magnification. 
 
 
4.4.2 HD Patients keratinocyte sample collection 
Patient hair sample collection was performed in the same way as for healthy individuals. 
However, there was a great variability in the quality of the samples collected and the 
subsequent good isolation and culture of the HF-keratinocytes. No HD-patient HF-keratinocytes 
culture could be expanded in sufficient number to allow mRNA reprogramming (Table 4-3). 
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Table 4-1 Repertory of the patient samples collected for this study.  
CAG corresponds to the CAG repeat number of HTT. 
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4.4.3 Keratinocytes reprogramming with synthetic modified mRNA 
4.4.3.1 Original Warren et al. (2010) mRNA reprogramming protocol 
Even though it was not possible to attempt reprogramming HD keratinocytes due to insufficient 
cell number derivation (Table 4-3) we tried the original Warren protocol on HF-keratinocytes 
isolated from healthy individuals. To do so, 0.6–1 x 105 HF-keratinocytes were plated on 3 x 105 
HFF-feeders/well of a 6-well dish and the cells were transfected daily with the mRNA 
reprogramming cocktail. As for the fibroblasts, excessive cell loss rapidly occurred no colony 
formation was observed. The experiments were terminated at day 15, without generating iPSCs 
(Figure 4-12). 
 
Figure 4-12: Representative morphology of healthy HF-keratinocytes plated on HFF-
feeders undergoing mRNA reprogramming with daily transfections.  
Images were taken at 40x magnification. After cell plating: Healthy HF-keratinocytes (black 
arrow) on an HFF-feeder layer. Day 1: Healthy HF-keratinocytes after the first transfection 
(black arrow). Day 3: Cell rounding, a pre-apoptotic sign (white arrows) can be observed. Day 
5: Overall cell loss is observed. Day 7: Excessive cell loss observed. Areas indicated by the 
white asterisks are completely depleted from cells. Day 9: No improvement and no signs of 
cells starting to reprogram. Day 11: Only a few HF-keratinocytes (black arrow) can be observed 
in culture. Their morphology indicates that they are not reprogramming. Day 13: No more 
healthy cells left in culture. The experiment was terminated at day 15. 
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4.4.3.2 Modified mRNA reprogramming protocol 
The modified mRNA reprogramming protocol using Pluriton medium was experimented on the 
HF-keratinocytes. Unlike with the fibroblasts, it did not improve mRNA reprogramming and did 
not give rise to iPSCs. After two days in Pluriton medium, the HF-keratinocytes differentiated 
and adopted a stratified morphology (Figure 4-13). Keratinocytes are sensitive to calcium-
induced differentiation, which can be triggered by extracellular calcium concentrations greater 
than 0.06 mM (Aasen and Belmonte, 2010). Pluriton’s calcium concentration is a proprietary 
information and we cannot confirm whether it is the cause for the keratinocyte differentiation we 
observed. The differentiated keratinocytes could not be transfected by our mRNA cocktails, as 
observed by the negative d2eGFP expression (data not shown). 
 
 
Figure 4-13: Keratinocytes cultured in Epilife (keratinocyte medium) and Pluriton (mRNA 
reprogramming medium) for 48h.  
Keratinocytes differentiated and exhibited a stratified morphology after exposure to Pluriton. 




We trialled the mRNA reprogramming protocol originally published by Warren et al. (2010) on 
fibroblasts but could not be reproduce it due to high cell death. We optimised the mRNA 
reprogramming protocol, notably by increasing the concentration of B18R and using NaBu with 
or without PTA-(. Both treatment groups successfully gave rise to iPSCs. One iPSC line from 
each treatment group (iKCL004 and iKCL011 respectively) was adapted to feeder-free culture 
before being characterised. Both iPSC lines equally maintained hESC-like morphology and 
tested positive for the presence of pluripotency markers. The lines were also differentiated in 
vivo and tested positive for the presence of the three germ layers. Finally, DNA fingerprinting 
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confirmed that the iKCL004 and iKCL011 iPSCs lines were derived from the same BJ fibroblast 
somatic donor line. 
Other groups have demonstrated transient inactivation of p53 during reprogramming is 
beneficial and leads to an increased reprogramming efficiency (Hong et al., 2009; Kawamura et 
al., 2009; Zhao, Y. et al., 2008; Marion et al., 2009). We observed an overall decreased cell 
death and more compact iPSC colonies in cells treated with PTA-(. We observed a 30% 
increase in iPSC colony numbers upon PTA-( treatment. Basic characterisation of iKCL004 and 
iKCL011 does not suggest any obvious differences between the lines. p53 mainly ensures 
fidelity of DNA replication and maintenance of cellular epigenetic stability, by inducing apoptosis 
in cells undergoing undesirable changes in order to prevent their proliferation (Jackson-Grusby 
et al., 2001; Leonova et al., 2013; Marion et al., 2009). Even though p53 activation during iPSC 
generation is partly responsible for poor reprogramming efficiency, it could also to some extent 
be seen as beneficial as it prevents the reprogramming of cells with DNA damages. In the 
absence of p53, interferon I-mediated cell death can take over to prevent the proliferation of 
cells with a disturbed epigenetic state (Leonova et al., 2013). Yet, our mRNA reprogramming 
protocol includes B18R, an interferon I inhibitor required to suppress the native immune 
response triggered by the multiple exogenous mRNA transfections required by our 
reprogramming protocol (Angel and Yanik, 2010; Warren et al., 2010). B18R treatment could 
prevent interferon-mediated cell death to take place in the absence of p53. Transient p53 
inactivation coupled with interferon I inhibition could lead to the generation of iPSC lines with 
higher DNA damage rates. Therefore, further complementary characterisation of iKCL004 and 
iKCL011 is necessary. It would include pairwise comparison of the iPSC lines for whole-genome 
DNA methylation and whole-exome sequencing. We are anticipating DNA demethylation of 
pluripotency-associated genes in both iPSCs lines compared to the BJ somatic donor line (Reik, 
2007; Guenther et al., 2010). When comparing to one of our hESC lines, we are likely to 
observe some differences as iPSCs have a distinct gene signature from hESCs, partly because 
of the persistence of some of the donor somatic cell’s gene expression even after 
reprogramming (Ghosh et al., 2010; Streckfuss-Bomeke et al., 2012; Ruiz et al., 2012; Chin et 
al., 2009). Yet, regardless of the donor cell type, iPSCs can have up to nearly 3% of 
differentially methylated CpG site, mainly due to de novo hypermethylations acquired during 
reprogramming. These epigenetic differences can then in turn be associated with changes in 
gene expression (Ruiz et al., 2012). It would be interesting to see if such differences are more 
prominent in iKCL011, our PTA-(-treated iPSC line. For complementary information, whole-
exome sequencing could be performed on our iPSCs. It would allow us to determine if PTA-( 
treatment induced any somatic mutations or rare genetic variants (Ng, S.B. et al., 2009). 
HF-keratinocytes was the ultimate somatic cell type to be reprogrammed using mRNA. For this, 
we derived HF-keratinocytes from anagen-phase hair follicles. This was achieved by 
successfully adapting the Aasen et al. (2008) protocol on hair follicles plucked from healthy 
donors. Keratin 14 positive keratinocytes cultures could be isolated and expanded. As for the 
fibroblasts, the original Warren et al. (2010) mRNA reprogramming protocol was tried on the 
HF-keratinocytes. No iPSCs could be derived due to high cell death. The protocol modifications 
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that led to a successful fibroblast mRNA reprogramming protocol could not be applied to the 
HF-keratinocytes. Indeed, the new reprogramming medium, Pluriton, led to HF-keratinocytes 
differentiation and cell cycle arrest. HF-keratinocytes are an attractive source of somatic cells for 
iPSC generation due to their higher efficiency and rapidity to reprogram compared to fibroblasts 
(Aasen et al., 2008). Several groups reprogrammed keratinocytes from various origins with 
retroviral or lentiviral vectors (Linta et al., 2012; Kim, K. et al., 2011; Zhu et al., 2010; Novak et 
al., 2010; Petit et al., 2012). However, it seems that in our hands HF-keratinocytes are not as 
robust as fibroblasts to survive the 18 consecutive mRNA transfections required by the Warren 
protocol. Furthermore, the Pluriton medium used in the optimised protocol induced 
differentiation of the HF-keratinocytes, which in turn prevented them from being transfected. 
The other constraint associated with HF-keratinocytes encountered in this project was the high 
variability in HF-keratinocytes derivation success. No HD HF-keratinocytes could be derived in 
sufficient number for reprogramming. Patients were in their mid 40s to 50s and age could 
explain less efficient HF-keratinocyte derivation. It was observed that HF-keratinocytes could 
not be derived from white hairs for instance. Other environmental factors could also be 
responsible for poor HF-keratinocytes derivation. Patient 6 was notably taking Methotrexate, a 
chemotherapy drug that can affect hair growth (Table 4-3). 
At the time of writing, no other group published iPSC lines generated using the original Warren 
et al. (2010) protocol. It has been acknowledged in recent publications by the authors that 
Pluriton medium is more robust and better to use with this protocol than Nutristem (Warren et 
al., 2012; Mandal and Rossi, 2013). One option to improve HF-keratinocytes mRNA 
reprogramming would be to progressively switch them from the HF-keratinocyte culture medium 
to the iPSC reprogramming medium in order to prevent calcium-induced HF-keratinocytes 
differentiation. Furthermore, the addition of 10 µM of Y-27632 during HF-keratinocytes 
reprogramming could be beneficial as ROCK inhibitor blocks keratinocyte terminal 
differentiation, increases cell proliferation and prevents apoptosis (Mcmullan et al., 2003; 
Chapman et al., 2010). 
It should also be highlighted that the NuFF-feeder cells play a crucial role on the favourable 
outcome of the reprogramming protocol. Indeed, even when using Pluriton medium, the protocol 
cannot be reproduced when using HFF-feeders other than NuFF cells from donor 11. It is not 
known how exactly these specific cells support better mRNA reprogramming but their central 
role in the protocol could explain why Warren had to further modify the synthetic mRNA in order 
to develop a feeder-free mRNA protocol (Warren et al., 2012). 
On top of the labour-intensity of the protocol, another significant limitation associated with 
mRNA reprogramming is its very high cost, which restricted the number of experimental 
conditions that could be tested. 
 
All in all, modified synthetic mRNA was, in our hands, not the right reprogramming vector for 
HF-keratinocytes. Multiple reprogramming method exist and choosing one depends i) on the 
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starting cell population e.g. keratinocytes, fibroblasts or adipocytes and ii) the purpose of 
reprogramming e.g. disease modeling or cell therapy. Fibroblasts are still the “go to” cells to be 
reprogrammed, as they are very easy to culture and robust to various reprogramming method. 
In our case, they survived the daily transfections required by synthetic modified mRNA 
reprogramming. Moreover, for the purpose of disease modeling, cell repositories such as Coriell 
bank disease fibroblasts, making it an easily available source of samples for scientists. Another 
source of patient sample that can be readily accessible to researcher are peripheral blood 
mononuclear cells (PBMCs). PBMCs can be reprogrammed to iPSCs with efficiencies 
comparable to fibroblasts (Loh et al, 2010). Keratinocytes are also a great source of patient 
samples, and their isolation via hair follicle collection is a non-invasive, non-painful procedure. 
Keratinocytes have been shown to reprogram up to 100-folds more efficiently and twofold faster 
than fibroblasts, probably due to their endogenous levels of KLF4 and c-MYC (Aasen et al., 
2008). Although not readily available, neural stem cells are also a competent source of cells for 
reprogramming due to their endogenous levels of reprogramming factors, leading them to being 
reprogrammed in the absence of SOX2 or c-MYC or with OCT4 alone (Kim, J. B. et al.,2008; 
Kim, J. B. et al.,2009). Though not applicable to any cell type, non-integrative reprogramming 
strategies such as synthetic modified mRNA reprogramming are attractive not only by their 
kinetics, but also by the great advantage of leaving no permanent genetic mutation, due to 
random viral transgene insertion, in the derived-iPSCS. This would reduce genetic 
heterogeneity amongst the generated iPSC lines. 
There are still many options to generate iPSCs derivation strategies. They still mainly depend 
on the available source of sample, purpose of reprogramming, reprogramming vector availability 
as well as time and budget limitations. 









hESC differentiation into 
cardiomyocytes 
Chapter 5 hESC DIFFERENTIATION INTO CARDIOMYOCYTES 
- 114 - 
5 Chapter 5 HESC DIFFERENTIATION INTO CARDIOMYOCYTES 
 
5.1 Cardiac failure and Huntington’s Disease 
HTT is ubiquitously expressed and despite neurodegeneration being the main phenotype of HD, 
non-CNS HD-associated pathologies have been reported (Van Der Burg et al., 2009; Sassone 
et al., 2009; Sathasivam et al., 1999). Epidemiology studies suggest that cardiac failure is the 
second cause of death amongst HD patients (Sorensen and Fenger, 1992; Lanska et al., 1988; 
Chiu and Alexander, 1982). Cardiac defects, including atrophy, have previously been described 
In HD murine models (Sathasivam et al., 1999; Mihm et al., 2007; Wood, 2012; Kiriazis et al., 
2012). HD-iPSCs have proven to be good in vitro models by replicating some HD-neuronal 
phenotypes (Zhang, N. et al., 2010; An et al., 2012; Camnasio et al., 2012;The HD iPSC 
Consortium, 2012). However, the HD cardiac phenotype is yet to be studied in vitro in order to 
determine whether the cardiac defects observed in HD murine models are due to a cell 
autonomous or a non-cell autonomous process. Therefore, here we differentiate the hESCs 
previously characterised in Chapter 3 into cardiomyocytes in order to address this and 
investigate possible HD-specific cardiac phenotypes. To our knowledge, this work is the first 
human cardiac HD in vitro model. 
 
 
5.2 hESCs cardiac differentiation 
This hESC cardiac differentiation work was first undertaken in collaboration with Prof. Harding’s 
groups (Imperial College London). The Harding group has successfully differentiated the H7 
hESCs line into hESC-derived cardiomyocytes (hESC-CM) (Thomson et al., 1998; Foldes et al., 
2011). This collaboration enabled us to use the H7 line as a positive control for the 
differentiation conditions. The observation of beating cell clusters no later than 30 days post-
initiation of differentiation was used as a cut-off point to determine the success of a 
differentiation protocol and the generation of functional cardiomyocytes. 
 
5.2.1 hESCs cultured in mTeSR1 
As described in Chapter 3, the eight hESC lines used in this study were successfully adapted to 
feeder-free culture conditions by culturing them in mTeSR1 medium in combination with GFR-
Matrigel coating matrix. The H7 hESC line was thus adapted to the latter and was maintained in 
it for at least three passages prior to cardiac differentiation induction. 
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5.2.1.1 Spontaneous cardiac differentiation of hESCs cultured in mTeSR1  
As described in Chapter 3, hESCs have the ability to spontaneously differentiate into all three 
germ layers in the presence of FBS and absence of bFGF. We explored to which extent they 
spontaneously differentiate into the mesoderm vs. other two germ layers (endoderm and 
ectoderm) when cultured under these conditions. This property was exploited to differentiate 
hESCs into cardiomyocytes. 
One commonly used method for cardiac differentiation relies on the formation of spherical 
aggregates known as EBs, which enable the hESCs to differentiate into derivatives of the three 
germ layers, including cardiomyocytes (Germanguz et al., 2011; Dolnikov et al., 2006; Ma et al., 
2012; Gherghiceanu et al., 2011; Xu et al., 2001; Kehat et al., 2001). To form EBs, H7 hESCs 
colonies were manually broken following dispase treatment as described in 2.1.6. Cell clusters 
were placed into low adherence dishes and fed daily with KOSR medium supplemented with 
20% FBS and without bFGF. After four days of culture in suspension, the EBs were plated onto 
0.5% gelatin-coated dishes, fed every two or three days and monitored for the formation of 
spontaneously beating areas. Although inefficient due to the cells also differentiating into 
endoderm and ectoderm derivatives (Xu et al., 2001), it is expected that approximately 8.1% of 
the plated EBs will give rise to contractile foci within 30 days of differentiation (Kehat et al., 
2001). The observation of spontaneously beating areas within 30 days of differentiation was 
considered as our endpoint to determine whether or not the hESCs had successfully 
differentiated into functional cardiomyocytes. No beating was observed within 30 days of plating 
for the H7 hESCs. 
The endocrine and chemical composition of FBS varies from batch-to-batch (Honn et al., 1975). 
One possibility to explain our negative outcome is that the batch of FBS used in this study was 
not supportive of cardiac differentiation. Another drawback associated with this EB-based 
differentiation protocol is that the size of manually generated EBs cannot be controlled. Yet, It 
has been demonstrated that EB-based differentiation outcomes can be greatly influenced by the 
initial EB size. EBs of 1,000 cells are optimal for cardiac differentiation (Bauwens et al., 2011). 
In order to generate size-controlled EBs of 1,000 cells/aggregate, Aggrewell plates (STEMCELL 
Technologies) were used. Aggrewell plates contain microwells that allow the even distribution of 
a single cell suspension in order to generate EBs of a chosen size. hESCs were seeded in 
Aggrewell plates in KOSR medium with 20% FBS and without bFGF to generate EBs of 1,000 
cells. After 24 h in the Aggrewell plates, EBs were placed into low-adhesion plates for four days 
before being plated on 0.5% gelatin (Figure 5-1). No beating was observed in wells with the H7 
hESC line within 30 days of differentiation. The protocol was repeated with EBs of 3,000 and 
10,000 cells. Indeed, the 1,000 cells EBs were smaller than the manually generated EBs that 
had a positive differentiation outcome in MEF-conditioned Medium (MEF-CM) cultured H7 
hESCs (Foldes et al., 2011) (personal communication from Dr. M. Mioulane). However, no 
beating was observed within 30 days of differentiation. 
Additionally, we trialled the EB-based spontaneous hESC cardiac differentiation using STEMDiff 
APEL medium (STEMCELL Technologies) as a basal medium, supplemented with 20 % FBS. 
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Its xeno-free, serum-free formulation was originally developed for EB-based hESC 
differentiation (Ng, E.S. et al., 2008). STEMCELL Technologies recommended it, as its 
formulation could be more suitable for cells cultured in mTeSR1. As summarised in Table 5-1, 
this differentiation condition was trialled with EBs of 1,000, 3,000 and 10,000 cells. No beating 
could be observed within 30 days of differentiation. 
 
 
Figure 5-1: Embryoid Body (EB) formation using the Aggrewell plates.  
Day 0: 1,000 cells per microwell were seeded in KOSR medium supplemented with 20% FBS 
and without bFGF. Day 1: 24 h later, EBs uniform in size could be cultured in suspension. 
Images were taken at 40x magnification. 
 
5.2.1.2 Directed cardiac differentiation of hESCs cultured in mTeSR1  
Due to the lack of success of the EB-based spontaneous cardiac differentiation protocol, a 
directed cardiac differentiation approach was trialled. Directed cardiac differentiation relies on 
exposing the hESCs to successive cytokine treatments to direct them into the cardiac lineage. 
Directed cardiac differentiation protocols also have the advantage of being fully defined and of 
bypassing the use of FBS. 
5.2.1.2.1 Yang protocol 
First, using H7 hESC line cultured in mTeSR1, we tested an EB-based protocol for directed 
cardiac differentiation (Yang, L. et al., 2008). However, the EBs rapidly disaggregated. One 
reason for this could be that the differentiation medium did not support survival of mTeSR1 
cultured cells. We repeated the protocol generating EBs of 1,000 cells as described in 5.2.1.1, 
using STEMDiff APEL medium as a basal medium. This time, the cells were left in the 
Aggrewell plate throughout the differentiation. However, within 15 days of differentiation, the 
EBs disaggregated and no beating could be observed (Figure 5-2). 
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Figure 5-2. DisaggregatIng EBs 15 days post differentiation in STEMDIff APEL.  
Image was taken at 100x magnification. 
 
5.2.1.2.2 Laflamme protocol 
Considering the negative outcomes of the EB-based differentiation protocols, we decided to try 
a monolayer directed differentiation protocol, which can be up to 50-fold more efficient than EB-
based cardiac differentiation protocols (Laflamme et al., 2007). As for the Yang protocol, the 
Laflamme protocol consists of a succession of cytokine treatments and is detailed in section 
2.3.2. This protocol was chosen because it is not FBS-based and is fully defined. More 
importantly, it was originally developed on the H7 hESC line and was since successfully 
reproduced by Prof. Harding’s group (Foldes et al., 2011). Using the H7 hESC line as a positive 
control, all the eight hESC lines used in this study were subjected to this protocol. Within 15 
days of differentiation, the cells formed clusters but none of them started beating within 30 days. 
Two examples of the clusters formed after 15 days of cardiac differentiation with the Laflamme 
protocol are presented in Figure 5-3. 
 
Figure 5-3: Day 15 day of cardiac differentiation in mTeSR1 medium (Laflamme protocol). 
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KCL020 (WT-hESC) and KCL036_HD7 (HD-hESC) formed clusters (arrows) 15 days post 
cardiac differentiation. No beating was observed within 30 days. Images were taken at 40x 
magnification. 
 
5.2.1.2.3 Lian protocol 
All of the above protocols were originally developed on cells cultured on MEF or on GFR-
Matrigel with MEF-CM, which could explain why they gave poor outcomes on cells cultured in 
mTeSR1. During our cardiac differentiation protocol development, Lian et al. (2012a) published 
a cardiac differentiation protocol that started with cells cultured feeder-free in mTeSR1 and 
GFR-Matrigel. It is based on the Laflamme protocol (Laflamme et al., 2007), with the addition of 
a three-day cell pre-treatment with a glycogen synthase kinase 3 (Gsk3) inhibitor (CHIR99021) 
and the use of a B27 supplement without insulin. Indeed, Lian et al. also published that low 
insulin levels were beneficial to cardiomyocytes differentiation (Lian et al., 2012b, 2013) One 
WT-hESC line (KCL031) and one HD-hESC line (KCL027_HD5) were subjected to this protocol. 
We also tested a range of CHIR99021 concentrations in combination with B27 with no insulin as 
indicated. 
Within eight days of the Lian cardiomyocytes differentiation protocol, cell survival decreased. No 
beating cardiomyocytes could be observed within 30 days of differentiation in the two cell lines 
tested (Figure 5-4). 
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Figure 5-4: Day 8 of cardiac differentiation in mTeSR1 medium (Lian protocol).  
Different concentrations of CHIR99021 were tested. KCL031 and KCL027_HD5 cell survival 
started decreasing from 8 days post cardiac differentiation. Images were taken at 40x 
magnification.
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medium Protocol Additional Info Beating 
mTeSR1 EB (20%FBS) 
Manually formed 
EBs Negative 
mTeSR1 EB (20%FBS) 1,000 cells/EB Negative 
mTeSR1 EB (20%FBS) 3,000 cells/EB Negative 
mTeSR1 EB (20%FBS) 10,000 cells/EB Negative 
mTeSR1 STEMDiff APEL + 20%FBS 1,000 cells/EB Negative 
mTeSR1 STEMDiff APEL + 20%FBS 3,000 cells/EB Negative 
mTeSR1 STEMDiff APEL + 20%FBS 10,000 cells/EB Negative 
mTeSR1 
Yang et al. (2008) 
Manually formed 
EBs Negative 
mTeSR1 Yang et al. (2008) 1,000 cells/EB Negative 
mTeSR1 
Laflamme et al. (2007) 
Monolayer of 2 x 105 
cells/cm2 Negative 
mTeSR1 Laflamme et al. (2007) with 
STEMDiff APEL as a basal 
medium 
Monolayer of 2 x 105 
cells/cm2 Negative 
mTeSR1 
Lian et al. (2012a) * 
Monolayer of 2 x 105 
cells/cm2 Negative 




Monolayer of 2 x 105 
cells/cm2 Positive 
Table 5-1: Summary of the cardiac differentiation conditions trialled on the H7 hESC lines 
cultured feeder-free in mTeSR1 medium or mouse embryonic fibroblast-conditioned 
medium (MEF-CM).  
* This condition was only trialled on WT-hESC KCL031 and HD-hESC KCL027_HD5 lines. 
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The differentiation conditions where the cells were cultured feeder-free in mTeSR1 medium all 
had a negative outcome (no beating within 30 days of differentiation) while the differentiation 
protocols were successful when the cells were cultured in MEF-CM prior to differentiation. This 
led to suggest that rather than the differentiation protocol; the undifferentiated hESC culture 
conditions could be impeding downstream cardiac differentiation. We thus decided to adapt the 
hESCs to a new culture medium. 
 
5.2.2 hESCs cultured In Nutristem 
All eight hESC lines but HD-hESC KCL012_HD3 could be adapted from culture in mTeSR1 
medium to culture in Nutristem medium (Stemgent) on GFR-Matrigel as a matrix. KCL012_HD3 
could not be cultured in these conditions for a minimum of three passages without excessive 
spontaneous differentiation and could thus not be used for cardiac differentiation. It cannot be 
excluded that KCL012_HD3 acquired a chromosomal abnormality during the study, which could 
explain the excessive differentiation. Nutristem was chosen over MEF-CM as it has a fully 
defined formulation, which would bypass any variability associated with different batches of 
MEFs. The hESCs were maintained in this culture condition for at least three passages prior to 
cardiac differentiation. 
 
5.2.2.1 Spontaneous cardiac differentiation of hESCs cultured in Nutristem 
Among seven feeder-free hESC lines adapted to Nutristem medium, and subjected to the 
spontaneous cardiac differentiation protocol described In 5.2.1.1, only one WT- (KCL031) and 
one HD- (KCL028_HD6) hESC line gave rise to beating clusters within 30 days of differentiation 
(Figure 5-5). 
 
Figure 5-5: hESCs cultured in Nutristem after 30 days of cardiac differentiation 
(Spontaneous EB-based protocol).  
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KCL031 and KCL028_HD6 formed beating clusters (arrows) 30 days post cardiac 
differentiation. Images were taken at 40x magnification. 
 
Considering this protocol only had a positive outcome on 2/7 hESC lines and the variability 
across different batches of FBS, we decided to differentiate the hESCs adapted to Nutristem 
feeder-free culture with the Laflamme directed differentiation protocol. This protocol offers a 
tighter control over the different variables of differentiation, which could lead to a better 
reproducibility across the seven different hESCs lines. 
 
5.2.2.2 Directed cardiac differentiation of hESCs cultured in Nutristem (Laflamme 
protocol) 
As in 5.2.1.2.2, we subjected seven hESCs lines adapted to Nutristem feeder-free culture to the 
Laflamme directed differentiation protocol. 
All the hESC lines but KCL040 presented beating areas within 30 days of differentiation. In our 
hands, the Laflamme protocol on cells cultured feeder-free in Nutristem medium was the most 
dependable despite a wide range of differentiation efficiency (summarised in Table 5-2). 
 
Cell line % wells with beating 
cardiomyocytes (day 30) 
KCL020 4.2% (2/48) 
KCL027_HD5 16.7% (8/48) 
KCL028_HD6 4.2% (2/48) 
KCL031 20.8% (10/48) 
KCL034 6.3% (3/48) 
KCL036_HD7 6.3% (3/48) 
KCL040 0% (0/48) 
Table 5-2: Summary of percentage of wells presenting beating areas by day 30 of cardiac 
differentiation by the Laflamme protocol. 
 
Next, the hESC line that presented beating by day 30 of the Laflamme differentiation protocol 
were analysed by qPCR for two pluripotency markers (NANOG and OCT3/4), two cardiac 
markers (NKX2.5 and TNNT2) and HTT. The relative gene expression and the gene expression 
normalised to the undifferentiated hESCs are presented in Table 5.3.A and B respectively. 
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Table 5-3: Gene expression of hESC and hESC-CM at day 30 of the Laflamme protocol.  
A. Relative gene expression of the hESC and hESC-CM (day 30). B. Gene expression levels in 
hESC-CMs normalised to the respective hESC line. 
 
The results presented in Table 5-3 confirm that the six hESC lines presenting beating areas by 
day 30 of the Laflamme differentiation protocol had a down-regulation of their pluripotency 
associated genes NANOG and OCT3/4, and an up-regulation of the cardiac-associated genes 
NKX2.5 and TNNT2. KCL031 and KCL027_HD5, which are the two cell lines that presented the 
most beating areas (Table 5-2), have the highest expression of NKX2.5 and TNNT2, whether 
looking at the relative or the normalised gene expression (Table 5-3). HTT expression remained 
similar between hESCs and hESC-CMs. 
The results presented in Table 5-3 support a study published by Allegrucci and Young 
(Allegrucci and Young, 2007) that demonstrated that hESC lines have variable in gene 
expressions. We have also observed this cell line variability, as shown in part A of Table 5-3, 
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where the undifferentiated hESCs have a wide array of expression of their pluripotency genes. 
This could explain the differences in differentiation efficiency observed. 
 
Next we assessed the gene expression of the normalised means of WT- and HD-hESCs and 
WT- and HD-hESC-CMs (Figure 5-6). This confirmed that both WT- and HD-hESCs had 
significant down-regulation of their pluripotency genes at 30 days of the Laflamme 
cardiomyocytes differentiation protocol. Both WT- and HD-hESCs had an up-regulation of 
cardiac-associated genes after 30 days of cardiac differentiation. However, the increase was 
only significant for NKX2.5 in WT-hESCs. HTT expression remained the same between both 
group in hESCs and hESC-CMs. 
 
Figure 5-6: Gene expression of the normalised means of WT-hESCs, WT-hESC-CM, HD-
hESCs and HD-hESC-CMs.  
WT-hESC are compared with WT-hESC-CM and HD-hESC are compared with HD-hESC-CM. 
Data are given by normalised mean ± standard error of the mean (n = 3); statistical significance 
was calculated by two-way ANOVA with Bonferroni post-hoc test. * P < 0.05, *** P < 0.01, NS: 
non significant. 
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We further confirmed the positive outcome of the Laflamme protocol and the presence of 
beating cardiomyocytes by immunostaining the cells against cardiac troponin T (cTnT), a 
cardiac marker specific to beating cardiomyocytes (Figure 5-7). 
 
Figure 5-7: Representative cardiac troponin T (cTnT) immunostaining on day 30 of 
cardiac differentiation.  
cTnT: green and Hoechst: blue. Images were taken at 400x magnification. 
 
After 30 days of cardiac differentiation, positive cTnT staining could be observed for three WT-
hESC-CM lines (KCL020, KCL031 and KCL034) and two HD-hESC-CM lines (KCL027_HD5 
and KCL036-HD7). cTnT immunostaining on HD-hESC-CM KCL028, which also presented 
beating areas within 30 days of differentiation, was not performed. We found no obvious 
difference between WT-hESC-CMs and HD-hESC-CMs, suggesting that HTT mutation does not 
prevent HD-hESCs from differentiating into cardiomyocytes. 
 
5.2.2.3 Comparison of WT- and HD-hESC-CMs. 
5.2.2.3.1 Cardiomyocyte-specific biomarker expression in WT- and HD-hESC-CMs 
We choose one WT- (KCL031) and one HD- (KCL027_HD5) hESC line with the best 
differentiation efficiency (20.8% and 16.7% respectively, see Table 5-2) and the highest gene 
expression of cardiac-associated genes to be screened for any disparities in differentiation 
potential and any potential molecular HD-specific phenotype. Samples from undifferentiated 
hESCs and hESC-CMs at day 30 of differentiation were analysed by qPCR using the Qiagen 
Human Cardiomyocyte Differentiation qBiomarker PCR Array. The array contains 19 
cardiomyocyte-specific biomarkers and two housekeeping genes for normalisation (summarised 
in Table 5-4). 
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Biomarker Gene 
Cardiomyocyte Structural Constituent: ACTN2 (Actinin alpha2), DES (Desmin), 
MYH7 (MyHC-beta), MYL2 (MLC-2, 
MLC-2v), MYL3, MYL7, TNNI3 (cTnI), 
TNNT2 (cTnT) 
Cardiomyocyte Transcription Factors GATA4, HAND2 (dHAND), NKX2-5 
Cardiomyocyte Receptors ADRB1, NPPA, RYR2, 
Cardiomyocyte Ion Channels KCNQ1, PLN, SLC8A1 
Cardiomyocyte Enzyme CKM 
Cardiomyocyte Transporter MB (myoglobin) 
Housekeeping Gene NAT1, GAPDH 
Table 5-4: List of cardiac biomarker genes present on the Qiagen Human Cardiomyocyte 
Differentiation qBiomarker PCR Array.  
Adapted from Qiagen (http://www.sabiosciences.com/qbiomarker_product/HTML/IPHS-
102A.html, accessed on 20/07/2013) 
 
Samples from the undifferentiated and the differentiated conditions for the two chosen hESC 
lines were run in technical triplicates on the qBiomarker array and were analysed using the 
Web-based Qiagen qBiomarker iPSC Data Analysis Software. Upon data analysis, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was determined to be the most stable 
housekeeping genes and the sample were normalised against its expression. A clustergram of 
the samples’ normalised gene expression was generated and is presented in Figure 5-8. 
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Figure 5-8: Clustergram of expression values of cardiac genes in undifferentiated hESCs 
and hESC-CM at day 30 of cardiac differentiation (Laflamme protocol).  
A) Undifferentiated KCL031, B) KCL031-CM, C) undifferentiated KCL027, D) KCL027-CM. 
Green colour represents minimal gene expression and red colour represents maximal gene 
expression. 
 
The results of the clustergram presented in Figure 5-8 show that the undifferentiated hESCs 
populations (A and C) are well separated from the differentiated hESCs populations (B and D). 
The data confirmed that the majority of cardiac-specific genes such as NKX2.5 and TNNT2 are 
minimally or not at all expressed in the undifferentiated hESCs populations (A and C) (the 
magnitude of gene expression is in green). This is in line with the data presented in Table 5-3 
and Figure 5-6. On the contrary, these genes were expressed in the differentiated hESCs 
populations (B and D), suggesting that the cardiac differentiation is taking place (the magnitude 
of gene expression is in red). Interestingly, a high proportion of cardiomyocyte biomarkers such 
as MYH7 and NKX2.5 appear to be less expressed in the HD-hESC-CMs (sample D) than in 
the WT-hESC-CMs (sample B) though whether this is of any significance should be confirmed. 
We next compared the cardiomyocyte biomarkers expression in KCL027_HD5-CM versus 
KCL031-CM and performed a scatter plot analysis where the Log10 of 2-^Delta-Ct expression 
of HD-hESC-CM KCL027 was plotted against the Log10 of 2-^Delta-Ct expression of WT-
hESC-CM KCL031. A fold change of two or more was considered significant. The scatter plot is 
presented in Figure 5-9 and a summary table of the genes with a fold change of two or more is 
presented in Table 5-5. 
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Figure 5-9: Relative comparison expression of cardiomyocyte biomarkers gene in 
KCL027_HD5-CM compared to KCL031-CM at day 30 of the Laflamme protocol.  
Scatter plot showing the Log10 of 2-^Delta-Ct expression of HD-hESC-CM KCL027 plotted 
against the Log10 of 2-^Delta-Ct expression of WT-hESC-CM KCL031. Green dots represent 
HD-hESC-CM genes with a fold expression lower than WT-hESC-CM and grey lines indicate e 2 folds expression. 
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Table 5-5: Summary table of the relative expression of cardiomyocyte biomarker genes 
with a fold change of two or more in HD-hESC-CM KCL027 compared to WT-hESC-CM 
KCL031. 
 
It can be seen from Figure 5-9 and Table 5-5 that day 30 KCL027_HD5-CMs have 12 genes 
with a lower expression by two folds or more compared to day 30 KCL031-CMs. This further 
confirms the trend indicated by the clustergram presented in Figure 5-8. The gene expression of 
ACTN2, NKX2.5, DES, MYL2 and MYH7 has been shown to increase as the hESC-CM mature 
(Segev et al., 2005; Puppala et al., 2013; Dubois et al., 2011). Their lower expression in day 30 
KCL027_HD5-CMs compared to day 30 KCL031-CMs suggest that the HD-hESC-CMs might 
be less mature than the WT-hESC-CMs. However, it cannot be excluded that this difference 
could be due to hESC variability and not HD. 
 
5.2.2.4 CAG repeat stability in HD-hESC-derived cardiomyocytes  
The trinucleotide HD mutation is subject to mosaicism in HD sufferers, especially in the CNS 
and gonads (Telenius et al., 1994). However, there are also contradictory reports on whether 
CAG repeats increase during PSC differentiation (The HD iPSC Consortium, 2012; Niclis et al., 
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2009; Seriola et al., 2011; Camnasio et al., 2012). We therefore looked at CAG repeat stability 
in the HD-hESC-CMs after 30 and 60 days of cardiac differentiation with the Laflamme protocol. 
The results are presented in Figure 5-10. 
 
 
Figure 5-10: CAG repeat number in undifferentiated hESC KCL027_HD5 P22 and post 30 
and 60 days of cardiac differentiation (Laflamme protocol).  
The CAG repeat number remained stable at 44 CAG repeats. CAG repeats of over 36 are HD 
positive. 
 
The CAG repeat number of KCL027_HD5 remained stable at 44 CAG repeats throughout 
differentiation. These results are consistent with some previously published studies that showed 
that the CAG repeats were stable in undifferentiated HD-hESCs even after multiple passages, 
as well as in differentiated hESCs (osteogenic progenitor-like, neural progenitors and neurons) 
(Seriola et al., 2011; Camnasio et al., 2012). However, this may not be a rule. In some other 
publications, CAG repeats have been found to be instable with documented trinucleotide 
expansion of five and eight repeats in neurons (Niclis et al., 2009; The HD iPSC Consortium, 
2012). 
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5.2.3 Discussion 
Here I described the development of the first HD-specific human cardiac in vitro model. To 
generate this model, we characterised eight hESCs lines, four WT (KCL020, KCL031, KCL034 
and KCL040) and four carrying HD-specific mutation (KCL012, KCL027, KCL028, and KCL036) 
(Chapter 3). 
Using the H7 hESC line as a positive control, we subjected all the hESC lines cultured feeder-
free in mTeSR1 medium on GFR-Matrigel substrate to one spontaneous (5.2.1.1) and three 
directed differentiation protocols (5.2.1.2). All four differentiation protocols were unsuccessful at 
giving rise to beating cardiomyocytes, our endpoint to determine whether a cardiac 
differentiation protocol successfully generated functional cardiomyocytes or not. During our 
cardiac differentiation protocol development, Ojala et al. published a study demonstrating that 
hESC culture conditions prior to cardiac differentiation can have an impact on the differentiation 
outcome. Notably, their study on the H7 line demonstrated that the mTeSR1 with GFR-Matrigel 
substrate culture condition was the least favourable one to give rise to beating cardiomyocytes 
(Ojala et al., 2012). However, they used a co-culture method with END2 endothelial cells to 
differentiate H7 into cardiomyocytes, a condition not tested in our study. Taking this report into 
account, we decided to adapt the eight hESC lines to Nutristem medium. All but KCL012_HD3 
could be adapted to feeder-free culture in Nutristem / GFR-Matrigel. In these conditions, 
KCL012_HD3 presented excessive spontaneous differentiation. It cannot be excluded that at 
the time of Nutristem adaptation the cell line had acquired karyotypic abnormalities resulting in 
poor maintenance of pluripotency in these culture conditions The seven remaining hESCs were 
subjected to the spontaneous differentiation protocol 5.2.2.1, which resulted in a positive 
outcome (beating), though in two cell lines only (KCL031 and KCL028_HD6). This highlights the 
poor outcome of this protocol in our hands. In order to increase the cardiac differentiation 
outcome, we subjected the seven remaining hESC lines to the Laflamme directed differentiation 
protocol (5.2.2.2). Beating could be observed with various efficiencies (refer to Table 5-2) within 
30 days Beating could be observed within 30 days in all lines except one, WT-hESC KCL040. 
Since the cells were cultured on an identical substrate (GFR-Matrigel) and the only difference in 
culture condition was the culture medium, this positive outcome across multiple hESC cell lines 
suggested that in our hands, mTeSR1 might have an inhibitory effect on cardiac differentiation 
in the hESC lines used in this study. Feeder-free hESC culture presents many advantages such 
as culture upscaling and prevention of feeder–cell contamination. However, as observed in this 
study, it can also inhibit downstream differentiation. One way to prevent this would be to use 
feeder-free culture as a transient step for feeder-cell depletion prior to differentiation, rather than 
for long term culture (>20 passages) as in this study. 
Although with a wide range of efficiency, the positive cardiac differentiation results across the 
six different hESC lines confirmed that like WT-hESCS, HD-hESCs could be differentiated into 
cardiomyocytes. This is not unexpected as HD is characterised by a late onset and slow 
progression, with individuals that develop normally. Furthermore, this is in line with findings on 
other human and murine in vitro HD ESC models that HD-hESCs can be differentiated into 
other cell types, notably neurons (Castiglioni et al., 2012; Niclis et al., 2009; Camnasio et al., 
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2012; Seriola et al., 2011; Lorincz and Zawistowski, 2009). Gene expression analysis and 
positive cTnT immunostaining of the five tested hESC-derived CMs lines at day 30 of the 
Laflamme protocol, further confirmed that both WT and HD-hESCs could be differentiated into 
cardiomyocytes with no significant difference. One WT-hESC line (KCL031) and one HD-hESC 
line (KCL027_HD5) were then chosen for the molecular characterisation of cardiomyocyte 
biomarkers as they had the highest differentiation efficiency. Analysis of the cardiomyocyte 
biomarkers expression 30 days post-differentiation revealed that both the WT-hESC and the 
HD-hESC cell lines had differentiated into cardiomyocytes, as the cardiomyocyte biomarkers 
were more expressed in differentiated cells than in undifferentiated cells. However, expression 
levels of cardiomyocyte-specific genes such as MYH7 and NKX2.5 were somewhat lower in the 
HD-hESC-CMs than in the WT-hESC-CMs, raising the interesting possibility that HD-hESC-
CMs might be less mature than the WT-hESC-CMs. 
Unfortunately, I ran out of time and I could not repeat the Laflamme differentiation protocol at 
least three times on all the lines in order to have differentiation triplicates on top of biological 
replicates. If results were consistent, to avoid the possibility of an hESC line-specific bias, I 
would repeat the Qiagen Human Cardiomyocyte Differentiation qBiomarker PCR Array on the 
six hESC lines that generated beating cardiomyocytes within 30 days of the Laflamme cardiac 
differentiation protocol (KCL020, KCL031, KCL034, KCL027_HD5, KCL028_HD6 and 
KCL036_HD7). This would enable me to generate a stronger baseline of WT cardiomyocyte 
biomarker gene expression. Comparing the HD-hESC-CMs to this baseline would then give a 
better insight on whether or not the lower cardiomyocyte biomarker gene expression is an HD-
specific phenotype or if it is a hESC line specificity. Results presented in Table 5-3 and Figure 
5-6 confirm that all the cell lines down-regulate their pluripotency-associated genes. This 
indicates that poor cardiac differentiation efficiency is likely due to the cells not committing to the 
cardiac lineage. This could be investigated by looking at the gene expression of genes from the 
ectoderm and endoderm cell lineages. Their expression should be minimal. Lower levels of 
cardiomyocyte-specific biomarker expression in HD-hESCs could be due to inefficient 
differentiation rather than an HD-specific phenotype. Until then, no definitive conclusion can be 
drawn from these results. Furthermore, quantitative analysis of the hESC-derived 
cardiomyocytes could be performed by flow cytometry for markers such as cTNT, MCL2a or 
SMA. This would enable us to further investigate whether or not there is a difference in 
cardiomyocyte differentiation propensity between WT-hESCs and HD-hESCs. Moreover, 
electrophysiological analysis of the WT-hESC-CM and HD-hESC-CM is necessary to further 
investigate a potential difference between the cell lines due to the HD mutation. 
Using the KCL027_HD5 hESC lines, we also investigated CAG repeat stability in the HD-hESC-
CMs after 30 and 60 days of cardiac differentiation with the Laflamme protocol. In our hands, 
the CAG repeats (44) of KCL027_HD5 remained unchanged throughout cardiac differentiation 
with this protocol. Other groups have published contradictory reports on whether CAG repeats 
increase during PSC differentiation (The HD iPSC Consortium, 2012; Niclis et al., 2009; Seriola 
et al., 2011; Camnasio et al., 2012). However, it has been established that like in patients, there 
is an in vitro CAG repeat expansion associated phenotype, notably in iPSC-derived neurons 
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(The HD iPSC Consortium, 2012). To confirm the presence of an in vitro HD-specific phenotype 
in HD-hESC-CMs, they should be generated from HD-PSCs with greater CAG repeat numbers. 
In this instance we tried to generate HD-iPSCs and aimed to target JHD patients. 
One drawback of the Laflamme directed differentiation protocol used in this study is that it does 
not generate a pure cardiomyocytes population (# 30%) (Laflamme et al., 2007), which was also 
observed from the wide range of differentiation efficiency presented in Table 5-2 and from the 
immunostaining presented in Figure 5-7. Treating the cells with 1-2% DMSO has recently been 
found to be beneficial for cardiac differentiation (Chetty et al., 2013). Removing insulin from 
certain stages of the differentiation protocol could also improve efficiency as the latter has been 
found to inhibit cardiac differentiation (Lian et al., 2012b; Burridge et al., 2011; Lian et al., 2013). 
Challenging the ratios of cytokines used in the differentiation protocol is another approach that 
could be beneficial for the cell lines used in this study. Thanks to an elegant NKX2.5 reporter 
hESC line, Elliot et al. could track cardiac differentiation. They tested 96 Activin A and BMP4 
concentration combinations and determined that in their differentiation conditions, a ratio of 
BMP4:Activin A of 1:1 or 1:2 was optimal (Elliott et al., 2011). Finally, the use of small molecules 
in addition to cytokines has the capacity to give differentiation of great efficiency. Even though 
our attempt with CHIR99021 compound was not successful (5.2.1.2.3), it helped give rise to a 
cTnT+ population of approximately 85% in the original study (Lian et al., 2012a). Another small 
molecule with great potential is KY02111, which can increase cardiac differentiation by 80 folds 
(Minami et al., 2012). Interestingly, both CHIR99021 and KY02111 modulate the Wnt signaling 
pathway, but in opposite ways. Indeed, the Wnt signaling pathway needs to be activated in 
order to promote mesoderm differentiation, and then inhibited at later stages in order to ensure 
cardiac differentiation and not differentiation into cells from the hematopoietic or vascular 
lineage (Mignone et al., 2010; Naito et al., 2006). Consequently, Lian et al. (2012a) used the 
CHIR99021 Wnt activator as a pre-treatment before starting cardiac differentation via cytokine 
induction, while Minami et al. (2012) used KY02111, a Wnt signaling inhibitor 3 days post-
cardiac differentiation induction. Another alternative is to modify the differentiation ECM. Zhang 
et al. could get up to 98% cTnT+ cells by using a GFR-Matrigel “sandwich” method. It is worth 
noting that Zhang et al. obtained these results with hESCs cultured in mTeSR1 prior to 
differentiation. However mTeSR1 was not used for long-term maintenance of undifferentiated 
hESCs but rather for feeder-cell depletion three to six days prior to starting cardiac 
differentiation (Zhang, J. et al., 2012). 
If cardiac differentiation cannot be enhanced, another approach is to perform “cardiac 
enrichment” in order to have a purer cell population prior to molecular analysis. Cardiomyocyte 
enrichment techniques include dissection of the beating areas prior to dissociation, or the use of 
a discontinuous Percoll gradient centrifugation step for density separation of the 
cardiomyocytes, which can lead to a four-fold enrichment (Xu et al., 2002). Another strategy 
could be to use the SIRPA or ALCAM cardiomyocytes surface markers for enrichment by 
fluorescence-activated cell sorting (FACS) or magnet-assisted cell separation (Dubois et al., 
2011; Rust et al., 2009). Finally, establishing hESC lines with a cardiomyocyte-specific promoter 
fluorescent reporter vector would also enable us to enrich the differentiated cell populations by 
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FACS. This approach has already been successful using &-myosin heavy chain, myosin light 
chain 2V and Troponin-I promoters (Kita-Matsuo et al., 2009;Ritner et al., 2011;Huber et al., 
2007;Gallo et al., 2008). However, there is a risk for random insertion of the transgene in the 
genome or for the transgene to rearrange. Thorough characterisation of the transgene’s 
expression and stability would thus be needed. 
Given more time and resources, I would also have characterised the cardiomyocytes by 
electrophysiological analysis to look at action potential properties. iPSC-derived cardiomyocytes 
from patients have already proven to replicate disease phenotypes of Timothy syndrome, long 
QT-disease, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and 
familial hypertrophic cardiomyopathy in vitro (Yazawa et al., 2011; Lahti et al., 2011; Ma et al., 
2012; Tse et al., 2013; Lan et al., 2013). The HD cardiac phenotypes found in the R6/2 murine 
model comprise a decreased heart weight and left ventricular defects, including a 50% 
reduction in cardiac output (Mihm et al., 2007; Wood, 2012). Interestingly, MYH7, which is 
mostly expressed in cardiac ventricles, was expressed # 20 folds lower in our HD-hESC-CMs 
(Table 5-5) than in our WT-hESC-CMs. However, in vivo, these phenotypes are found in 12 
weeks old mice that have a very aggressive and rapid form of HD. Such phenotype might not 
develop in HD hESC-derived cardiomyocytes within the timeframe allowed by their in vitro 
culture, even if it can reach several months. Furthermore, R6/2 mice present severe 
neurodegeneration at this age and lose a lot of weight, including heart weight. It cannot be 
excluded that the cardiac phenotype observed in these studies is only an indirect consequence 
of the latter. This hypothesis is reinforced by a recent publication from Kiriazis et al., which 
suggests in their study of the R6/1 murine HD model that the observed cardiac defects are 
consequences of neurocardiac dysregulations and neurogenic arrhythmias (Kiriazis et al., 
2012). R6/1 and WT mice displayed different heart rate responses to isoprotenerol and 
atropine. The action potential of our HD-hESC-CM could be studied and such drug treatments 
could be replicated, with the unique advantage of not having any neuronal influence. This would 
give further highlight on whether HD cardiac defects are a direct or indirect consequence of HD. 
Finally, given more time and resources, I would have liked to study the HD-hESC-CMs calcium 
handling properties. Our model displays a 20-fold lower expression of MYH7. A $MYH (chick 
analogue of MYH7) knockdown in cardiac ventricle shows calcium transients deregulations, 
notably by the induction of a decrease in the rise time during the calcium transient. Correct 
calcium transients are essential for the cardiomyocytes to contract and beat properly (Rutland et 
al., 2011; Lan et al., 2013). 
HD cardiac mitochondria have a disrupted morphology and density in 12 weeks old R6/2 mice 
(Mihm et al., 2007). High magnification microscopic techniques, like e.g. Transmission Electron 
Microscopy (TEM) could be used to verify this phenotype in our model. TEM has enabled the 
modelling of pathological cardiac phenotypes in iPSC-derived cardiomyocytes, such as 
increased cell width, disorganised Z-band and differences in lipid droplets (Ma et al., 2012). 
TEM could be used in our in vitro model to compare the ultra-structure of HD-hESC-CM and 
WT-hESC-CM, notably for the mitochondria, and to look for the presence of aggregates. 
Aggregates have been found in sparse quantities in hearts of the HdhQ150 and the R6/2 
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murine models of HD (Moffitt et al., 2009; Sathasivam et al., 1999) and a study on 
polyglutamine amyloids revealed that transgenic mice expressing 83 CAG repeats residues in 
the cardiac tissues only suffered from reduced cardiac function and dilation by five months and 
died by eight months (Pattison et al., 2008). However, for practical reasons, TEM needs to be 
prepared from EB-based cardiomyocytes (Dr. G. Vizcay-Barrena, personal communication) so 
the TEM sample preparation does not interfere with cardiomyocyte morphology. This correlates 
with recent methods described in the literature where TEM was performed on contractile EBs or 
cardiac bodies (Ma et al., 2012; Gherghiceanu et al., 2011; Yu, T. et al., 2013; Tse et al., 2013; 
Kensah et al., 2013). Cardiomyocytes derived by the Laflamme differentiation protocol would 
not be suitable for TEM analysis. 
A good positive control would be to try replicating in our HD-hESC lines some HD-phenotypes 
found in another in vitro HD modeling study, such as higher lysosomal activation (Camnasio et 
al., 2012). Even though it has been stressed previously that this study requires more biological 
replicates in order to generate a baseline of WT gene expression, the best control would be to 
have isogenic hESC lines where only the HD mutation would differ. Such HD-hESCs were 
successfully generated by insertion of HTT exon 1 transgene baring different CAG repeats 
length into the H9 WT-hESC line (Lu and Palacino, 2013) or by homologous recombination 
where the 72 CAG repeats allele was corrected to 21 CAG repeats. This latter correction did not 
affect the pluripotency of hESCs nor their neuronal differentiation potential, and allowed the 
correction of HD-specific phenotype such as elevated caspase-3/7 activity (An et al., 2012). 
Isogenic iPSCs have also been generated for Rett syndrome by X-Chromosome inactivation 
selection (Ananiev et al., 2011), and by zinc finger nuclease (ZFN)-mediated genome editing for 
Parkinson’s disease iPSCs (Soldner et al., 2011). Genetic engineering of hESCs is also 
possible with Transcription Activation-Like Effector Nucleases (TALENs), which offer more 
flexibility in the sequence reading than ZFN and have the advantage of recognising single 
nucleotides (Hockemeyer et al., 2011; Miller et al., 2011). 
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Chapter 6 Summary 
 
6.1 Development of pluripotent models of HD 
The work presented in this thesis focuses on the characterisation, development and 
differentiation of pluripotent stem cell models of HD. HD is an autosomal dominant, late onset 
disease caused by a single mutation, which offers a large window for therapy. In vivo and in 
vitro disease models were therefore developed for a better understanding of the disease, 
phenotype identification and therapeutic compound screening and development. Yet, at the 
beginning of this project, existing cellular models of HD had been developed from tumour cell 
lines using genome-integrating lentiviral delivery system carrying a mutated HTT exon 1. These 
models were not optimal, as the cells would always have non-innate extra copies of HTT, with 
CAG repeat sizes rarely seen in patients, and whose expression was driven by an exogenous 
promoter. Furthermore, none of the existing human HD cellular models were pluripotent, 
therefore restricting the somatic cell type in which the mutation could be studied.  
In order to circumvent this, we aimed to develop two human pluripotent stem cell models of HD. 
The first model was HD-hESCs, isolated after PGD and donated to research by consenting 
couples. Seven HD-hESC lines were derived at the ACU, Guy’s Hospital, King’s College 
London. The second model to be developed was iPSCs generated from HF-keratinocytes using 
synthetic modified mRNA as a reprogramming vector. Although the technique was successfully 
optimised to reprogramme WT-fibroblasts, in the timeframe of this project I was not successful 
in optimising the protocol for the mRNA reprogramming of HF-keratinocytes. One possibility for 
the future would be to reprogramme HD fibroblasts with the optimised mRNA reprogramming 
protocol instead of HD-HF-keratinocytes. 
 
 
6.2 Characterisation of HD-PSCs 
Five HD-hESC lines were fully characterised in this study, along with four WT-hESC 
counterparts. I also characterised two iPSC lines generated with the optimised mRNA 
reprogramming protocol. The PSCs were characterised according to seven criteria: their 
morphology, the presence of pluripotency markers, their ability to differentiated in vitro and in 
vivo, DNA fingerprinting, genomic stability and HLA typing. Only one hESC line (KCL013_HD4) 
presented with genomic instability and was eliminated from this study. The other eight hESC 
lines were suitable for downstream differentiation. 
The iPSCs generated in this study were exposed to different treatments, one of which 
comprised the transient inhibition of the p53 pathway. One iPSC line from each treatment group 
was selected for further investigation. Upon preliminary characterisation, no differences could 
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be observed between the two lines. Additionally, they behaved similarly to the hESCs used in 
this study. Nevertheless, future characterisation of these iPSCs would include full-exome 
sequencing and whole-genome DNA methylation analysis to confirm whether or not the 
transient p53 treatment could have induced any somatic mutations. 
 
 
6.3 HD-PSC differentiation 
Prior to their differentiation, the PSC were adapted to feeder-free culture conditions. The feeder-
dependant culture system is not fully defined, requires manual passaging, which is labour-
intensive and time consuming, this limits the scalability of PSC culture. Therefore, I trialled two 
different feeder-free matrices: GFR-Matrigel and decelullarised feeders matrix and two fully 
defined pluripotent stem cell media: complete KOSR and mTeSR1, for the feeder-free 
adaptation of the PSCs used in this study. It was determined that GFR-Matrigel and mTeSR1 
was the best combination for feeder-free culture and PSC culture expansion. These results are 
in accordance with those published by a multicentre investigation that also determined that 
these were the best, defined, feeder-free PSC culture conditions (Akopian et al., 2010). Once 
adapted to feeder-free culture conditions, the PSCs could be differentiated. For time constraints, 
it was decided to focus on the differentiation of the eight hESCs only. 
HD is primarily a neurodegenerative disorder. Nevertheless, HTT is an ubiquitously expressed 
protein and disease-specific phenotypes are also present in peripheral tissues (Van Der Burg et 
al., 2009; Sassone et al., 2009; Sathasivam et al., 1999). Epidemiology studies show that 
cardiac defects are a prevalent cause of death amongst HD patients (Sorensen and Fenger, 
1992; Lanska et al., 1988; Chiu and Alexander, 1982). Furthermore, cardiac defects, including 
atrophy, have previously been described in HD murine models (Sathasivam et al., 1999; Mihm 
et al., 2007; Wood, 2012; Kiriazis et al., 2012). For these reasons, it was decided to differentiate 
the hESCs into cardiomyocytes in order to explore the HD phenotype in this cell type, and 
determine if the reported cardiac defects are a cell autonomous or non-cell autonomous 
consequence of HD. To our knowledge, other in vitro human HD cardiomyocytes model 
currently does not exist. 
Several cardiac differentiation protocols were tried, either based on spontaneous or directed 
cardiac differentiation. In our hands, mTeSR1 had an inhibitory effect on cardiac differentiation. 
This observation was further supported by a study by Ojala et al. (2012) that also reported GFR-
Matrigel and mTeSR1 to be the least favourable for cardiac differentiation. Consequently, the 
hESCs were adapted to another fully defined medium, Nutristem. All the hESCs lines but 
KCL012_HD3 could be adapted to it. KCL012_HD3 presented with a lot of spontaneous 
differentiation in these new culture conditions and was excluded from the rest of the study. It 
cannot be excluded that KCL012_HD3 could have acquired a chromosomal abnormality which 
could explain this increased rate of spontaneous differentiation. 
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Using Nutristem and GFR-Matrigel, the Laflamme directed cardiac differentiation protocol 
(Laflamme et al., 2007) was the most dependable in our hands. All the differentiated hESC lines 
but KCL040 presented beating areas within 30 days of differentiation. Despite a range of 
efficiency, the observation of beating areas, the positive immunofluorescence and gene 
expression study of cardiac-specific markers confirmed that the HD-hESCs could be 
differentiated into cardiomyocytes similarly to WT-hESCs. I next chose one WT- and one HD-
hESC line (KCL031 and KCL027_HD5 respectively) with the best cardiac differentiation 
efficiency at 30 days for further investigation. In these samples, I looked at the gene expression 
of 16 cardiac-specific biomarkers. This further confirmed that the HD-hESCs differentiated into 
cardiomyocytes. However, the data also suggested that the HD-hESCs could be less mature 
than the WT-hESCs at 30 days of cardiac differentiation with the Laflamme protocol. 
Next, I looked at the stability of the CAG mutation in the HD-hESC line KCL027_HD5 in 
undifferentiated samples and after 30 and 60 days of cardiac differentiation with the Laflamme 
protocol. The mutation (44 CAG) remained stable throughout differentiation. 
 
 
6.4 Future prospects of HD-PSC modelling 
HD being a late-onset disease, one could wonder if in vitro HD-PSCs could display HD-specific 
phenotypes. Several HD studies have identified HD specific in vitro phenotypes, such as 
increased lysosomal activity in undifferentiated hESCs (Camnasio et al., 2012) and elevated 
caspase in HD-iPSCs derived neurons (Zhang, N. et al., 2010). In the work presented in this 
study our undifferentiated HD-hESCs cannot be distinguished from WT-hESCs. They can also 
be differentiated into cardiomyocytes to study the HD mutation in this somatic cell type. 
However, it is known that there is variability in gene expression in hESCs (Allegrucci and 
Young, 2007), an observation that could also be made in our undifferentiated hESCs (Table 
5.3). Therefore, it is recommended to repeat the cardiac differentiation of the hESCs used in 
this study to further distinguish what could be a potential HD-specific phenotype from cell line 
variability. To completely exclude this possibility, it would be best to work with isogenic lines. An 
et al. (2012) were able to correct the HD mutation by homologous recombination and rescue the 
HD phenotype in their lines this way.  
In this study, gene expression was analysed at 30 days post differentiation. HD being a 
progressive disease, it would be interesting to study later time points. . Further investigation of 
HD-specific cardiac phenotypes could also be complemented by electrophysiology work at the 
single cell level by patch-clamping for instance. Indeed, this technique allows distinguishing 
between different types of cardiomyocytes action potential i.e. ventricular-, atrial- or nodal-like. 
In the case of Long-QT Syndrome iPSC-derived cardiomyocytes, patch clamping revealed 
differences in spontaneous beating of ventricular and atrial Long-QT Syndrome cardiomyocytes 
compared to wild-type cardiomyocytes, while no significant differences could be reported for 
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nodal Long-QT Syndrome cardiomyocytes compared to wild-type cardiomyocytes (Moretti et al., 
2010). On top of studying spontaneous cardiomyocyte beating, the WT-hESC-CMs and the HD-
hESC-CMs could also be electrically stimulated in order to study their adaptive response to 
changing rates of electrical stimulation. Other functional studies that could be performed on the 
cardiomyocytes generated in this study could include comparing the $-adrenergic regulation of 
the WT-hESC-CMs and the HD-hESC-CMs. To do so, the cardiomyocytes could be treated with 
a nonselective $-adrenergic receptor agonist such as isoproterenol. If the cardiomyocytes are 
functional, an increase in heart and decrease in action potential should be observed. Finally, 
analyzing the calcium transients during spontaneous or stimuli-induced beating of the WT-
hESC-CMs and the HD-hESC-CMs could be used for the characterization of the calcium 
channels.  
Recent studies on HD-iPSC-derived neurons observed increased cell death and increase 
caspase activity after growth factor removal (An et al., 2012; Zhang, N. et al., 2010; The HD 
iPSC Consortium, 2012). Stressing the cells by the use of toxic agents or growth factor removal 
might be required in order to observe a phenotype in HD-hESC-CMs. Lastly, as discussed in 
chapter 5, even though beating was observed after 30 days of differentiation in six hESC lines, 
to further explore the HD in vitro cardiac phenotype, the yield of cardiomyocytes needs to be 
improved. This could be achieved by further optimising the cardiac differentiation protocol or by 
enriching the cardiomyocyte population post-differentiation. 
The HD iPSC consortium recently published that the positive correlation between CAG repeat 
size and severity of symptoms observed in HD patients could also be observed in vitro in HD-
iPSC derived neurons (The HD iPSC Consortium, 2012). Even though the CAG-repeat 
expansion associated phenotypes were already reported in transgenic models of HD, this is of 
critical importance as it is from the endogenous mutation. These data further highlight the need 
to generate HD-iPSCs with a wider range of repeats, possibly from JHD patients in the future. 
 
 










- 142 - 
REFERENCES 
Aasen, T. & Belmonte, J. C. 2010. Isolation and cultivation of human keratinocytes from skin or 
plucked hair for the generation of induced pluripotent stem cells. Nat. Protoc., 5, 371-
82. 
Aasen, T., Raya, A., Barrero, M. J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilic, 
J., Pekarik, V., Tiscornia, G., Edel, M., Boue, S. & Izpisua Belmonte, J. C. 2008. 
Efficient and rapid generation of induced pluripotent stem cells from human 
keratinocytes. Nat. Biotechnol., 26, 1276-84. 
Akopian, V., Andrews, P. W., Beil, S., Benvenisty, N., Brehm, J., Christie, M., Ford, A., Fox, V., 
Gokhale, P. J., Healy, L., Holm, F., Hovatta, O., Knowles, B. B., Ludwig, T. E., Mckay, 
R. D., Miyazaki, T., Nakatsuji, N., Oh, S. K., Pera, M. F., Rossant, J., Stacey, G. N. & 
Suemori, H. 2010. Comparison of defined culture systems for feeder cell free 
propagation of human embryonic stem cells. In vitro cellular & developmental biology. 
Animal, 46, 247-58. 
Allegrucci, C. & Young, L. E. 2007. Differences between human embryonic stem cell lines. 
Hum. Reprod. Update, 13, 103-20. 
Alonso, L. & Fuchs, E. 2006. The hair cycle. J. Cell Sci., 119, 391-3. 
Amit, M., Shariki, C., Margulets, V. & Itskovitz-Eldor, J. 2004. Feeder layer- and serum-free 
culture of human embryonic stem cells. Biol. Reprod., 70, 837-45. 
Amps, K., Andrews, P. W., Anyfantis, G., Armstrong, L., Avery, S., Baharvand, H., Baker, J., 
Baker, D., Munoz, M. B., Beil, S., Benvenisty, N., Ben-Yosef, D., Biancotti, J. C., 
Bosman, A., Brena, R. M., Brison, D., Caisander, G., Camarasa, M. V., Chen, J., Chiao, 
E., Choi, Y. M., Choo, A. B., Collins, D., Colman, A., Crook, J. M., Daley, G. Q., Dalton, 
A., De Sousa, P. A., Denning, C., Downie, J., Dvorak, P., Montgomery, K. D., Feki, A., 
Ford, A., Fox, V., Fraga, A. M., Frumkin, T., Ge, L., Gokhale, P. J., Golan-Lev, T., 
Gourabi, H., Gropp, M., Lu, G., Hampl, A., Harron, K., Healy, L., Herath, W., Holm, F., 
Hovatta, O., Hyllner, J., Inamdar, M. S., Irwanto, A. K., Ishii, T., Jaconi, M., Jin, Y., 
Kimber, S., Kiselev, S., Knowles, B. B., Kopper, O., Kukharenko, V., Kuliev, A., 
Lagarkova, M. A., Laird, P. W., Lako, M., Laslett, A. L., Lavon, N., Lee, D. R., Lee, J. E., 
Li, C., Lim, L. S., Ludwig, T. E., Ma, Y., Maltby, E., Mateizel, I., Mayshar, Y., 
Mileikovsky, M., Minger, S. L., Miyazaki, T., Moon, S. Y., Moore, H., Mummery, C., 
Nagy, A., Nakatsuji, N., Narwani, K., Oh, S. K., Olson, C., Otonkoski, T., Pan, F., Park, 
I. H., Pells, S., Pera, M. F., Pereira, L. V., Qi, O., Raj, G. S., Reubinoff, B., Robins, A., 
Robson, P., Rossant, J., Salekdeh, G. H., Schulz, T. C., et al. 2011. Screening 
ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal 
amplicon conferring growth advantage. Nat. Biotechnol., 29, 1132-44. 
An, M. C., Zhang, N., Scott, G., Montoro, D., Wittkop, T., Mooney, S., Melov, S. & Ellerby, L. M. 
2012. Genetic correction of Huntington's disease phenotypes in induced pluripotent 
stem cells. Cell Stem Cell, 11, 253-63. 
Ananiev, G., Williams, E. C., Li, H. & Chang, Q. 2011. Isogenic pairs of wild type and mutant 
induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro 
disease model. PLoS One, 6, e25255. 
Angel, M. & Yanik, M. F. 2010. Innate immune suppression enables frequent transfection with 
RNA encoding reprogramming proteins. PLoS One, 5, e11756. 
Anokye-Danso, F., Trivedi, C. M., Juhr, D., Gupta, M., Cui, Z., Tian, Y., Zhang, Y., Yang, W., 
Gruber, P. J., Epstein, J. A. & Morrisey, E. E. 2011. Highly efficient miRNA-mediated 
reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell, 8, 
376-88. 
Apostol, B. L., Kazantsev, A., Raffioni, S., Illes, K., Pallos, J., Bodai, L., Slepko, N., Bear, J. E., 
Gertler, F. B., Hersch, S., Housman, D. E., Marsh, J. L. & Thompson, L. M. 2003. A cell-
based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease 
and validation in Drosophila. Proc. Natl. Acad. Sci. U. S. A., 100, 5950-5. 
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. 2004. Inclusion body 
formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 
431, 805-10. 
Bari, M., Battista, N., Valenza, M., Mastrangelo, N., Malaponti, M., Catanzaro, G., Centonze, D., 
Finazzi-Agro, A., Cattaneo, E. & Maccarrone, M. 2013. In vitro and in vivo models of 
Huntington's disease show alterations in the endocannabinoid system. The FEBS 
journal, 280, 3376-88. 
Bates, G. P. & Hockly, E. 2003. Experimental therapeutics in Huntington's disease: are models 
useful for therapeutic trials? Curr. Opin. Neurol., 16, 465-70. 
REFERENCES 
- 143 - 
Batista, L. F., Pech, M. F., Zhong, F. L., Nguyen, H. N., Xie, K. T., Zaug, A. J., Crary, S. M., 
Choi, J., Sebastiano, V., Cherry, A., Giri, N., Wernig, M., Alter, B. P., Cech, T. R., 
Savage, S. A., Reijo Pera, R. A. & Artandi, S. E. 2011. Telomere shortening and loss of 
self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature, 474, 399-
402. 
Bauwens, C. L., Song, H., Thavandiran, N., Ungrin, M., Masse, S., Nanthakumar, K., Seguin, C. 
& Zandstra, P. W. 2011. Geometric control of cardiomyogenic induction in human 
pluripotent stem cells. Tissue Eng Part A, 17, 1901-9. 
Beacham, D. A., Amatangelo, M. D. & Cukierman, E. 2007. Preparation of extracellular matrices 
produced by cultured and primary fibroblasts. Curr. Protoc. Cell Biol., Chapter 10, Unit 
10 9. 
Braam, S. R., Zeinstra, L., Litjens, S., Ward-Van Oostwaard, D., Van Den Brink, S., Van Laake, 
L., Lebrin, F., Kats, P., Hochstenbach, R., Passier, R., Sonnenberg, A. & Mummery, C. 
L. 2008. Recombinant vitronectin is a functionally defined substrate that supports 
human embryonic stem cell self-renewal via alphavbeta5 integrin. Stem Cells, 26, 2257-
65. 
Burridge, P. W., Thompson, S., Millrod, M. A., Weinberg, S., Yuan, X., Peters, A., Mahairaki, V., 
Koliatsos, V. E., Tung, L. & Zambidis, E. T. 2011. A universal system for highly efficient 
cardiac differentiation of human induced pluripotent stem cells that eliminates interline 
variability. PLoS One, 6, e18293. 
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., 
Nolan, T., Pfaffl, M. W., Shipley, G. L., Vandesompele, J. & Wittwer, C. T. 2011. Primer 
sequence disclosure: a clarification of the MIQE guidelines. Clin. Chem., 57, 919-21. 
Camnasio, S., Carri, A. D., Lombardo, A., Grad, I., Mariotti, C., Castucci, A., Rozell, B., Riso, P. 
L., Castiglioni, V., Zuccato, C., Rochon, C., Takashima, Y., Diaferia, G., Biunno, I., 
Gellera, C., Jaconi, M., Smith, A., Hovatta, O., Naldini, L., Di Donato, S., Feki, A. & 
Cattaneo, E. 2012. The first reported generation of several induced pluripotent stem cell 
lines from homozygous and heterozygous Huntington's disease patients demonstrates 
mutation related enhanced lysosomal activity. Neurobiol. Dis., 46, 41-51. 
Canals, J. M., Pineda, J. R., Torres-Peraza, J. F., Bosch, M., Martin-Ibanez, R., Munoz, M. T., 
Mengod, G., Ernfors, P. & Alberch, J. 2004. Brain-derived neurotrophic factor regulates 
the onset and severity of motor dysfunction associated with enkephalinergic neuronal 
degeneration in Huntington's disease. The Journal of neuroscience : the official journal 
of the Society for Neuroscience, 24, 7727-39. 
Castiglioni, V., Onorati, M., Rochon, C. & Cattaneo, E. 2012. Induced pluripotent stem cell lines 
from Huntington's disease mice undergo neuronal differentiation while showing 
alterations in the lysosomal pathway. Neurobiol. Dis., 46, 30-40. 
Catalina, P., Montes, R., Ligero, G., Sanchez, L., De La Cueva, T., Bueno, C., Leone, P. E. & 
Menendez, P. 2008. Human ESCs predisposition to karyotypic instability: Is a matter of 
culture adaptation or differential vulnerability among hESC lines due to inherent 
properties? Mol. Cancer, 7, 76. 
Chapman, S., Liu, X., Meyers, C., Schlegel, R. & Mcbride, A. A. 2010. Human keratinocytes are 
efficiently immortalized by a Rho kinase inhibitor. The Journal of clinical investigation, 
120, 2619-26. 
Chetty, S., Pagliuca, F. W., Honore, C., Kweudjeu, A., Rezania, A. & Melton, D. A. 2013. A 
simple tool to improve pluripotent stem cell differentiation. Nature methods, 10, 553-6. 
Chin, M. H., Mason, M. J., Xie, W., Volinia, S., Singer, M., Peterson, C., Ambartsumyan, G., 
Aimiuwu, O., Richter, L., Zhang, J., Khvorostov, I., Ott, V., Grunstein, M., Lavon, N., 
Benvenisty, N., Croce, C. M., Clark, A. T., Baxter, T., Pyle, A. D., Teitell, M. A., 
Pelegrini, M., Plath, K. & Lowry, W. E. 2009. Induced pluripotent stem cells and 
embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell, 
5, 111-23. 
Chiu, E. & Alexander, L. 1982. Causes of death in Huntington's disease. The Medical journal of 
Australia, 1, 153. 
Ciammola, A., Sassone, J., Alberti, L., Meola, G., Mancinelli, E., Russo, M. A., Squitieri, F. & 
Silani, V. 2006. Increased apoptosis, Huntingtin inclusions and altered differentiation in 
muscle cell cultures from Huntington's disease subjects. Cell Death Differ., 13, 2068-78. 
Davies, S. W., Turmaine, M., Cozens, B. A., Difiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, 
E., Wanker, E. E., Mangiarini, L. & Bates, G. P. 1997. Formation of neuronal 
intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the 
HD mutation. Cell, 90, 537-48. 
Dolnikov, K., Shilkrut, M., Zeevi-Levin, N., Gerecht-Nir, S., Amit, M., Danon, A., Itskovitz-Eldor, 
J. & Binah, O. 2006. Functional properties of human embryonic stem cell-derived 
REFERENCES 
- 144 - 
cardiomyocytes: intracellular Ca2+ handling and the role of sarcoplasmic reticulum in 
the contraction. Stem Cells, 24, 236-45. 
Dragatsis, I., Levine, M. S. & Zeitlin, S. 2000. Inactivation of Hdh in the brain and testis results 
in progressive neurodegeneration and sterility in mice. Nat. Genet., 26, 300-6. 
Draper, J. S., Smith, K., Gokhale, P., Moore, H. D., Maltby, E., Johnson, J., Meisner, L., Zwaka, 
T. P., Thomson, J. A. & Andrews, P. W. 2004. Recurrent gain of chromosomes 17q and 
12 in cultured human embryonic stem cells. Nat. Biotechnol., 22, 53-4. 
Dubois, N. C., Craft, A. M., Sharma, P., Elliott, D. A., Stanley, E. G., Elefanty, A. G., Gramolini, 
A. & Keller, G. 2011. SIRPA is a specific cell-surface marker for isolating 
cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 
Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., 
Ross, C., Franz, M., Abbott, M. & Et Al. 1993. Trinucleotide repeat length instability and 
age of onset in Huntington's disease. Nat. Genet., 4, 387-92. 
Elliott, D. A., Braam, S. R., Koutsis, K., Ng, E. S., Jenny, R., Lagerqvist, E. L., Biben, C., 
Hatzistavrou, T., Hirst, C. E., Yu, Q. C., Skelton, R. J., Ward-Van Oostwaard, D., Lim, 
S. M., Khammy, O., Li, X., Hawes, S. M., Davis, R. P., Goulburn, A. L., Passier, R., 
Prall, O. W., Haynes, J. M., Pouton, C. W., Kaye, D. M., Mummery, C. L., Elefanty, A. 
G. & Stanley, E. G. 2011. NKX2-5(eGFP/w) hESCs for isolation of human cardiac 
progenitors and cardiomyocytes. Nat Methods. 
Epping, E. A. & Paulsen, J. S. 2011. Depression in the early stages of Huntington disease. 
Neurodegener. Dis. Manag., 1, 407-414. 
Fath, S., Bauer, A. P., Liss, M., Spriestersbach, A., Maertens, B., Hahn, P., Ludwig, C., Schafer, 
F., Graf, M. & Wagner, R. 2011. Multiparameter RNA and codon optimization: a 
standardized tool to assess and enhance autologous mammalian gene expression. 
PLoS One, 6, e17596. 
Foldes, G., Mioulane, M., Wright, J. S., Liu, A. Q., Novak, P., Merkely, B., Gorelik, J., Schneider, 
M. D., Ali, N. N. & Harding, S. E. 2011. Modulation of human embryonic stem cell-
derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy? J. 
Mol. Cell. Cardiol., 50, 367-76. 
Fortson, W. S., Kayarthodi, S., Fujimura, Y., Xu, H., Matthews, R., Grizzle, W. E., Rao, V. N., 
Bhat, G. K. & Reddy, E. S. 2011. Histone deacetylase inhibitors, valproic acid and 
trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive 
prostate cancer cells. Int. J. Oncol., 39, 111-9. 
Fox, J. H., Barber, D. S., Singh, B., Zucker, B., Swindell, M. K., Norflus, F., Buzescu, R., 
Chopra, R., Ferrante, R. J., Kazantsev, A. & Hersch, S. M. 2004. Cystamine increases 
L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model 
of polyglutamine aggregation. J. Neurochem., 91, 413-22. 
Frenkel, G. D., Walcott, A. & Middleton, C. 1987. Inhibition of RNA and DNA polymerases by 
the product of the reaction of selenite with sulfhydryl compounds. Mol. Pharmacol., 31, 
112-6. 
Fujiki, R., Sato, A., Fujitani, M. & Yamashita, T. 2013. A proapoptotic effect of valproic acid on 
progenitors of embryonic stem cell-derived glutamatergic neurons. Cell Death Dis., 4, 
e677. 
Furue, M. K., Na, J., Jackson, J. P., Okamoto, T., Jones, M., Baker, D., Hata, R., Moore, H. D., 
Sato, J. D. & Andrews, P. W. 2008. Heparin promotes the growth of human embryonic 
stem cells in a defined serum-free medium. Proc. Natl. Acad. Sci. U. S. A., 105, 13409-
14. 
Fusaki, N., Ban, H., Nishiyama, A., Saeki, K. & Hasegawa, M. 2009. Efficient induction of 
transgene-free human pluripotent stem cells using a vector based on Sendai virus, an 
RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B Phys. 
Biol. Sci., 85, 348-62. 
Gallo, P., Grimaldi, S., Latronico, M. V., Bonci, D., Pagliuca, A., Ausoni, S., Peschle, C. & 
Condorelli, G. 2008. A lentiviral vector with a short troponin-I promoter for tracking 
cardiomyocyte differentiation of human embryonic stem cells. Gene Ther., 15, 161-70. 
Germanguz, I., Sedan, O., Zeevi-Levin, N., Shtrichman, R., Barak, E., Ziskind, A., Eliyahu, S., 
Meiry, G., Amit, M., Itskovitz-Eldor, J. & Binah, O. 2011. Molecular characterization and 
functional properties of cardiomyocytes derived from human inducible pluripotent stem 
cells. J. Cell. Mol. Med., 15, 38-51. 
Gherghiceanu, M., Barad, L., Novak, A., Reiter, I., Itskovitz-Eldor, J., Binah, O. & Popescu, L. 
M. 2011. Cardiomyocytes derived from human embryonic and induced pluripotent stem 
cells: comparative ultrastructure. J. Cell. Mol. Med., 15, 2539-51. 
REFERENCES 
- 145 - 
Ghosh, Z., Wilson, K. D., Wu, Y., Hu, S., Quertermous, T. & Wu, J. C. 2010. Persistent donor 
cell gene expression among human induced pluripotent stem cells contributes to 
differences with human embryonic stem cells. PLoS One, 5, e8975. 
Graichen, R., Xu, X., Braam, S. R., Balakrishnan, T., Norfiza, S., Sieh, S., Soo, S. Y., Tham, S. 
C., Mummery, C., Colman, A., Zweigerdt, R. & Davidson, B. P. 2008. Enhanced 
Cardiomyogenesis Of Human Embryonic Stem Cells By A Small Molecular Inhibitor Of 
P38 MAPK. Differentiation, 76, 357-70. 
Gray, M., Shirasaki, D. I., Cepeda, C., Andre, V. M., Wilburn, B., Lu, X. H., Tao, J., Yamazaki, I., 
Li, S. H., Sun, Y. E., Li, X. J., Levine, M. S. & Yang, X. W. 2008. Full-length human 
mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective 
neuropathogenesis in BACHD mice. The Journal of neuroscience : the official journal of 
the Society for Neuroscience, 28, 6182-95. 
Guenther, M. G., Frampton, G. M., Soldner, F., Hockemeyer, D., Mitalipova, M., Jaenisch, R. & 
Young, R. A. 2010. Chromatin structure and gene expression programs of human 
embryonic and induced pluripotent stem cells. Cell Stem Cell, 7, 249-57. 
Handyside, A. H., Kontogianni, E. H., Hardy, K. & Winston, R. M. 1990. Pregnancies from 
biopsied human preimplantation embryos sexed by Y-specific DNA amplification. 
Nature, 344, 768-70. 
Harjes, P. & Wanker, E. E. 2003. The hunt for huntingtin function: interaction partners tell many 
different stories. Trends Biochem. Sci., 28, 425-33. 
Heath, K. E., Day, I. N. & Humphries, S. E. 2000. Universal primer quantitative fluorescent 
multiplex (UPQFM) PCR: a method to detect major and minor rearrangements of the 
low density lipoprotein receptor gene. J. Med. Genet., 37, 272-80. 
Hockemeyer, D., Wang, H., Kiani, S., Lai, C. S., Gao, Q., Cassady, J. P., Cost, G. J., Zhang, L., 
Santiago, Y., Miller, J. C., Zeitler, B., Cherone, J. M., Meng, X., Hinkley, S. J., Rebar, E. 
J., Gregory, P. D., Urnov, F. D. & Jaenisch, R. 2011. Genetic engineering of human 
pluripotent cells using TALE nucleases. Nat. Biotechnol., 29, 731-4. 
Hockly, E., Woodman, B., Mahal, A., Lewis, C. M. & Bates, G. 2003. Standardization and 
statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull., 61, 469-
79. 
Hodgson, J. G., Agopyan, N., Gutekunst, C. A., Leavitt, B. R., Lepiane, F., Singaraja, R., Smith, 
D. J., Bissada, N., Mccutcheon, K., Nasir, J., Jamot, L., Li, X. J., Stevens, M. E., 
Rosemond, E., Roder, J. C., Phillips, A. G., Rubin, E. M., Hersch, S. M. & Hayden, M. 
R. 1999. A YAC mouse model for Huntington's disease with full-length mutant 
huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 23, 
181-92. 
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K. & 
Yamanaka, S. 2009. Suppression of induced pluripotent stem cell generation by the 
p53-p21 pathway. Nature, 460, 1132-5. 
Honn, K. V., Singley, J. A. & Chavin, W. 1975. Fetal bovine serum: a multivariate standard. 
Proceedings of the Society for Experimental Biology and Medicine. Society for 
Experimental Biology and Medicine, 149, 344-7. 
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., Muhlestein, W. & 
Melton, D. A. 2008. Induction of pluripotent stem cells from primary human fibroblasts 
with only Oct4 and Sox2. Nat. Biotechnol., 26, 1269-75. 
Huber, I., Itzhaki, I., Caspi, O., Arbel, G., Tzukerman, M., Gepstein, A., Habib, M., Yankelson, 
L., Kehat, I. & Gepstein, L. 2007. Identification and selection of cardiomyocytes during 
human embryonic stem cell differentiation. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology, 21, 2551-63. 
Huntington, G. 1872. On Chorea. Medical and Surgical Reporter, 26, 317-321. 
Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., 
Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C. & Braude, P. 2012. 
Derivation and feeder-free propagation of human embryonic stem cells under xeno-free 
conditions. Cytotherapy, 14, 122-8. 
Irwin, E. F., Gupta, R., Dashti, D. C. & Healy, K. E. 2011. Engineered polymer-media interfaces 
for the long-term self-renewal of human embryonic stem cells. Biomaterials, 32, 6912-9. 
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van 
Gorp, S., Nazor, K. L., Boscolo, F. S., Carson, C. T., Laurent, L. C., Marsala, M., Gage, 
F. H., Remes, A. M., Koo, E. H. & Goldstein, L. S. 2012. Probing sporadic and familial 
Alzheimer's disease using induced pluripotent stem cells. Nature, 482, 216-20. 
Itskovitz-Eldor, J., Schuldiner, M., Karsenti, D., Eden, A., Yanuka, O., Amit, M., Soreq, H. & 
Benvenisty, N. 2000. Differentiation of human embryonic stem cells into embryoid 
bodies compromising the three embryonic germ layers. Mol. Med., 6, 88-95. 
REFERENCES 
- 146 - 
Jackson, G. R., Salecker, I., Dong, X., Yao, X., Arnheim, N., Faber, P. W., Macdonald, M. E. & 
Zipursky, S. L. 1998. Polyglutamine-expanded human huntingtin transgenes induce 
degeneration of Drosophila photoreceptor neurons. Neuron, 21, 633-42. 
Jackson-Grusby, L., Beard, C., Possemato, R., Tudor, M., Fambrough, D., Csankovszki, G., 
Dausman, J., Lee, P., Wilson, C., Lander, E. & Jaenisch, R. 2001. Loss of genomic 
methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat. Genet., 
27, 31-9. 
Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J., Al-Bedaery, R., Renwick, P., 
Ogilvie, C., Vaughan, R. & Ilic, D. 2013. Strategy for the creation of clinical grade hESC 
line banks that HLA-match a target population. EMBO Mol Med, 5, 10-7. 
Jacobsen, J. C., Bawden, C. S., Rudiger, S. R., Mclaughlan, C. J., Reid, S. J., Waldvogel, H. J., 
Macdonald, M. E., Gusella, J. F., Walker, S. K., Kelly, J. M., Webb, G. C., Faull, R. L., 
Rees, M. I. & Snell, R. G. 2010. An ovine transgenic Huntington's disease model. Hum. 
Mol. Genet., 19, 1873-82. 
Jovicic, A., Zaldivar Jolissaint, J. F., Moser, R., Silva Santos Mde, F. & Luthi-Carter, R. 2013. 
MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic 
effects and may also target specific Huntington's disease-related mechanisms. PLoS 
One, 8, e54222. 
Kaufman, D. S., Hanson, E. T., Lewis, R. L., Auerbach, R. & Thomson, J. A. 2001. 
Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc. 
Natl. Acad. Sci. U. S. A., 98, 10716-21. 
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M. & 
Izpisua Belmonte, J. C. 2009. Linking the p53 tumour suppressor pathway to somatic 
cell reprogramming. Nature, 460, 1140-4. 
Kehat, I., Kenyagin-Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, 
O., Itskovitz-Eldor, J. & Gepstein, L. 2001. Human embryonic stem cells can 
differentiate into myocytes with structural and functional properties of cardiomyocytes. 
The Journal of clinical investigation, 108, 407-14. 
Kennedy, L., Evans, E., Chen, C. M., Craven, L., Detloff, P. J., Ennis, M. & Shelbourne, P. F. 
2003. Dramatic tissue-specific mutation length increases are an early molecular event 
in Huntington disease pathogenesis. Hum. Mol. Genet., 12, 3359-67. 
Kensah, G., Roa Lara, A., Dahlmann, J., Zweigerdt, R., Schwanke, K., Hegermann, J., Skvorc, 
D., Gawol, A., Azizian, A., Wagner, S., Maier, L. S., Krause, A., Drager, G., Ochs, M., 
Haverich, A., Gruh, I. & Martin, U. 2013. Murine and human pluripotent stem cell-
derived cardiac bodies form contractile myocardial tissue in vitro. Eur. Heart J., 34, 
1134-46. 
Kim, D., Kim, C. H., Moon, J. I., Chung, Y. G., Chang, M. Y., Han, B. S., Ko, S., Yang, E., Cha, 
K. Y., Lanza, R. & Kim, K. S. 2009. Generation of human induced pluripotent stem cells 
by direct delivery of reprogramming proteins. Cell Stem Cell, 4, 472-6. 
Kim, H. T., Lee, K. I., Kim, D. W. & Hwang, D. Y. 2013. An ECM-based culture system for the 
generation and maintenance of xeno-free human iPS cells. Biomaterials, 34, 1041-50. 
Kim, K., Zhao, R., Doi, A., Ng, K., Unternaehrer, J., Cahan, P., Hongguang, H., Loh, Y. H., 
Aryee, M. J., Lensch, M. W., Li, H., Collins, J. J., Feinberg, A. P. & Daley, G. Q. 2011. 
Donor cell type can influence the epigenome and differentiation potential of human 
induced pluripotent stem cells. Nat. Biotechnol. 
Kim, K. Y., Hysolli, E. & Park, I. H. 2011. Neuronal maturation defect in induced pluripotent stem 
cells from patients with Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 
Kim, M., Lee, H. S., Laforet, G., Mcintyre, C., Martin, E. J., Chang, P., Kim, T. W., Williams, M., 
Reddy, P. H., Tagle, D., Boyce, F. M., Won, L., Heller, A., Aronin, N. & Difiglia, M. 1999. 
Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation 
and neuronal survival by caspase inhibition. The Journal of neuroscience : the official 
journal of the Society for Neuroscience, 19, 964-73. 
Kiriazis, H., Jennings, N. L., Davern, P., Lambert, G., Su, Y., Pang, T., Du, X., La Greca, L., 
Head, G. A., Hannan, A. J. & Du, X. J. 2012. Neurocardiac dysregulation and 
neurogenic arrhythmias in a transgenic mouse model of Huntington's disease. The 
Journal of physiology, 590, 5845-60. 
Kita-Matsuo, H., Barcova, M., Prigozhina, N., Salomonis, N., Wei, K., Jacot, J. G., Nelson, B., 
Spiering, S., Haverslag, R., Kim, C., Talantova, M., Bajpai, R., Calzolari, D., Terskikh, 
A., Mcculloch, A. D., Price, J. H., Conklin, B. R., Chen, H. S. & Mercola, M. 2009. 
Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking 
and drug resistance selection of cardiomyocytes. PLoS One, 4, e5046. 
REFERENCES 
- 147 - 
Kleinman, H. K., Mcgarvey, M. L., Liotta, L. A., Robey, P. G., Tryggvason, K. & Martin, G. R. 
1982. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate 
proteoglycan from the EHS sarcoma. Biochemistry, 21, 6188-93. 
Klimanskaya, I., Chung, Y., Meisner, L., Johnson, J., West, M. D. & Lanza, R. 2005. Human 
embryonic stem cells derived without feeder cells. Lancet, 365, 1636-41. 
Laflamme, M. A., Chen, K. Y., Naumova, A. V., Muskheli, V., Fugate, J. A., Dupras, S. K., 
Reinecke, H., Xu, C., Hassanipour, M., Police, S., O'sullivan, C., Collins, L., Chen, Y., 
Minami, E., Gill, E. A., Ueno, S., Yuan, C., Gold, J. & Murry, C. E. 2007. 
Cardiomyocytes derived from human embryonic stem cells in pro-survival factors 
enhance function of infarcted rat hearts. Nat. Biotechnol., 25, 1015-24. 
Lahti, A. L., Kujala, V. J., Chapman, H., Koivisto, A. P., Pekkanen-Mattila, M., Kerkela, E., 
Hyttinen, J., Kontula, K., Swan, H., Conklin, B. R., Yamanaka, S., Silvennoinen, O. & 
Aalto-Setala, K. 2011. Model for long QT syndrome type 2 using human iPS cells 
demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 
Lan, F., Lee, A. S., Liang, P., Sanchez-Freire, V., Nguyen, P. K., Wang, L., Han, L., Yen, M., 
Wang, Y., Sun, N., Abilez, O. J., Hu, S., Ebert, A. D., Navarrete, E. G., Simmons, C. S., 
Wheeler, M., Pruitt, B., Lewis, R., Yamaguchi, Y., Ashley, E. A., Bers, D. M., Robbins, 
R. C., Longaker, M. T. & Wu, J. C. 2013. Abnormal calcium handling properties underlie 
familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent 
stem cells. Cell Stem Cell, 12, 101-13. 
Landles, C. & Bates, G. P. 2004. Huntingtin and the molecular pathogenesis of Huntington's 
disease. Fourth in molecular medicine review series. EMBO reports, 5, 958-63. 
Lanska, D. J., Lavine, L., Lanska, M. J. & Schoenberg, B. S. 1988. Huntington's disease 
mortality in the United States. Neurology, 38, 769-72. 
Laowtammathron, C., Cheng, E. C., Cheng, P.-H., Snyder, B. R., Yang, S.-H., Johnson, Z., 
Lorthongpanich, C., Kuo, H.-C., Parnpai, R. & Chan, A. W. S. 2010. Monkey hybrid 
stem cells develop cellular features of Huntington's disease. BMC Cell Biol., 11, 12. 
Lefort, N., Feyeux, M., Bas, C., Feraud, O., Bennaceur-Griscelli, A., Tachdjian, G., Peschanski, 
M. & Perrier, A. L. 2008. Human embryonic stem cells reveal recurrent genomic 
instability at 20q11.21. Nat. Biotechnol., 26, 1364-6. 
Legleiter, J., Mitchell, E., Lotz, G. P., Sapp, E., Ng, C., Difiglia, M., Thompson, L. M. & 
Muchowski, P. J. 2010. Mutant huntingtin fragments form oligomers in a polyglutamine 
length-dependent manner in vitro and in vivo. The Journal of biological chemistry, 285, 
14777-90. 
Leonova, K. I., Brodsky, L., Lipchick, B., Pal, M., Novototskaya, L., Chenchik, A. A., Sen, G. C., 
Komarova, E. A. & Gudkov, A. V. 2013. p53 cooperates with DNA methylation and a 
suicidal interferon response to maintain epigenetic silencing of repeats and noncoding 
RNAs. Proc. Natl. Acad. Sci. U. S. A., 110, E89-98. 
Levine, M. S., Klapstein, G. J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M. E., Jokel, E. S., 
Carpenter, E. M., Zanjani, H., Hurst, R. S., Efstratiadis, A., Zeitlin, S. & Chesselet, M. F. 
1999. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic 
and knockin mouse models of Huntington's disease. J. Neurosci. Res., 58, 515-32. 
Li, S. H., Schilling, G., Young, W. S., 3rd, Li, X. J., Margolis, R. L., Stine, O. C., Wagster, M. V., 
Abbott, M. H., Franz, M. L., Ranen, N. G. & Et Al. 1993. Huntington's disease gene 
(IT15) is widely expressed in human and rat tissues. Neuron, 11, 985-93. 
Li, Y., Powell, S., Brunette, E., Lebkowski, J. & Mandalam, R. 2005. Expansion of human 
embryonic stem cells in defined serum-free medium devoid of animal-derived products. 
Biotechnol. Bioeng., 91, 688-98. 
Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., Raval, K. K., Zhang, J., 
Kamp, T. J. & Palecek, S. P. 2012a. Robust cardiomyocyte differentiation from human 
pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. 
Acad. Sci. U. S. A. 
Lian, X., Zhang, J., Zhu, K., Kamp, T. J. & Palecek, S. P. 2012b. Insulin Inhibits Cardiac 
Mesoderm, not Mesendoderm, formation during Cardiac Differentiation of Human 
Pluripotent Stem Cells and Modulation of Canonical Wnt Signaling Can Rescue this 
Inhibition. Stem Cells. 
Lian, X., Zhang, J., Zhu, K., Kamp, T. J. & Palecek, S. P. 2013. Insulin inhibits cardiac 
mesoderm, not mesendoderm, formation during cardiac differentiation of human 
pluripotent stem cells and modulation of canonical Wnt signaling can rescue this 
inhibition. Stem Cells, 31, 447-57. 
Lim, H. C., Lee, S. T., Chu, K., Joo, K. M., Kang, L., Im, W. S., Park, J. E., Kim, S. U., Kim, M. & 
Cha, C. I. 2008. Neuroprotective effect of neural stem cell-conditioned media in in vitro 
model of Huntington's disease. Neurosci. Lett., 435, 175-80. 
REFERENCES 
- 148 - 
Linta, L., Stockmann, M., Kleinhans, K. N., Bockers, A., Storch, A., Zaehres, H., Lin, Q., Barbi, 
G., Bockers, T. M., Kleger, A. & Liebau, S. 2012. Rat embryonic fibroblasts improve 
reprogramming of human keratinocytes into induced pluripotent stem cells. Stem cells 
and development, 21, 965-76. 
Lorincz, M. T. & Zawistowski, V. A. 2009. Expanded CAG repeats in the murine Huntington's 
disease gene increases neuronal differentiation of embryonic and neural stem cells. 
Mol. Cell. Neurosci., 40, 1-13. 
Loser, P., Schirm, J., Guhr, A., Wobus, A. M. & Kurtz, A. 2010. Human embryonic stem cell 
lines and their use in international research. Stem Cells, 28, 240-6. 
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T. & 
Plath, K. 2008. Generation of human induced pluripotent stem cells from dermal 
fibroblasts. Proc. Natl. Acad. Sci. U. S. A., 105, 2883-8. 
Lu, B. & Palacino, J. 2013. A novel human embryonic stem cell-derived Huntington's disease 
neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-
dependent neurodegeneration. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology, 27, 1820-9. 
Ludwig, T. & J, A. T. 2007. Defined, feeder-independent medium for human embryonic stem cell 
culture. Curr. Protoc. Stem Cell Biol., Chapter 1, Unit 1C 2. 
Lunkes, A. & Mandel, J. L. 1998. A cellular model that recapitulates major pathogenic steps of 
Huntington's disease. Hum. Mol. Genet., 7, 1355-61. 
Ma, D., Wei, H., Lu, J., Ho, S., Zhang, G., Sun, X., Oh, Y., Tan, S. H., Ng, M. L., Shim, W., 
Wong, P. & Liew, R. 2012. Generation of patient-specific induced pluripotent stem cell-
derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular 
cardiomyopathy. Eur. Heart J. 
Maherali, N., Ahfeldt, T., Rigamonti, A., Utikal, J., Cowan, C. & Hochedlinger, K. 2008. A high-
efficiency system for the generation and study of human induced pluripotent stem cells. 
Cell Stem Cell, 3, 340-5. 
Maitra, A., Arking, D. E., Shivapurkar, N., Ikeda, M., Stastny, V., Kassauei, K., Sui, G., Cutler, D. 
J., Liu, Y., Brimble, S. N., Noaksson, K., Hyllner, J., Schulz, T. C., Zeng, X., Freed, W. 
J., Crook, J., Abraham, S., Colman, A., Sartipy, P., Matsui, S., Carpenter, M., Gazdar, 
A. F., Rao, M. & Chakravarti, A. 2005. Genomic alterations in cultured human 
embryonic stem cells. Nat. Genet., 37, 1099-103. 
Mandal, P. K. & Rossi, D. J. 2013. Reprogramming human fibroblasts to pluripotency using 
modified mRNA. Nat. Protoc., 8, 568-82. 
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., 
Trottier, Y., Lehrach, H., Davies, S. W. & Bates, G. P. 1996. Exon 1 of the HD gene with 
an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in 
transgenic mice. Cell, 87, 493-506. 
Margolis, R. L. & Ross, C. A. 2003. Diagnosis of Huntington disease. Clin. Chem., 49, 1726-32. 
Marion, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., 
Serrano, M. & Blasco, M. A. 2009. A p53-mediated DNA damage response limits 
reprogramming to ensure iPS cell genomic integrity. Nature, 460, 1149-53. 
Mason, R. P. & Giorgini, F. 2011. Modeling Huntington disease in yeast: perspectives and 
future directions. Prion, 5, 269-76. 
Mayshar, Y., Ben-David, U., Lavon, N., Biancotti, J. C., Yakir, B., Clark, A. T., Plath, K., Lowry, 
W. E. & Benvenisty, N. 2010. Identification and classification of chromosomal 
aberrations in human induced pluripotent stem cells. Cell Stem Cell, 7, 521-31. 
Mcmullan, R., Lax, S., Robertson, V. H., Radford, D. J., Broad, S., Watt, F. M., Rowles, A., 
Croft, D. R., Olson, M. F. & Hotchin, N. A. 2003. Keratinocyte differentiation is regulated 
by the Rho and ROCK signaling pathway. Current biology : CB, 13, 2185-9. 
Melkoumian, Z., Weber, J. L., Weber, D. M., Fadeev, A. G., Zhou, Y., Dolley-Sonneville, P., 
Yang, J., Qiu, L., Priest, C. A., Shogbon, C., Martin, A. W., Nelson, J., West, P., Beltzer, 
J. P., Pal, S. & Brandenberger, R. 2010. Synthetic peptide-acrylate surfaces for long-
term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. 
Nat. Biotechnol., 28, 606-10. 
Menalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S. & Chesselet, M. F. 2003. Time course of 
early motor and neuropathological anomalies in a knock-in mouse model of 
Huntington's disease with 140 CAG repeats. The Journal of comparative neurology, 
465, 11-26. 
Mendel, G. 1865. Versuche über Pflanzenhybriden. Proc. Nat. Hist. Soc. Brunn 4, 3-47. 
Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A. & Hoyt, K. R. 
2007. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol. 
Dis., 25, 297-308. 
REFERENCES 
- 149 - 
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., 
Leung, E., Hinkley, S. J., Dulay, G. P., Hua, K. L., Ankoudinova, I., Cost, G. J., Urnov, 
F. D., Zhang, H. S., Holmes, M. C., Zhang, L., Gregory, P. D. & Rebar, E. J. 2011. A 
TALE nuclease architecture for efficient genome editing. Nat. Biotechnol., 29, 143-8. 
Minami, I., Yamada, K., Otsuji, T. G., Yamamoto, T., Shen, Y., Otsuka, S., Kadota, S., Morone, 
N., Barve, M., Asai, Y., Tenkova-Heuser, T., Heuser, J. E., Uesugi, M., Aiba, K. & 
Nakatsuji, N. 2012. A small molecule that promotes cardiac differentiation of human 
pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell reports, 2, 
1448-60. 
Miyoshi, N., Ishii, H., Nagano, H., Haraguchi, N., Dewi, D. L., Kano, Y., Nishikawa, S., 
Tanemura, M., Mimori, K., Tanaka, F., Saito, T., Nishimura, J., Takemasa, I., 
Mizushima, T., Ikeda, M., Yamamoto, H., Sekimoto, M., Doki, Y. & Mori, M. 2011. 
Reprogramming of mouse and human cells to pluripotency using mature microRNAs. 
Cell Stem Cell, 8, 633-8. 
Moffitt, H., Mcphail, G. D., Woodman, B., Hobbs, C. & Bates, G. P. 2009. Formation of 
polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in 
mouse model of Huntington's disease. PLoS One, 4, e8025. 
Morton, A. J. & Avanzo, L. 2011. Executive decision-making in the domestic sheep. PLoS One, 
6, e15752. 
Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G. & Erlich, H. 1986. Specific enzymatic 
amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb. Symp. 
Quant. Biol., 51 Pt 1, 263-73. 
Mummery, C., Ward-Van Oostwaard, D., Doevendans, P., Spijker, R., Van Den Brink, S., 
Hassink, R., Van Der Heyden, M., Opthof, T., Pera, M., De La Riviere, A. B., Passier, R. 
& Tertoolen, L. 2003. Differentiation of human embryonic stem cells to cardiomyocytes: 
role of coculture with visceral endoderm-like cells. Circulation, 107, 2733-40. 
Nagaoka, M., Si-Tayeb, K., Akaike, T. & Duncan, S. A. 2010. Culture of human pluripotent stem 
cells using completely defined conditions on a recombinant E-cadherin substratum. 
BMC Dev. Biol., 10, 60. 
Ng, E. S., Davis, R., Stanley, E. G. & Elefanty, A. G. 2008. A protocol describing the use of a 
recombinant protein-based, animal product-free medium (APEL) for human embryonic 
stem cell differentiation as spin embryoid bodies. Nat. Protoc., 3, 768-76. 
Ng, S. B., Turner, E. H., Robertson, P. D., Flygare, S. D., Bigham, A. W., Lee, C., Shaffer, T., 
Wong, M., Bhattacharjee, A., Eichler, E. E., Bamshad, M., Nickerson, D. A. & Shendure, 
J. 2009. Targeted capture and massively parallel sequencing of 12 human exomes. 
Nature, 461, 272-6. 
Niclis, J. C., Trounson, A. O., Dottori, M., Ellisdon, A. M., Bottomley, S. P., Verlinsky, Y. & Cram, 
D. S. 2009a. Human embryonic stem cell models of Huntington disease. Reprod 
Biomed Online, 19, 106-13. 
Niclis, J. C., Trounson, A. O., Dottori, M., Ellisdon, A. M., Bottomley, S. P., Verlinsky, Y. & Cram, 
D. S. 2009b. Human embryonic stem cell models of Huntington disease. Reproductive 
Biomedicine Online, 19, 106-13. 
Novak, A., Shtrichman, R., Germanguz, I., Segev, H., Zeevi-Levin, N., Fishman, B., Mandel, Y. 
E., Barad, L., Domev, H., Kotton, D., Mostoslavsky, G., Binah, O. & Itskovitz-Eldor, J. 
2010. Enhanced reprogramming and cardiac differentiation of human keratinocytes 
derived from plucked hair follicles, using a single excisable lentivirus. Cellular 
Reprogramming, 12, 665-78. 
Ojala, M., Rajala, K., Pekkanen-Mattila, M., Miettinen, M., Huhtala, H. & Aalto-Setala, K. 2012. 
Culture conditions affect cardiac differentiation potential of human pluripotent stem 
cells. PLoS One, 7, e48659. 
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T. & Yamanaka, S. 2008. Generation of 
mouse induced pluripotent stem cells without viral vectors. Science, 322, 949-53. 
Olmer, R., Haase, A., Merkert, S., Cui, W., Palecek, J., Ran, C., Kirschning, A., Scheper, T., 
Glage, S., Miller, K., Curnow, E. C., Hayes, E. S. & Martin, U. 2010. Long term 
expansion of undifferentiated human iPS and ES cells in suspension culture using a 
defined medium. Stem cell research, 5, 51-64. 
Park, Y., Kim, J. H., Lee, S. J., Choi, I. Y., Park, S. J., Lee, S. R., Sung, H. J., Yoo, Y. D., Geum, 
D. H., Choi, C. W., Kim, S. H. & Kim, B. S. 2011. Human Feeder Cells Can Support the 
Undifferentiated Growth of Human and Mouse Embryonic Stem Cells Using Their Own 
Basic Fibroblast Growth Factors. Stem Cells Dev. 
Parker, J. A., Connolly, J. B., Wellington, C., Hayden, M., Dausset, J. & Neri, C. 2001. 
Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and 
REFERENCES 
- 150 - 
severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. 
Acad. Sci. U. S. A., 98, 13318-23. 
Pasca, S. P., Portmann, T., Voineagu, I., Yazawa, M., Shcheglovitov, A., Pasca, A. M., Cord, 
B., Palmer, T. D., Chikahisa, S., Nishino, S., Bernstein, J. A., Hallmayer, J., Geschwind, 
D. H. & Dolmetsch, R. E. 2011. Using iPSC-derived neurons to uncover cellular 
phenotypes associated with Timothy syndrome. Nat. Med., 17, 1657-62. 
Pattison, J. S., Sanbe, A., Maloyan, A., Osinska, H., Klevitsky, R. & Robbins, J. 2008. 
Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. 
Circulation, 117, 2743-51. 
Petit, I., Kesner, N. S., Karry, R., Robicsek, O., Aberdam, E., Muller, F. J., Aberdam, D. & Ben-
Shachar, D. 2012. Induced pluripotent stem cells from hair follicles as a cellular model 
for neurodevelopmental disorders. Stem Cell Res, 8, 134-40. 
Puppala, D., Collis, L. P., Sun, S. Z., Bonato, V., Chen, X., Anson, B., Pletcher, M., Fermini, B. 
& Engle, S. J. 2013. Comparative gene expression profiling in human-induced 
pluripotent stem cell--derived cardiocytes and human and cynomolgus heart tissue. 
Toxicological sciences : an official journal of the Society of Toxicology, 131, 292-301. 
Ramaswamy, S., Mcbride, J. L. & Kordower, J. H. 2007. Animal models of Huntington's disease. 
ILAR journal / National Research Council, Institute of Laboratory Animal Resources, 48, 
356-73. 
Reik, W. 2007. Stability and flexibility of epigenetic gene regulation in mammalian development. 
Nature, 447, 425-32. 
Rigamonti, D., Bauer, J. H., De-Fraja, C., Conti, L., Sipione, S., Sciorati, C., Clementi, E., 
Hackam, A., Hayden, M. R., Li, Y., Cooper, J. K., Ross, C. A., Govoni, S., Vincenz, C. & 
Cattaneo, E. 2000. Wild-type huntingtin protects from apoptosis upstream of caspase-3. 
The Journal of neuroscience : the official journal of the Society for Neuroscience, 20, 
3705-13. 
Ritner, C., Wong, S. S., King, F. W., Mihardja, S. S., Liszewski, W., Erle, D. J., Lee, R. J. & 
Bernstein, H. S. 2011. An engineered cardiac reporter cell line identifies human 
embryonic stem cell-derived myocardial precursors. PLoS One, 6, e16004. 
Robinton, D. A. & Daley, G. Q. 2012. The promise of induced pluripotent stem cells in research 
and therapy. Nature, 481, 295-305. 
Ruiz, S., Diep, D., Gore, A., Panopoulos, A. D., Montserrat, N., Plongthongkum, N., Kumar, S., 
Fung, H. L., Giorgetti, A., Bilic, J., Batchelder, E. M., Zaehres, H., Kan, N. G., Scholer, 
H. R., Mercola, M., Zhang, K. & Izpisua Belmonte, J. C. 2012. Identification of a specific 
reprogramming-associated epigenetic signature in human induced pluripotent stem 
cells. Proc. Natl. Acad. Sci. U. S. A., 109, 16196-201. 
Rust, W., Balakrishnan, T. & Zweigerdt, R. 2009. Cardiomyocyte enrichment from human 
embryonic stem cell cultures by selection of ALCAM surface expression. Regen. Med., 
4, 225-37. 
Rutland, C. S., Polo-Parada, L., Ehler, E., Alibhai, A., Thorpe, A., Suren, S., Emes, R. D., Patel, 
B. & Loughna, S. 2011. Knockdown of embryonic myosin heavy chain reveals an 
essential role in the morphology and function of the developing heart. Development, 
138, 3955-66. 
Sahl, S. J., Weiss, L. E., Duim, W. C., Frydman, J. & Moerner, W. E. 2012. Cellular inclusion 
bodies of mutant huntingtin exon 1 obscure small fibrillar aggregate species. Sci. Rep., 
2, 895. 
Sassone, J., Colciago, C., Cislaghi, G., Silani, V. & Ciammola, A. 2009. Huntington's disease: 
the current state of research with peripheral tissues. Exp. Neurol., 219, 385-97. 
Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E. E., 
Doherty, P., Davies, S. W. & Bates, G. P. 1999. Formation of polyglutamine inclusions 
in non-CNS tissue. Hum. Mol. Genet., 8, 813-22. 
Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M. E. 1998. Huntingtin acts in the nucleus 
to induce apoptosis but death does not correlate with the formation of intranuclear 
inclusions. Cell, 95, 55-66. 
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, 
G. P., Davies, S. W., Lehrach, H. & Wanker, E. E. 1997. Huntingtin-encoded 
polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell, 
90, 549-58. 
Schulman, J. D., Black, S. H., Handyside, A. & Nance, W. E. 1996. Preimplantation genetic 
testing for Huntington disease and certain other dominantly inherited disorders. Clin. 
Genet., 49, 57-8. 
REFERENCES 
- 151 - 
Segev, H., Kenyagin-Karsenti, D., Fishman, B., Gerecht-Nir, S., Ziskind, A., Amit, M., Coleman, 
R. & Itskovitz-Eldor, J. 2005. Molecular analysis of cardiomyocytes derived from human 
embryonic stem cells. Development, growth & differentiation, 47, 295-306. 
Seriola, A., Spits, C., Simard, J. P., Hilven, P., Haentjens, P., Pearson, C. E. & Sermon, K. 
2011. Huntington's and myotonic dystrophy hESCs: down-regulated trinucleotide repeat 
instability and mismatch repair machinery expression upon differentiation. Hum. Mol. 
Genet., 20, 176-85. 
Sharp, A. H., Loev, S. J., Schilling, G., Li, S. H., Li, X. J., Bao, J., Wagster, M. V., Kotzuk, J. A., 
Steiner, J. P., Lo, A. & Et Al. 1995. Widespread expression of Huntington's disease 
gene (IT15) protein product. Neuron, 14, 1065-74. 
Shelbourne, P. F., Killeen, N., Hevner, R. F., Johnston, H. M., Tecott, L., Lewandoski, M., Ennis, 
M., Ramirez, L., Li, Z., Iannicola, C., Littman, D. R. & Myers, R. M. 1999. A Huntington's 
disease CAG expansion at the murine Hdh locus is unstable and associated with 
behavioural abnormalities in mice. Hum. Mol. Genet., 8, 763-74. 
Si-Tayeb, K., Noto, F. K., Sepac, A., Sedlic, F., Bosnjak, Z. J., Lough, J. W. & Duncan, S. A. 
2010. Generation of human induced pluripotent stem cells by simple transient 
transfection of plasmid DNA encoding reprogramming factors. BMC Dev. Biol., 10, 81. 
Siesling, S., Vegter-Van Der Vlis, M. & Roos, R. A. 1997. Juvenile Huntington disease in the 
Netherlands. Pediatr. Neurol., 17, 37-43. 
Sipione, S. & Cattaneo, E. 2001. Modeling Huntington's disease in cells, flies, and mice. Mol. 
Neurobiol., 23, 21-51. 
Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J., Kooperberg, C., 
Olson, J. M. & Cattaneo, E. 2002. Early transcriptional profiles in huntingtin-inducible 
striatal cells by microarray analyses. Hum. Mol. Genet., 11, 1953-65. 
Slow, E. J., Van Raamsdonk, J., Rogers, D., Coleman, S. H., Graham, R. K., Deng, Y., Oh, R., 
Bissada, N., Hossain, S. M., Yang, Y. Z., Li, X. J., Simpson, E. M., Gutekunst, C. A., 
Leavitt, B. R. & Hayden, M. R. 2003. Selective striatal neuronal loss in a YAC128 
mouse model of Huntington disease. Hum. Mol. Genet., 12, 1555-67. 
Smith, D. L. & Bates, G. P. 2004. Monitoring aggregate formation in organotypic slice cultures 
from transgenic mice. Methods Mol. Biol., 277, 161-71. 
Soldner, F., Laganiere, J., Cheng, A. W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, 
V., Golbe, L. I., Myers, R. H., Lindquist, S., Zhang, L., Guschin, D., Fong, L. K., Vu, B. 
J., Meng, X., Urnov, F. D., Rebar, E. J., Gregory, P. D., Zhang, H. S. & Jaenisch, R. 
2011. Generation of isogenic pluripotent stem cells differing exclusively at two early 
onset Parkinson point mutations. Cell, 146, 318-31. 
Somers, A., Jean, J. C., Sommer, C. A., Omari, A., Ford, C. C., Mills, J. A., Ying, L., Sommer, A. 
G., Jean, J. M., Smith, B. W., Lafyatis, R. A., Demierre, M. F., Weiss, D. J., French, D. 
L., Gadue, P., Murphy, G. J., Mostoslavsky, G. & Kotton, D. N. 2010. Generation of 
Transgene-Free Lung Disease-Specific Human iPS Cells Using a Single Excisable 
Lentiviral Stem Cell Cassette. Stem Cells. 
Sommer, C. A., Stadtfeld, M., Murphy, G. J., Hochedlinger, K., Kotton, D. N. & Mostoslavsky, G. 
2009. Induced pluripotent stem cell generation using a single lentiviral stem cell 
cassette. Stem Cells, 27, 543-9. 
Sontag, E. M., Lotz, G. P., Agrawal, N., Tran, A., Aron, R., Yang, G., Necula, M., Lau, A., 
Finkbeiner, S., Glabe, C., Marsh, J. L., Muchowski, P. J. & Thompson, L. M. 2012. 
Methylene blue modulates huntingtin aggregation intermediates and is protective in 
Huntington's disease models. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 32, 11109-19. 
Sorensen, S. A. & Fenger, K. 1992. Causes of death in patients with Huntington's disease and 
in unaffected first degree relatives. J. Med. Genet., 29, 911-4. 
Squitieri, F., Cannella, M., Giallonardo, P., Maglione, V., Mariotti, C. & Hayden, M. R. 2001. 
Onset and pre-onset studies to define the Huntington's disease natural history. Brain 
Res. Bull., 56, 233-8. 
Stadtfeld, M., Brennand, K. & Hochedlinger, K. 2008a. Reprogramming of pancreatic beta cells 
into induced pluripotent stem cells. Current biology : CB, 18, 890-4. 
Stadtfeld, M., Maherali, N., Breault, D. T. & Hochedlinger, K. 2008b. Defining molecular 
cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell, 2, 
230-40. 
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G. & Hochedlinger, K. 2008c. Induced pluripotent 
stem cells generated without viral integration. Science, 322, 945-9. 
Stephenson, E., Ilic, D., Jacquet, L., Genbacev, O. & Fisher, S. J. 2014. PGD and Human 
Embryonic  Stem Cell Technology. In: T. El-Toukhy (ed.) Preimplantation Genetic 
Diagnosis in Clinical Practice. London: Springer-Verlag London 2014. 
REFERENCES 
- 152 - 
Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., 
Dajani, Y., Braude, P. & Ilic, D. 2012. Derivation and propagation of human embryonic 
stem cell lines from frozen embryos in an animal product-free environment. Nat. 
Protoc., 7, 1366-81. 
Stojkovic, P., Lako, M., Przyborski, S., Stewart, R., Armstrong, L., Evans, J., Zhang, X. & 
Stojkovic, M. 2005. Human-serum matrix supports undifferentiated growth of human 
embryonic stem cells. Stem Cells, 23, 895-902. 
Streckfuss-Bomeke, K., Wolf, F., Azizian, A., Stauske, M., Tiburcy, M., Wagner, S., Hubscher, 
D., Dressel, R., Chen, S., Jende, J., Wulf, G., Lorenz, V., Schon, M. P., Maier, L. S., 
Zimmermann, W. H., Hasenfuss, G. & Guan, K. 2012. Comparative study of human-
induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and 
skin fibroblasts. Eur. Heart J. 
Strong, T. V., Tagle, D. A., Valdes, J. M., Elmer, L. W., Boehm, K., Swaroop, M., Kaatz, K. W., 
Collins, F. S. & Albin, R. L. 1993. Widespread expression of the human and rat 
Huntington's disease gene in brain and nonneural tissues. Nat. Genet., 5, 259-65. 
Strulovici, Y., Leopold, P. L., O'connor, T. P., Pergolizzi, R. G. & Crystal, R. G. 2007. Human 
embryonic stem cells and gene therapy. Molecular therapy : the journal of the American 
Society of Gene Therapy, 15, 850-66. 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. & Yamanaka, S. 
2007. Induction of pluripotent stem cells from adult human fibroblasts by defined 
factors. Cell, 131, 861-72. 
Takahashi, K. & Yamanaka, S. 2006. Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell, 126, 663-76. 
Takai, N., Desmond, J. C., Kumagai, T., Gui, D., Said, J. W., Whittaker, S., Miyakawa, I. & 
Koeffler, H. P. 2004. Histone deacetylase inhibitors have a profound antigrowth activity 
in endometrial cancer cells. Clinical cancer research : an official journal of the American 
Association for Cancer Research, 10, 1141-9. 
Telenius, H., Kremer, B., Goldberg, Y. P., Theilmann, J., Andrew, S. E., Zeisler, J., Adam, S., 
Greenberg, C., Ives, E. J., Clarke, L. A. & Et Al. 1994. Somatic and gonadal mosaicism 
of the Huntington disease gene CAG repeat in brain and sperm. Nat. Genet., 6, 409-14. 
Telenius, H., Kremer, H. P., Theilmann, J., Andrew, S. E., Almqvist, E., Anvret, M., Greenberg, 
C., Greenberg, J., Lucotte, G., Squitieri, F. & Et Al. 1993. Molecular analysis of juvenile 
Huntington disease: the major influence on (CAG)n repeat length is the sex of the 
affected parent. Hum. Mol. Genet., 2, 1535-40. 
The HD iPSC Consortium. 2012. Induced Pluripotent Stem Cells from Patients with 
Huntington’s Disease Show CAG-Repeat Expansion Associated Phenotypes. Cell Stem 
Cell, 11, 264-278. 
The Huntington Disease Collaborative Research Group 1993. A novel gene containing a 
trinucleotide repeat that is expanded and unstable on Huntington's disease 
chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-
83. 
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. 
S. & Jones, J. M. 1998. Embryonic Stem Cell Lines Derived from Human Blastocysts. 
Science, 282, 1145-1147. 
Tiscornia, G., Vivas, E. L., Matalonga, L., Berniakovich, I., Barragan Monasterio, M., Eguizabal, 
C., Gort, L., Gonzalez, F., Ortiz Mellet, C., Garcia Fernandez, J. M., Ribes, A., Veiga, A. 
& Izpisua Belmonte, J. C. 2013. Neuronopathic Gaucher's disease: induced pluripotent 
stem cells for disease modelling and testing chaperone activity of small compounds. 
Hum. Mol. Genet., 22, 633-45. 
Tong, Y., Ha, T. J., Liu, L., Nishimoto, A., Reiner, A. & Goldowitz, D. 2011. Spatial and temporal 
requirements for huntingtin (Htt) in neuronal migration and survival during brain 
development. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 31, 14794-9. 
Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V. C., Sharp, A. H., Persichetti, F., 
Cattaneo, E. & Macdonald, M. E. 2000. Dominant phenotypes produced by the HD 
mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet., 9, 2799-809. 
Trottier, Y., Biancalana, V. & Mandel, J. L. 1994. Instability of CAG repeats in Huntington's 
disease: relation to parental transmission and age of onset. J. Med. Genet., 31, 377-82. 
Tse, H. F., Ho, J. C., Choi, S. W., Lee, Y. K., Butler, A. W., Ng, K. M., Siu, C. W., Simpson, M. 
A., Lai, W. H., Chan, Y. C., Au, K. W., Zhang, J., Lay, K. W., Esteban, M. A., Nicholls, J. 
M., Colman, A. & Sham, P. C. 2013. Patient-specific induced-pluripotent stem cells-
derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated 
REFERENCES 
- 153 - 
cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. 
Hum. Mol. Genet., 22, 1395-403. 
Van Der Burg, J. M., Bjorkqvist, M. & Brundin, P. 2009. Beyond the brain: widespread pathology 
in Huntington's disease. Lancet Neurol., 8, 765-74. 
Verlinsky, Y., Strelchenko, N., Kukharenko, V., Rechitsky, S., Verlinsky, O., Galat, V. & Kuliev, 
A. 2005. Human embryonic stem cell lines with genetic disorders. Reproductive 
Biomedicine Online, 10, 105-110. 
Vlodavsky, I. 2001. Preparation of extracellular matrices produced by cultured corneal 
endothelial and PF-HR9 endodermal cells. Curr. Protoc. Cell Biol., Chapter 10, Unit 10 
4. 
Waelter, S., Boeddrich, A., Lurz, R., Scherzinger, E., Lueder, G., Lehrach, H. & Wanker, E. E. 
2001. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies 
as a result of insufficient protein degradation. Mol. Biol. Cell, 12, 1393-407. 
Wang, G. H., Mitsui, K., Kotliarova, S., Yamashita, A., Nagao, Y., Tokuhiro, S., Iwatsubo, T., 
Kanazawa, I. & Nukina, N. 1999. Caspase activation during apoptotic cell death induced 
by expanded polyglutamine in N2a cells. Neuroreport, 10, 2435-8. 
Wang, Q., Mou, X., Cao, H., Meng, Q., Ma, Y., Han, P., Jiang, J. & Zhang, H. 2012. A novel 
xeno-free and feeder-cell-free system for human pluripotent stem cell culture. Protein & 
cell, 3, 51-9. 
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, 
Z. D., Meissner, A., Daley, G. Q., Brack, A. S., Collins, J. J., Cowan, C., Schlaeger, T. 
M. & Rossi, D. J. 2010. Highly Efficient Reprogramming to Pluripotency and Directed 
Differentiation of Human Cells with Synthetic Modified mRNA. Cell Stem Cell. 
Warren, L., Ni, Y., Wang, J. & Guo, X. 2012. Feeder-free derivation of human induced 
pluripotent stem cells with messenger RNA. Sci. Rep., 2, 657. 
Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., Takahashi, J. 
B., Nishikawa, S., Muguruma, K. & Sasai, Y. 2007. A ROCK inhibitor permits survival of 
dissociated human embryonic stem cells. Nat. Biotechnol., 25, 681-6. 
Weiss, A., Roscic, A. & Paganetti, P. 2009. Inducible mutant huntingtin expression in HN10 
cells reproduces Huntington's disease-like neuronal dysfunction. Mol. Neurodegener., 
4, 11. 
Wheeler, V. C., White, J. K., Gutekunst, C. A., Vrbanac, V., Weaver, M., Li, X. J., Li, S. H., Yi, 
H., Vonsattel, J. P., Gusella, J. F., Hersch, S., Auerbach, W., Joyner, A. L. & 
Macdonald, M. E. 2000. Long glutamine tracts cause nuclear localization of a novel 
form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in 
mice. Hum. Mol. Genet., 9, 503-13. 
Woltjen, K., Michael, I. P., Mohseni, P., Desai, R., Mileikovsky, M., Hamalainen, R., Cowling, R., 
Wang, W., Liu, P., Gertsenstein, M., Kaji, K., Sung, H. K. & Nagy, A. 2009. piggyBac 
transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 458, 766-
70. 
Wood, N. I., Sawiak, S.J., Buonincontri, G., Niu, Y., Kane, A.D., Carpenter, T.A., Giussanic, 
D.A., & Morton, J.A 2012. Direct Evidence of Progressive Cardiac Dysfunction in a 
Transgenic Mouse Model of Huntington’s Disease. Journal of Huntington’s Disease 1, 
57–64. 
Wulhfard, S., Baldi, L., Hacker, D. L. & Wurm, F. 2010. Valproic acid enhances recombinant 
mRNA and protein levels in transiently transfected Chinese hamster ovary cells. J. 
Biotechnol., 148, 128-132. 
Xu, C., Inokuma, M. S., Denham, J., Golds, K., Kundu, P., Gold, J. D. & Carpenter, M. K. 2001. 
Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol., 
19, 971-4. 
Xu, C., Police, S., Rao, N. & Carpenter, M. K. 2002. Characterization and enrichment of 
cardiomyocytes derived from human embryonic stem cells. Circ. Res., 91, 501-8. 
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H. & 
Suzuki, N. 2011. Modeling familial Alzheimer's disease with induced pluripotent stem 
cells. Hum. Mol. Genet., 20, 4530-9. 
Yamamoto, A., Cremona, M. L. & Rothman, J. E. 2006. Autophagy-mediated clearance of 
huntingtin aggregates triggered by the insulin-signaling pathway. The Journal of cell 
biology, 172, 719-31. 
Yang, D., Wang, C. E., Zhao, B., Li, W., Ouyang, Z., Liu, Z., Yang, H., Fan, P., O'neill, A., Gu, 
W., Yi, H., Li, S., Lai, L. & Li, X. J. 2010. Expression of Huntington's disease protein 
results in apoptotic neurons in the brains of cloned transgenic pigs. Hum. Mol. Genet., 
19, 3983-94. 
REFERENCES 
- 154 - 
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, 
E., Bonham, K., Abbott, G. W., Linden, R. M., Field, L. J. & Keller, G. M. 2008. Human 
cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived 
population. Nature, 453, 524-8. 
Yang, S. H., Cheng, P. H., Banta, H., Piotrowska-Nitsche, K., Yang, J. J., Cheng, E. C., Snyder, 
B., Larkin, K., Liu, J., Orkin, J., Fang, Z. H., Smith, Y., Bachevalier, J., Zola, S. M., Li, S. 
H., Li, X. J. & Chan, A. W. 2008. Towards a transgenic model of Huntington's disease in 
a non-human primate. Nature, 453, 921-4. 
Yazawa, M., Hsueh, B., Jia, X., Pasca, A. M., Bernstein, J. A., Hallmayer, J. & Dolmetsch, R. E. 
2011. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy 
syndrome. Nature, 471, 230-4. 
Yoon, T. M., Chang, B., Kim, H. T., Jee, J. H., Kim, D. W. & Hwang, D. Y. 2010. Human 
embryonic stem cells (hESCs) cultured under distinctive feeder-free culture conditions 
display global gene expression patterns similar to hESCs from feeder-dependent 
culture conditions. Stem cell reviews, 6, 425-37. 
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., 
Jonsdottir, G. A., Ruotti, V., Stewart, R., Slukvin, Ii & Thomson, J. A. 2007. Induced 
pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917-20. 
Yu, T., Miyagawa, S., Miki, K., Saito, A., Fukushima, S., Higuchi, T., Kawamura, M., Kawamura, 
T., Ito, E., Kawaguchi, N., Sawa, Y. & Matsuura, N. 2013. In vivo differentiation of 
induced pluripotent stem cell-derived cardiomyocytes. Circulation journal : official 
journal of the Japanese Circulation Society, 77, 1297-306. 
Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. 1995. Increased 
apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease 
gene homologue. Nat. Genet., 11, 155-63. 
Zhang, J., Klos, M., Wilson, G. F., Herman, A. M., Lian, X., Raval, K. K., Barron, M. R., Hou, L., 
Soerens, A. G., Yu, J., Palecek, S. P., Lyons, G. E., Thomson, J. A., Herron, T. J., 
Jalife, J. & Kamp, T. J. 2012. Extracellular matrix promotes highly efficient cardiac 
differentiation of human pluripotent stem cells: the matrix sandwich method. Circ. Res., 
111, 1125-36. 
Zhang, N., An, M. C., Montoro, D. & Ellerby, L. M. 2010. Characterization of Human 
Huntington's Disease Cell Model from Induced Pluripotent Stem Cells. PLoS Curr, 2, 
RRN1193. 
Zhang, Z., Gao, Y., Gordon, A., Wang, Z. Z., Qian, Z. & Wu, W. S. 2011. Efficient generation of 
fully reprogrammed human iPS cells via polycistronic retroviral vector and a new 
cocktail of chemical compounds. PLoS One, 6, e26592. 
Zhao, M., Yang, H., Jiang, X., Zhou, W., Zhu, B., Zeng, Y., Yao, K. & Ren, C. 2008. 
Lipofectamine RNAiMAX: an efficient siRNA transfection reagent in human embryonic 
stem cells. Mol. Biotechnol., 40, 19-26. 
Zhao, Y., Yin, X., Qin, H., Zhu, F., Liu, H., Yang, W., Zhang, Q., Xiang, C., Hou, P., Song, Z., 
Liu, Y., Yong, J., Zhang, P., Cai, J., Liu, M., Li, H., Li, Y., Qu, X., Cui, K., Zhang, W., 
Xiang, T., Wu, Y., Liu, C., Yu, C., Yuan, K., Lou, J., Ding, M. & Deng, H. 2008. Two 
supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem 
Cell, 3, 475-9. 
Zhou, H., Wu, S., Joo, J. Y., Zhu, S., Han, D. W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., 
Siuzdak, G., Scholer, H. R., Duan, L. & Ding, S. 2009. Generation of induced pluripotent 
stem cells using recombinant proteins. Cell Stem Cell, 4, 381-4. 
Zhou, W. & Freed, C. R. 2009. Adenoviral gene delivery can reprogram human fibroblasts to 
induced pluripotent stem cells. Stem Cells, 27, 2667-74. 
Zhu, S., Li, W., Zhou, H., Wei, W., Ambasudhan, R., Lin, T., Kim, J., Zhang, K. & Ding, S. 2010. 
Reprogramming of human primary somatic cells by OCT4 and chemical compounds. 
Cell Stem Cell, 7, 651-5. 
 - 155 - 
LIST OF PUBLICATIONS 
 
Stephenson, E., Ilic, D., Jacquet, L., Genbacev, O. & Fisher, S. J. 2014. PGD and Human 
Embryonic  Stem Cell Technology. In: T. El-Toukhy (ed.) Preimplantation Genetic 
Diagnosis in Clinical Practice. London: Springer-Verlag London 2014. 
Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J., Al-Bedaery, R., Renwick, P., 
Ogilvie, C., Vaughan, R. & Ilic, D. 2013. Strategy for the creation of clinical grade hESC 
line banks that HLA-match a target population. EMBO Mol. Med., 5, 10-7. 
Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., 
Dajani, Y., Braude, P. & Ilic, D. 2012. Derivation and propagation of human embryonic 
stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc., 
7, 1366-81. 
Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., 
Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C. & Braude, P. 2012. 
Derivation and feeder-free propagation of human embryonic stem cells under xeno-free 
conditions. Cytotherapy, 14, 122-8. 
Stephenson, E., Ogilvie, C. M., Patel, H., Cornwell, G., Jacquet, L., Kadeva, N., Braude, P. & 
Ilic, D. 2010. Safety paradigm: genetic evaluation of therapeutic grade human 
embryonic stem cells. Journal of the Royal Society, Interface / the Royal Society, 7 
Suppl 6, S677-88. 
APPENDIX I hESC CHARACTERISATION 
- 156 - 




APPENDIX I hESC CHARACTERISATION 
- 157 - 
 
KCL013_HD4 Characterisation. a) Morphological criteria. Initial outgrowth (left), KCL012_HD4 
cell colony on HFF (middle) and feeder-free condition (right). b) Pluripotency markers: alkaline 
phosphatase (AP) activity, NANOG, OCT4, TRA-1–60 and TRA-1–81. c) In vitro differentiation 
markers for the three germ layers: (-fetoprotein (endoderm), $-III tubulin (ectoderm) and 
smooth muscle actin (mesoderm). d) Genotyping: microsatellite markers specific for 
chromosomes 13, 18, 21, X and Y were amplified. The allele sizes in base pair for markers on 
chromosomes 13, 18, and 21 are listed in the table. Array comparative genomic hybridization 
(CGH) did not detect any copy number changes using Promega female G1521 as a standard. 





KCL020 Characterisation. a) Genotyping: microsatellite markers specific for chromosomes 13, 
18, 21, X and Y were amplified. The allele sizes in base pair for markers on chromosomes 13, 
18, and 21 are listed in the table. Array comparative genomic hybridization (CGH) did not detect 
any copy number changes using Promega female G1521 as a standard. b) Pluripotency 
markers: alkaline phosphatase activity, NANOG, OCT4, TRA-1–60 and TRA-1–81. c) HLA 
typing. d) In vitro differentiation markers for the three germ layers: smooth muscle actin 
(mesoderm), $-III tubulin (ectoderm) and (-fetoprotein (endoderm). Images were taken at 40x 
magnification. 
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KCL027_HD5 
KCL027_HD5 Characterisation. a) Genotyping: microsatellite markers specific for 
chromosomes 13, 18, 21, X and Y were amplified. The allele sizes in base pair for markers on 
chromosomes 13, 18, and 21 are listed in the table. Array comparative genomic hybridization 
(CGH) did not detect any copy number changes using Promega female G1521 as a standard. 
b) Pluripotency markers: alkaline phosphatase activity, NANOG, OCT4, TRA-1–60 and TRA-1–
81. c) HLA typing. d) In vitro differentiation markers for the three germ layers: smooth muscle 
actin (mesoderm), $-III tubulin (ectoderm) and (-fetoprotein (endoderm). e) In vivo 
differentiation. Teratoma sections were counterstained with hematoxylin and eosin and specific 
stains are either light blue (Alcian blue) or brown (all immunohistochemistry). Mesoderm germ 
layer markers: Alcian blue– and periodic acid–Schiff (PAS)-stained cartilage and desmin. 
Ectoderm germ layer markers: $-III tubulin and glial fibrillary acidic protein (GFAP). Endoderm 
germ layer marker: GATA4 and (-fetoprotein. Positive immunostaining for complex IV type II 
marker confirms the human origin of the tumour (adjacent section of the one stained for 
desmin). Images were taken at 40x magnification. Images were taken at 40x magnification. 
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KCL027_HD5 CAG repeat sizing. 
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KCL028_HD6 
 
KCL026_HD6 Characterisation. a) Genotyping: microsatellite markers specific for 
chromosomes 13, 18, 21, X and Y were amplified. The allele sizes in base pair for markers on 
chromosomes 13, 18, and 21 are listed in the table. Array comparative genomic hybridization 
(CGH) did not detect any copy number changes using Promega female G1521 as a standard. 
b) Pluripotency markers: alkaline phosphatase activity, NANOG, OCT4, TRA-1–60 and TRA-1–
81. c) HLA typing. d) In vitro differentiation markers for the three germ layers: smooth muscle 
actin (mesoderm), $-III tubulin (ectoderm) and (-fetoprotein (endoderm). e) In vivo 
differentiation. Teratoma sections were counterstained with hematoxylin and eosin and specific 
stains are either light blue (Alcian blue) or brown (all immunohistochemistry). Mesoderm germ 
layer markers: Alcian blue– and periodic acid–Schiff (PAS)-stained cartilage and desmin. 
Ectoderm germ layer markers: $-III tubulin and glial fibrillary acidic protein (GFAP). Endoderm 
germ layer marker: GATA4 and (-fetoprotein. Positive immunostaining for complex IV type II 
marker confirms the human origin of the tumour (adjacent section of the one stained for 
desmin). Images were taken at 40x magnification. Images were taken at 40x magnification. 
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KCL028_HD6 CAG repeat sizing. 
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KCL031 
KCL031 Characterisation. a) Genotyping: microsatellite markers specific for chromosomes 13, 
18, 21, X and Y were amplified. The allele sizes in base pair for markers on chromosomes 13, 
18, and 21 are listed in the table. Array comparative genomic hybridization (CGH) did not detect 
any copy number changes using Promega female G1521 as a standard. b) Pluripotency 
markers: alkaline phosphatase activity, NANOG, OCT4, TRA-1–60 and TRA-1–81. c) HLA 
typing. d) In vitro differentiation markers for the three germ layers: smooth muscle actin 
(mesoderm), $-III tubulin (ectoderm) and (-fetoprotein (endoderm). e) In vivo differentiation. 
Teratoma sections were counterstained with hematoxylin and eosin and specific stains are 
either light blue (Alcian blue) or brown (all immunohistochemistry). Mesoderm germ layer 
markers: Alcian blue– and periodic acid–Schiff (PAS)-stained cartilage and desmin. Ectoderm 
germ layer markers: $-III tubulin and glial fibrillary acidic protein (GFAP). Endoderm germ layer 
marker: GATA4 and (-fetoprotein. Positive immunostaining for complex IV type II marker 
confirms the human origin of the tumour (adjacent section of the one stained for desmin). 
Images were taken at 40x magnification.  
APPENDIX I hESC CHARACTERISATION 
- 163 - 
KCL034 
KCL034 Characterisation. a) Genotyping: microsatellite markers specific for chromosomes 13, 
18, 21, X and Y were amplified. The allele sizes in base pair for markers on chromosomes 13, 
18, and 21 are listed in the table. Array comparative genomic hybridization (CGH) did not detect 
any copy number changes using Promega female G1521 as a standard. b) Pluripotency 
markers: alkaline phosphatase activity, NANOG, OCT4, TRA-1–60 and TRA-1–81. c) HLA 
typing. d) In vitro differentiation markers for the three germ layers: smooth muscle actin 
(mesoderm), $-III tubulin (ectoderm) and (-fetoprotein (endoderm). e) In vivo differentiation. 
Teratoma sections were counterstained with hematoxylin and eosin and specific stains are 
either light blue (Alcian blue) or brown (all immunohistochemistry). Mesoderm germ layer 
markers: Alcian blue– and periodic acid–Schiff (PAS)-stained cartilage and desmin. Ectoderm 
germ layer markers: $-III tubulin and glial fibrillary acidic protein (GFAP). Endoderm germ layer 
marker: GATA4 and (-fetoprotein. Positive immunostaining for complex IV type II marker 
confirms the human origin of the tumour (adjacent section of the one stained for desmin). 
Images were taken at 40x magnification. Images were taken at 40x magnification.   
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KCL036_HD7 
KCL036_HD7 Characterisation. a) Genotyping: microsatellite markers specific for 
chromosomes 13, 18, 21, X and Y were amplified. The allele sizes in base pair for markers on 
chromosomes 13, 18, and 21 are listed in the table. Array comparative genomic hybridization 
(CGH) did not detect any copy number changes using Promega female G1521 as a standard. 
b) Pluripotency markers: alkaline phosphatase activity, NANOG, OCT4, TRA-1–60 and TRA-1–
81. c) HLA typing. d) In vitro differentiation markers for the three germ layers: smooth muscle 
actin (mesoderm), $-III tubulin (ectoderm) and (-fetoprotein (endoderm). e) In vivo 
differentiation. Teratoma sections were counterstained with hematoxylin and eosin and specific 
stains are either light blue (Alcian blue) or brown (all immunohistochemistry). Mesoderm germ 
layer markers: Alcian blue– and periodic acid–Schiff (PAS)-stained cartilage and desmin. 
Ectoderm germ layer markers: $-III tubulin and glial fibrillary acidic protein (GFAP). Endoderm 
germ layer marker: GATA4 and (-fetoprotein. Positive immunostaining for complex IV type II 
marker confirms the human origin of the tumour (adjacent section of the one stained for 
desmin). Images were taken at 40x magnification. Images were taken at 40x magnification.   
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KCL040 Characterisation. a) Genotyping: microsatellite markers specific for chromosomes 13, 
18, 21, X and Y were amplified. The allele sizes in base pair for markers on chromosomes 13, 
18, and 21 are listed in the table. Array comparative genomic hybridization (CGH) did not detect 
any copy number changes using Promega female G1521 as a standard. b) Pluripotency 
markers: alkaline phosphatase activity, NANOG, OCT4, TRA-1–60 and TRA-1–81. c) HLA 
typing. d) In vitro differentiation markers for the three germ layers: smooth muscle actin 
(mesoderm), $-III tubulin (ectoderm) and (-fetoprotein (endoderm). Images were taken at 40x 
magnification. 
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APPENDIX II Modified mRNA synthesis 
 
Coding sequences of the different genes used for the generation of modified synthetic mRNA. 










































APPENDIX II MODIFIED MRNA SYNTHESIS 
- 167 - 












































APPENDIX II MODIFIED MRNA SYNTHESIS 



























APPENDIX II MODIFIED MRNA SYNTHESIS 
- 169 - 
pTNT vector circular map (Promega). 
 
 
